#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Rare damaging variants in DNA repair and cell cycle pathways are associated with hippocampal and cognitive dysfunction: a combined genetic imaging study in first-episode treatment-naive patients with schizophrenia
1-1	0-4	Rare	_	
1-2	5-13	damaging	_	
1-3	14-22	variants	_	
1-4	23-25	in	_	
1-5	26-29	DNA	_	
1-6	30-36	repair	_	
1-7	37-40	and	_	
1-8	41-45	cell	_	
1-9	46-51	cycle	_	
1-10	52-60	pathways	_	
1-11	61-64	are	_	
1-12	65-75	associated	_	
1-13	76-80	with	_	
1-14	81-92	hippocampal	_	
1-15	93-96	and	_	
1-16	97-106	cognitive	_	
1-17	107-118	dysfunction	_	
1-18	118-119	:	_	
1-19	120-121	a	_	
1-20	122-130	combined	_	
1-21	131-138	genetic	_	
1-22	139-146	imaging	_	
1-23	147-152	study	_	
1-24	153-155	in	_	
1-25	156-169	first-episode	_	
1-26	170-185	treatment-naive	_	
1-27	186-194	patients	_	
1-28	195-199	with	_	
1-29	200-213	schizophrenia	_	

#Text=Schizophrenia is a complex neurodevelopmental disorder where changes in both hippocampus and memory-related cognitive functions are central. However, the exact relationship between neurodevelopmental-genetic factors and hippocampal-cognitive dysfunction remains unclear. The general aim of our study is to link the occurrence of rare damaging mutations involved in susceptibility gene pathways to the structure and function of hippocampus in order to define genetically and phenotypically based subgroups in schizophrenia. In the present study, by analyzing the exome sequencing and magnetic resonance imaging data in 94 first-episode treatment-naive schizophrenia patients and 134 normal controls, we identified that a cluster of rare damaging variants (RDVs) enriched in DNA repair and cell cycle pathways was present only in a subgroup including 39 schizophrenic patients. Furthermore, we found that schizophrenic patients with this RDVs show increased resting-state functional connectivity (rsFC) between left hippocampus (especially for left dentate gyrus) and left inferior parietal cortex, as well as decreased rsFC between left hippocampus and cerebellum. Moreover, abnormal rsFC was related to the deficits of spatial working memory (SWM; that is known to recruit the hippocampus) in patients with the RDVs. Taken together, our data demonstrate for the first time, to our knowledge, that damaging rare variants of genes in DNA repair and cell cycle pathways are associated with aberrant hippocampal rsFC, which was further relative to cognitive deficits in first-episode treatment-naive schizophrenia. Therefore, our data provide some evidence for the occurrence of phenotypic alterations in hippocampal and SWM function in a genetically defined subgroup of schizophrenia.
2-1	214-227	Schizophrenia	_	
2-2	228-230	is	_	
2-3	231-232	a	_	
2-4	233-240	complex	_	
2-5	241-259	neurodevelopmental	_	
2-6	260-268	disorder	_	
2-7	269-274	where	_	
2-8	275-282	changes	_	
2-9	283-285	in	_	
2-10	286-290	both	_	
2-11	291-302	hippocampus	_	
2-12	303-306	and	_	
2-13	307-321	memory-related	_	
2-14	322-331	cognitive	_	
2-15	332-341	functions	_	
2-16	342-345	are	_	
2-17	346-353	central	_	
2-18	353-354	.	_	
2-19	355-362	However	_	
2-20	362-363	,	_	
2-21	364-367	the	_	
2-22	368-373	exact	_	
2-23	374-386	relationship	_	
2-24	387-394	between	_	
2-25	395-421	neurodevelopmental-genetic	_	
2-26	422-429	factors	_	
2-27	430-433	and	_	
2-28	434-455	hippocampal-cognitive	_	
2-29	456-467	dysfunction	_	
2-30	468-475	remains	_	
2-31	476-483	unclear	_	
2-32	483-484	.	_	
2-33	485-488	The	_	
2-34	489-496	general	_	
2-35	497-500	aim	_	
2-36	501-503	of	_	
2-37	504-507	our	_	
2-38	508-513	study	_	
2-39	514-516	is	_	
2-40	517-519	to	_	
2-41	520-524	link	_	
2-42	525-528	the	_	
2-43	529-539	occurrence	_	
2-44	540-542	of	_	
2-45	543-547	rare	_	
2-46	548-556	damaging	_	
2-47	557-566	mutations	_	
2-48	567-575	involved	_	
2-49	576-578	in	_	
2-50	579-593	susceptibility	_	
2-51	594-598	gene	_	
2-52	599-607	pathways	_	
2-53	608-610	to	_	
2-54	611-614	the	_	
2-55	615-624	structure	_	
2-56	625-628	and	_	
2-57	629-637	function	_	
2-58	638-640	of	_	
2-59	641-652	hippocampus	_	
2-60	653-655	in	_	
2-61	656-661	order	_	
2-62	662-664	to	_	
2-63	665-671	define	_	
2-64	672-683	genetically	_	
2-65	684-687	and	_	
2-66	688-702	phenotypically	_	
2-67	703-708	based	_	
2-68	709-718	subgroups	_	
2-69	719-721	in	_	
2-70	722-735	schizophrenia	_	
2-71	735-736	.	_	
2-72	737-739	In	_	
2-73	740-743	the	_	
2-74	744-751	present	_	
2-75	752-757	study	_	
2-76	757-758	,	_	
2-77	759-761	by	_	
2-78	762-771	analyzing	_	
2-79	772-775	the	_	
2-80	776-781	exome	_	
2-81	782-792	sequencing	_	
2-82	793-796	and	_	
2-83	797-805	magnetic	_	
2-84	806-815	resonance	_	
2-85	816-823	imaging	_	
2-86	824-828	data	_	
2-87	829-831	in	_	
2-88	832-834	94	_	
2-89	835-848	first-episode	_	
2-90	849-864	treatment-naive	_	
2-91	865-878	schizophrenia	_	
2-92	879-887	patients	_	
2-93	888-891	and	_	
2-94	892-895	134	_	
2-95	896-902	normal	_	
2-96	903-911	controls	_	
2-97	911-912	,	_	
2-98	913-915	we	_	
2-99	916-926	identified	_	
2-100	927-931	that	_	
2-101	932-933	a	_	
2-102	934-941	cluster	_	
2-103	942-944	of	_	
2-104	945-949	rare	_	
2-105	950-958	damaging	_	
2-106	959-967	variants	_	
2-107	968-969	(	_	
2-108	969-973	RDVs	_	
2-109	973-974	)	_	
2-110	975-983	enriched	_	
2-111	984-986	in	_	
2-112	987-990	DNA	_	
2-113	991-997	repair	_	
2-114	998-1001	and	_	
2-115	1002-1006	cell	_	
2-116	1007-1012	cycle	_	
2-117	1013-1021	pathways	_	
2-118	1022-1025	was	_	
2-119	1026-1033	present	_	
2-120	1034-1038	only	_	
2-121	1039-1041	in	_	
2-122	1042-1043	a	_	
2-123	1044-1052	subgroup	_	
2-124	1053-1062	including	_	
2-125	1063-1065	39	_	
2-126	1066-1079	schizophrenic	_	
2-127	1080-1088	patients	_	
2-128	1088-1089	.	_	
2-129	1090-1101	Furthermore	_	
2-130	1101-1102	,	_	
2-131	1103-1105	we	_	
2-132	1106-1111	found	_	
2-133	1112-1116	that	_	
2-134	1117-1130	schizophrenic	_	
2-135	1131-1139	patients	_	
2-136	1140-1144	with	_	
2-137	1145-1149	this	_	
2-138	1150-1154	RDVs	_	
2-139	1155-1159	show	_	
2-140	1160-1169	increased	_	
2-141	1170-1183	resting-state	_	
2-142	1184-1194	functional	_	
2-143	1195-1207	connectivity	_	
2-144	1208-1209	(	_	
2-145	1209-1213	rsFC	_	
2-146	1213-1214	)	_	
2-147	1215-1222	between	_	
2-148	1223-1227	left	_	
2-149	1228-1239	hippocampus	_	
2-150	1240-1241	(	_	
2-151	1241-1251	especially	_	
2-152	1252-1255	for	_	
2-153	1256-1260	left	_	
2-154	1261-1268	dentate	_	
2-155	1269-1274	gyrus	_	
2-156	1274-1275	)	_	
2-157	1276-1279	and	_	
2-158	1280-1284	left	_	
2-159	1285-1293	inferior	_	
2-160	1294-1302	parietal	_	
2-161	1303-1309	cortex	_	
2-162	1309-1310	,	_	
2-163	1311-1313	as	_	
2-164	1314-1318	well	_	
2-165	1319-1321	as	_	
2-166	1322-1331	decreased	_	
2-167	1332-1336	rsFC	_	
2-168	1337-1344	between	_	
2-169	1345-1349	left	_	
2-170	1350-1361	hippocampus	_	
2-171	1362-1365	and	_	
2-172	1366-1376	cerebellum	_	
2-173	1376-1377	.	_	
2-174	1378-1386	Moreover	_	
2-175	1386-1387	,	_	
2-176	1388-1396	abnormal	_	
2-177	1397-1401	rsFC	_	
2-178	1402-1405	was	_	
2-179	1406-1413	related	_	
2-180	1414-1416	to	_	
2-181	1417-1420	the	_	
2-182	1421-1429	deficits	_	
2-183	1430-1432	of	_	
2-184	1433-1440	spatial	_	
2-185	1441-1448	working	_	
2-186	1449-1455	memory	_	
2-187	1456-1457	(	_	
2-188	1457-1460	SWM	_	
2-189	1460-1461	;	_	
2-190	1462-1466	that	_	
2-191	1467-1469	is	_	
2-192	1470-1475	known	_	
2-193	1476-1478	to	_	
2-194	1479-1486	recruit	_	
2-195	1487-1490	the	_	
2-196	1491-1502	hippocampus	_	
2-197	1502-1503	)	_	
2-198	1504-1506	in	_	
2-199	1507-1515	patients	_	
2-200	1516-1520	with	_	
2-201	1521-1524	the	_	
2-202	1525-1529	RDVs	_	
2-203	1529-1530	.	_	
2-204	1531-1536	Taken	_	
2-205	1537-1545	together	_	
2-206	1545-1546	,	_	
2-207	1547-1550	our	_	
2-208	1551-1555	data	_	
2-209	1556-1567	demonstrate	_	
2-210	1568-1571	for	_	
2-211	1572-1575	the	_	
2-212	1576-1581	first	_	
2-213	1582-1586	time	_	
2-214	1586-1587	,	_	
2-215	1588-1590	to	_	
2-216	1591-1594	our	_	
2-217	1595-1604	knowledge	_	
2-218	1604-1605	,	_	
2-219	1606-1610	that	_	
2-220	1611-1619	damaging	_	
2-221	1620-1624	rare	_	
2-222	1625-1633	variants	_	
2-223	1634-1636	of	_	
2-224	1637-1642	genes	_	
2-225	1643-1645	in	_	
2-226	1646-1649	DNA	_	
2-227	1650-1656	repair	_	
2-228	1657-1660	and	_	
2-229	1661-1665	cell	_	
2-230	1666-1671	cycle	_	
2-231	1672-1680	pathways	_	
2-232	1681-1684	are	_	
2-233	1685-1695	associated	_	
2-234	1696-1700	with	_	
2-235	1701-1709	aberrant	_	
2-236	1710-1721	hippocampal	_	
2-237	1722-1726	rsFC	_	
2-238	1726-1727	,	_	
2-239	1728-1733	which	_	
2-240	1734-1737	was	_	
2-241	1738-1745	further	_	
2-242	1746-1754	relative	_	
2-243	1755-1757	to	_	
2-244	1758-1767	cognitive	_	
2-245	1768-1776	deficits	_	
2-246	1777-1779	in	_	
2-247	1780-1793	first-episode	_	
2-248	1794-1809	treatment-naive	_	
2-249	1810-1823	schizophrenia	_	
2-250	1823-1824	.	_	
2-251	1825-1834	Therefore	_	
2-252	1834-1835	,	_	
2-253	1836-1839	our	_	
2-254	1840-1844	data	_	
2-255	1845-1852	provide	_	
2-256	1853-1857	some	_	
2-257	1858-1866	evidence	_	
2-258	1867-1870	for	_	
2-259	1871-1874	the	_	
2-260	1875-1885	occurrence	_	
2-261	1886-1888	of	_	
2-262	1889-1899	phenotypic	_	
2-263	1900-1911	alterations	_	
2-264	1912-1914	in	_	
2-265	1915-1926	hippocampal	_	
2-266	1927-1930	and	_	
2-267	1931-1934	SWM	_	
2-268	1935-1943	function	_	
2-269	1944-1946	in	_	
2-270	1947-1948	a	_	
2-271	1949-1960	genetically	_	
2-272	1961-1968	defined	_	
2-273	1969-1977	subgroup	_	
2-274	1978-1980	of	_	
2-275	1981-1994	schizophrenia	_	
2-276	1994-1995	.	_	

#Text=Introduction
3-1	1996-2008	Introduction	_	

#Text=Schizophrenia, which affects ~1% of the population, is a devastating mental disorder characterized by a range of symptoms including abnormal perception, thinking, cognitive, emotion and social behavior and so on. It is widely accepted that a complex interplay of genetic and environmental factors contributes to the etiology of schizophrenia, which therefore is regarded a neurodevelopmental disorder. During the last decades, researchers have made significant strides in teasing apart schizophrenia's convoluted genetic vulnerabilities. These included initial epidemiology studies within family, twin and adoption, and then linkage studies mainly using microsatellite markers to candidate genes and genome-wide association studies.
4-1	2009-2022	Schizophrenia	_	
4-2	2022-2023	,	_	
4-3	2024-2029	which	_	
4-4	2030-2037	affects	_	
4-5	2038-2039	~	_	
4-6	2039-2041	1%	_	
4-7	2042-2044	of	_	
4-8	2045-2048	the	_	
4-9	2049-2059	population	_	
4-10	2059-2060	,	_	
4-11	2061-2063	is	_	
4-12	2064-2065	a	_	
4-13	2066-2077	devastating	_	
4-14	2078-2084	mental	_	
4-15	2085-2093	disorder	_	
4-16	2094-2107	characterized	_	
4-17	2108-2110	by	_	
4-18	2111-2112	a	_	
4-19	2113-2118	range	_	
4-20	2119-2121	of	_	
4-21	2122-2130	symptoms	_	
4-22	2131-2140	including	_	
4-23	2141-2149	abnormal	_	
4-24	2150-2160	perception	_	
4-25	2160-2161	,	_	
4-26	2162-2170	thinking	_	
4-27	2170-2171	,	_	
4-28	2172-2181	cognitive	_	
4-29	2181-2182	,	_	
4-30	2183-2190	emotion	_	
4-31	2191-2194	and	_	
4-32	2195-2201	social	_	
4-33	2202-2210	behavior	_	
4-34	2211-2214	and	_	
4-35	2215-2217	so	_	
4-36	2218-2220	on	_	
4-37	2220-2221	.	_	
4-38	2222-2224	It	_	
4-39	2225-2227	is	_	
4-40	2228-2234	widely	_	
4-41	2235-2243	accepted	_	
4-42	2244-2248	that	_	
4-43	2249-2250	a	_	
4-44	2251-2258	complex	_	
4-45	2259-2268	interplay	_	
4-46	2269-2271	of	_	
4-47	2272-2279	genetic	_	
4-48	2280-2283	and	_	
4-49	2284-2297	environmental	_	
4-50	2298-2305	factors	_	
4-51	2306-2317	contributes	_	
4-52	2318-2320	to	_	
4-53	2321-2324	the	_	
4-54	2325-2333	etiology	_	
4-55	2334-2336	of	_	
4-56	2337-2350	schizophrenia	_	
4-57	2350-2351	,	_	
4-58	2352-2357	which	_	
4-59	2358-2367	therefore	_	
4-60	2368-2370	is	_	
4-61	2371-2379	regarded	_	
4-62	2380-2381	a	_	
4-63	2382-2400	neurodevelopmental	_	
4-64	2401-2409	disorder	_	
4-65	2409-2410	.	_	
4-66	2411-2417	During	_	
4-67	2418-2421	the	_	
4-68	2422-2426	last	_	
4-69	2427-2434	decades	_	
4-70	2434-2435	,	_	
4-71	2436-2447	researchers	_	
4-72	2448-2452	have	_	
4-73	2453-2457	made	_	
4-74	2458-2469	significant	_	
4-75	2470-2477	strides	_	
4-76	2478-2480	in	_	
4-77	2481-2488	teasing	_	
4-78	2489-2494	apart	_	
4-79	2495-2510	schizophrenia's	_	
4-80	2511-2521	convoluted	_	
4-81	2522-2529	genetic	_	
4-82	2530-2545	vulnerabilities	_	
4-83	2545-2546	.	_	
4-84	2547-2552	These	_	
4-85	2553-2561	included	_	
4-86	2562-2569	initial	_	
4-87	2570-2582	epidemiology	_	
4-88	2583-2590	studies	_	
4-89	2591-2597	within	_	
4-90	2598-2604	family	_	
4-91	2604-2605	,	_	
4-92	2606-2610	twin	_	
4-93	2611-2614	and	_	
4-94	2615-2623	adoption	_	
4-95	2623-2624	,	_	
4-96	2625-2628	and	_	
4-97	2629-2633	then	_	
4-98	2634-2641	linkage	_	
4-99	2642-2649	studies	_	
4-100	2650-2656	mainly	_	
4-101	2657-2662	using	_	
4-102	2663-2677	microsatellite	_	
4-103	2678-2685	markers	_	
4-104	2686-2688	to	_	
4-105	2689-2698	candidate	_	
4-106	2699-2704	genes	_	
4-107	2705-2708	and	_	
4-108	2709-2720	genome-wide	_	
4-109	2721-2732	association	_	
4-110	2733-2740	studies	_	
4-111	2740-2741	.	_	

#Text=Recently, genome-wide association studies identified that some common variants with small to moderate effects as well as rare but gene-disrupting copy number variants are significantly associated with schizophrenia. Studies using the whole-exome sequencing technologies have also revealed that rare damaging nonsense and loss-of-function variants and/or de novo variants conferred higher risk to schizophrenia. However, to validate these variants in population remains challenging because of the low frequency and effect sizes. Converging evidence from studies of common and rare variants identified broad classes of genes and pathways involved in calcium ion channel, synaptic plasticity and neurodevelopment processes, chromatin remodeling and synaptic network. Although these results show significant leads for identifying susceptibility genes of schizophrenia, the exact and specific genetic factors contributing to the abnormal neurodevelopment processes in schizophrenia remain inconclusive.
5-1	2742-2750	Recently	_	
5-2	2750-2751	,	_	
5-3	2752-2763	genome-wide	_	
5-4	2764-2775	association	_	
5-5	2776-2783	studies	_	
5-6	2784-2794	identified	_	
5-7	2795-2799	that	_	
5-8	2800-2804	some	_	
5-9	2805-2811	common	_	
5-10	2812-2820	variants	_	
5-11	2821-2825	with	_	
5-12	2826-2831	small	_	
5-13	2832-2834	to	_	
5-14	2835-2843	moderate	_	
5-15	2844-2851	effects	_	
5-16	2852-2854	as	_	
5-17	2855-2859	well	_	
5-18	2860-2862	as	_	
5-19	2863-2867	rare	_	
5-20	2868-2871	but	_	
5-21	2872-2887	gene-disrupting	_	
5-22	2888-2892	copy	_	
5-23	2893-2899	number	_	
5-24	2900-2908	variants	_	
5-25	2909-2912	are	_	
5-26	2913-2926	significantly	_	
5-27	2927-2937	associated	_	
5-28	2938-2942	with	_	
5-29	2943-2956	schizophrenia	_	
5-30	2956-2957	.	_	
5-31	2958-2965	Studies	_	
5-32	2966-2971	using	_	
5-33	2972-2975	the	_	
5-34	2976-2987	whole-exome	_	
5-35	2988-2998	sequencing	_	
5-36	2999-3011	technologies	_	
5-37	3012-3016	have	_	
5-38	3017-3021	also	_	
5-39	3022-3030	revealed	_	
5-40	3031-3035	that	_	
5-41	3036-3040	rare	_	
5-42	3041-3049	damaging	_	
5-43	3050-3058	nonsense	_	
5-44	3059-3062	and	_	
5-45	3063-3079	loss-of-function	_	
5-46	3080-3088	variants	_	
5-47	3089-3092	and	_	
5-48	3092-3093	/	_	
5-49	3093-3095	or	_	
5-50	3096-3098	de	_	
5-51	3099-3103	novo	_	
5-52	3104-3112	variants	_	
5-53	3113-3122	conferred	_	
5-54	3123-3129	higher	_	
5-55	3130-3134	risk	_	
5-56	3135-3137	to	_	
5-57	3138-3151	schizophrenia	_	
5-58	3151-3152	.	_	
5-59	3153-3160	However	_	
5-60	3160-3161	,	_	
5-61	3162-3164	to	_	
5-62	3165-3173	validate	_	
5-63	3174-3179	these	_	
5-64	3180-3188	variants	_	
5-65	3189-3191	in	_	
5-66	3192-3202	population	_	
5-67	3203-3210	remains	_	
5-68	3211-3222	challenging	_	
5-69	3223-3230	because	_	
5-70	3231-3233	of	_	
5-71	3234-3237	the	_	
5-72	3238-3241	low	_	
5-73	3242-3251	frequency	_	
5-74	3252-3255	and	_	
5-75	3256-3262	effect	_	
5-76	3263-3268	sizes	_	
5-77	3268-3269	.	_	
5-78	3270-3280	Converging	_	
5-79	3281-3289	evidence	_	
5-80	3290-3294	from	_	
5-81	3295-3302	studies	_	
5-82	3303-3305	of	_	
5-83	3306-3312	common	_	
5-84	3313-3316	and	_	
5-85	3317-3321	rare	_	
5-86	3322-3330	variants	_	
5-87	3331-3341	identified	_	
5-88	3342-3347	broad	_	
5-89	3348-3355	classes	_	
5-90	3356-3358	of	_	
5-91	3359-3364	genes	_	
5-92	3365-3368	and	_	
5-93	3369-3377	pathways	_	
5-94	3378-3386	involved	_	
5-95	3387-3389	in	_	
5-96	3390-3397	calcium	_	
5-97	3398-3401	ion	_	
5-98	3402-3409	channel	_	
5-99	3409-3410	,	_	
5-100	3411-3419	synaptic	_	
5-101	3420-3430	plasticity	_	
5-102	3431-3434	and	_	
5-103	3435-3451	neurodevelopment	_	
5-104	3452-3461	processes	_	
5-105	3461-3462	,	_	
5-106	3463-3472	chromatin	_	
5-107	3473-3483	remodeling	_	
5-108	3484-3487	and	_	
5-109	3488-3496	synaptic	_	
5-110	3497-3504	network	_	
5-111	3504-3505	.	_	
5-112	3506-3514	Although	_	
5-113	3515-3520	these	_	
5-114	3521-3528	results	_	
5-115	3529-3533	show	_	
5-116	3534-3545	significant	_	
5-117	3546-3551	leads	_	
5-118	3552-3555	for	_	
5-119	3556-3567	identifying	_	
5-120	3568-3582	susceptibility	_	
5-121	3583-3588	genes	_	
5-122	3589-3591	of	_	
5-123	3592-3605	schizophrenia	_	
5-124	3605-3606	,	_	
5-125	3607-3610	the	_	
5-126	3611-3616	exact	_	
5-127	3617-3620	and	_	
5-128	3621-3629	specific	_	
5-129	3630-3637	genetic	_	
5-130	3638-3645	factors	_	
5-131	3646-3658	contributing	_	
5-132	3659-3661	to	_	
5-133	3662-3665	the	_	
5-134	3666-3674	abnormal	_	
5-135	3675-3691	neurodevelopment	_	
5-136	3692-3701	processes	_	
5-137	3702-3704	in	_	
5-138	3705-3718	schizophrenia	_	
5-139	3719-3725	remain	_	
5-140	3726-3738	inconclusive	_	
5-141	3738-3739	.	_	

#Text=A key brain region in schizophrenia is the hippocampus where reduced volume in especially left (rather than right) hippocampus as well as resting-state functional connectivity (rsFC) differences to other regions have been observed. This corresponds to the observation of neuropsychological deficits, especially dysfunctional spatial working memory (SWM) and logical memory in patients with schizophrenia. However, the exact linkage between hippocampus and memory deficits on the one hand and underlying genetic-neurodevelopmental changes on the other hand remain unclear.
6-1	3740-3741	A	_	
6-2	3742-3745	key	_	
6-3	3746-3751	brain	_	
6-4	3752-3758	region	_	
6-5	3759-3761	in	_	
6-6	3762-3775	schizophrenia	_	
6-7	3776-3778	is	_	
6-8	3779-3782	the	_	
6-9	3783-3794	hippocampus	_	
6-10	3795-3800	where	_	
6-11	3801-3808	reduced	_	
6-12	3809-3815	volume	_	
6-13	3816-3818	in	_	
6-14	3819-3829	especially	_	
6-15	3830-3834	left	_	
6-16	3835-3836	(	_	
6-17	3836-3842	rather	_	
6-18	3843-3847	than	_	
6-19	3848-3853	right	_	
6-20	3853-3854	)	_	
6-21	3855-3866	hippocampus	_	
6-22	3867-3869	as	_	
6-23	3870-3874	well	_	
6-24	3875-3877	as	_	
6-25	3878-3891	resting-state	_	
6-26	3892-3902	functional	_	
6-27	3903-3915	connectivity	_	
6-28	3916-3917	(	_	
6-29	3917-3921	rsFC	_	
6-30	3921-3922	)	_	
6-31	3923-3934	differences	_	
6-32	3935-3937	to	_	
6-33	3938-3943	other	_	
6-34	3944-3951	regions	_	
6-35	3952-3956	have	_	
6-36	3957-3961	been	_	
6-37	3962-3970	observed	_	
6-38	3970-3971	.	_	
6-39	3972-3976	This	_	
6-40	3977-3988	corresponds	_	
6-41	3989-3991	to	_	
6-42	3992-3995	the	_	
6-43	3996-4007	observation	_	
6-44	4008-4010	of	_	
6-45	4011-4029	neuropsychological	_	
6-46	4030-4038	deficits	_	
6-47	4038-4039	,	_	
6-48	4040-4050	especially	_	
6-49	4051-4064	dysfunctional	_	
6-50	4065-4072	spatial	_	
6-51	4073-4080	working	_	
6-52	4081-4087	memory	_	
6-53	4088-4089	(	_	
6-54	4089-4092	SWM	_	
6-55	4092-4093	)	_	
6-56	4094-4097	and	_	
6-57	4098-4105	logical	_	
6-58	4106-4112	memory	_	
6-59	4113-4115	in	_	
6-60	4116-4124	patients	_	
6-61	4125-4129	with	_	
6-62	4130-4143	schizophrenia	_	
6-63	4143-4144	.	_	
6-64	4145-4152	However	_	
6-65	4152-4153	,	_	
6-66	4154-4157	the	_	
6-67	4158-4163	exact	_	
6-68	4164-4171	linkage	_	
6-69	4172-4179	between	_	
6-70	4180-4191	hippocampus	_	
6-71	4192-4195	and	_	
6-72	4196-4202	memory	_	
6-73	4203-4211	deficits	_	
6-74	4212-4214	on	_	
6-75	4215-4218	the	_	
6-76	4219-4222	one	_	
6-77	4223-4227	hand	_	
6-78	4228-4231	and	_	
6-79	4232-4242	underlying	_	
6-80	4243-4269	genetic-neurodevelopmental	_	
6-81	4270-4277	changes	_	
6-82	4278-4280	on	_	
6-83	4281-4284	the	_	
6-84	4285-4290	other	_	
6-85	4291-4295	hand	_	
6-86	4296-4302	remain	_	
6-87	4303-4310	unclear	_	
6-88	4310-4311	.	_	

#Text=The general aim of our study was to conduct multilevel genetic imaging cognitive investigation in a unique large sample of first-episode treatment-naive schizophrenic patients. For that purpose, we combined genetic analysis of neurodevelopmentally related genes with structural and functional imaging of the hippocampus and related cognitive measures. Specifically, genetic investigation in schizophrenic (and healthy) subjects served to determine specific genetic neurodevelopmentally relevant subtypes, which were then further characterized phenotypically using structural and functional hippocampal imaging as well as related cognitive, that is, memory measures.
7-1	4312-4315	The	_	
7-2	4316-4323	general	_	
7-3	4324-4327	aim	_	
7-4	4328-4330	of	_	
7-5	4331-4334	our	_	
7-6	4335-4340	study	_	
7-7	4341-4344	was	_	
7-8	4345-4347	to	_	
7-9	4348-4355	conduct	_	
7-10	4356-4366	multilevel	_	
7-11	4367-4374	genetic	_	
7-12	4375-4382	imaging	_	
7-13	4383-4392	cognitive	_	
7-14	4393-4406	investigation	_	
7-15	4407-4409	in	_	
7-16	4410-4411	a	_	
7-17	4412-4418	unique	_	
7-18	4419-4424	large	_	
7-19	4425-4431	sample	_	
7-20	4432-4434	of	_	
7-21	4435-4448	first-episode	_	
7-22	4449-4464	treatment-naive	_	
7-23	4465-4478	schizophrenic	_	
7-24	4479-4487	patients	_	
7-25	4487-4488	.	_	
7-26	4489-4492	For	_	
7-27	4493-4497	that	_	
7-28	4498-4505	purpose	_	
7-29	4505-4506	,	_	
7-30	4507-4509	we	_	
7-31	4510-4518	combined	_	
7-32	4519-4526	genetic	_	
7-33	4527-4535	analysis	_	
7-34	4536-4538	of	_	
7-35	4539-4559	neurodevelopmentally	_	
7-36	4560-4567	related	_	
7-37	4568-4573	genes	_	
7-38	4574-4578	with	_	
7-39	4579-4589	structural	_	
7-40	4590-4593	and	_	
7-41	4594-4604	functional	_	
7-42	4605-4612	imaging	_	
7-43	4613-4615	of	_	
7-44	4616-4619	the	_	
7-45	4620-4631	hippocampus	_	
7-46	4632-4635	and	_	
7-47	4636-4643	related	_	
7-48	4644-4653	cognitive	_	
7-49	4654-4662	measures	_	
7-50	4662-4663	.	_	
7-51	4664-4676	Specifically	_	
7-52	4676-4677	,	_	
7-53	4678-4685	genetic	_	
7-54	4686-4699	investigation	_	
7-55	4700-4702	in	_	
7-56	4703-4716	schizophrenic	_	
7-57	4717-4718	(	_	
7-58	4718-4721	and	_	
7-59	4722-4729	healthy	_	
7-60	4729-4730	)	_	
7-61	4731-4739	subjects	_	
7-62	4740-4746	served	_	
7-63	4747-4749	to	_	
7-64	4750-4759	determine	_	
7-65	4760-4768	specific	_	
7-66	4769-4776	genetic	_	
7-67	4777-4797	neurodevelopmentally	_	
7-68	4798-4806	relevant	_	
7-69	4807-4815	subtypes	_	
7-70	4815-4816	,	_	
7-71	4817-4822	which	_	
7-72	4823-4827	were	_	
7-73	4828-4832	then	_	
7-74	4833-4840	further	_	
7-75	4841-4854	characterized	_	
7-76	4855-4869	phenotypically	_	
7-77	4870-4875	using	_	
7-78	4876-4886	structural	_	
7-79	4887-4890	and	_	
7-80	4891-4901	functional	_	
7-81	4902-4913	hippocampal	_	
7-82	4914-4921	imaging	_	
7-83	4922-4924	as	_	
7-84	4925-4929	well	_	
7-85	4930-4932	as	_	
7-86	4933-4940	related	_	
7-87	4941-4950	cognitive	_	
7-88	4950-4951	,	_	
7-89	4952-4956	that	_	
7-90	4957-4959	is	_	
7-91	4959-4960	,	_	
7-92	4961-4967	memory	_	
7-93	4968-4976	measures	_	
7-94	4976-4977	.	_	

#Text=The first specific aim was to unravel unique rare damaging variants (RDVs) in a unique sample of first-episode treatment-naive schizophrenia patients relative to healthy controls by using whole-exome sequencing approach, and then apply Gene Ontology (GO) enrichment strategy to identify gene pathways. Consequently, we focused on the RDVs in DNA repair and cell cycle pathways for the following reasons. First, the majority of these genes in DNA repair and cell cycle pathways are most highly expressed in various brain regions, such as hippocampus; previous studies suggested indeed that genes involved in the regulation of cell cycle and DNA repair significantly influence the hippocampus function in schizophrenia. However, how the expression profile of these genes in cell cycle and DNA repair pathways map spatially and temporally during the critical neurodevelopmental stage in specifically the hippocampus in schizophrenia remains unclear. We therefore hypothesized that we could distinguish two genetic subtypes in schizophrenia, one with RDVs and one without RDVs, as related to hippocampal developmental function.
8-1	4978-4981	The	_	
8-2	4982-4987	first	_	
8-3	4988-4996	specific	_	
8-4	4997-5000	aim	_	
8-5	5001-5004	was	_	
8-6	5005-5007	to	_	
8-7	5008-5015	unravel	_	
8-8	5016-5022	unique	_	
8-9	5023-5027	rare	_	
8-10	5028-5036	damaging	_	
8-11	5037-5045	variants	_	
8-12	5046-5047	(	_	
8-13	5047-5051	RDVs	_	
8-14	5051-5052	)	_	
8-15	5053-5055	in	_	
8-16	5056-5057	a	_	
8-17	5058-5064	unique	_	
8-18	5065-5071	sample	_	
8-19	5072-5074	of	_	
8-20	5075-5088	first-episode	_	
8-21	5089-5104	treatment-naive	_	
8-22	5105-5118	schizophrenia	_	
8-23	5119-5127	patients	_	
8-24	5128-5136	relative	_	
8-25	5137-5139	to	_	
8-26	5140-5147	healthy	_	
8-27	5148-5156	controls	_	
8-28	5157-5159	by	_	
8-29	5160-5165	using	_	
8-30	5166-5177	whole-exome	_	
8-31	5178-5188	sequencing	_	
8-32	5189-5197	approach	_	
8-33	5197-5198	,	_	
8-34	5199-5202	and	_	
8-35	5203-5207	then	_	
8-36	5208-5213	apply	_	
8-37	5214-5218	Gene	_	
8-38	5219-5227	Ontology	_	
8-39	5228-5229	(	_	
8-40	5229-5231	GO	_	
8-41	5231-5232	)	_	
8-42	5233-5243	enrichment	_	
8-43	5244-5252	strategy	_	
8-44	5253-5255	to	_	
8-45	5256-5264	identify	_	
8-46	5265-5269	gene	_	
8-47	5270-5278	pathways	_	
8-48	5278-5279	.	_	
8-49	5280-5292	Consequently	_	
8-50	5292-5293	,	_	
8-51	5294-5296	we	_	
8-52	5297-5304	focused	_	
8-53	5305-5307	on	_	
8-54	5308-5311	the	_	
8-55	5312-5316	RDVs	_	
8-56	5317-5319	in	_	
8-57	5320-5323	DNA	_	
8-58	5324-5330	repair	_	
8-59	5331-5334	and	_	
8-60	5335-5339	cell	_	
8-61	5340-5345	cycle	_	
8-62	5346-5354	pathways	_	
8-63	5355-5358	for	_	
8-64	5359-5362	the	_	
8-65	5363-5372	following	_	
8-66	5373-5380	reasons	_	
8-67	5380-5381	.	_	
8-68	5382-5387	First	_	
8-69	5387-5388	,	_	
8-70	5389-5392	the	_	
8-71	5393-5401	majority	_	
8-72	5402-5404	of	_	
8-73	5405-5410	these	_	
8-74	5411-5416	genes	_	
8-75	5417-5419	in	_	
8-76	5420-5423	DNA	_	
8-77	5424-5430	repair	_	
8-78	5431-5434	and	_	
8-79	5435-5439	cell	_	
8-80	5440-5445	cycle	_	
8-81	5446-5454	pathways	_	
8-82	5455-5458	are	_	
8-83	5459-5463	most	_	
8-84	5464-5470	highly	_	
8-85	5471-5480	expressed	_	
8-86	5481-5483	in	_	
8-87	5484-5491	various	_	
8-88	5492-5497	brain	_	
8-89	5498-5505	regions	_	
8-90	5505-5506	,	_	
8-91	5507-5511	such	_	
8-92	5512-5514	as	_	
8-93	5515-5526	hippocampus	_	
8-94	5526-5527	;	_	
8-95	5528-5536	previous	_	
8-96	5537-5544	studies	_	
8-97	5545-5554	suggested	_	
8-98	5555-5561	indeed	_	
8-99	5562-5566	that	_	
8-100	5567-5572	genes	_	
8-101	5573-5581	involved	_	
8-102	5582-5584	in	_	
8-103	5585-5588	the	_	
8-104	5589-5599	regulation	_	
8-105	5600-5602	of	_	
8-106	5603-5607	cell	_	
8-107	5608-5613	cycle	_	
8-108	5614-5617	and	_	
8-109	5618-5621	DNA	_	
8-110	5622-5628	repair	_	
8-111	5629-5642	significantly	_	
8-112	5643-5652	influence	_	
8-113	5653-5656	the	_	
8-114	5657-5668	hippocampus	_	
8-115	5669-5677	function	_	
8-116	5678-5680	in	_	
8-117	5681-5694	schizophrenia	_	
8-118	5694-5695	.	_	
8-119	5696-5703	However	_	
8-120	5703-5704	,	_	
8-121	5705-5708	how	_	
8-122	5709-5712	the	_	
8-123	5713-5723	expression	_	
8-124	5724-5731	profile	_	
8-125	5732-5734	of	_	
8-126	5735-5740	these	_	
8-127	5741-5746	genes	_	
8-128	5747-5749	in	_	
8-129	5750-5754	cell	_	
8-130	5755-5760	cycle	_	
8-131	5761-5764	and	_	
8-132	5765-5768	DNA	_	
8-133	5769-5775	repair	_	
8-134	5776-5784	pathways	_	
8-135	5785-5788	map	_	
8-136	5789-5798	spatially	_	
8-137	5799-5802	and	_	
8-138	5803-5813	temporally	_	
8-139	5814-5820	during	_	
8-140	5821-5824	the	_	
8-141	5825-5833	critical	_	
8-142	5834-5852	neurodevelopmental	_	
8-143	5853-5858	stage	_	
8-144	5859-5861	in	_	
8-145	5862-5874	specifically	_	
8-146	5875-5878	the	_	
8-147	5879-5890	hippocampus	_	
8-148	5891-5893	in	_	
8-149	5894-5907	schizophrenia	_	
8-150	5908-5915	remains	_	
8-151	5916-5923	unclear	_	
8-152	5923-5924	.	_	
8-153	5925-5927	We	_	
8-154	5928-5937	therefore	_	
8-155	5938-5950	hypothesized	_	
8-156	5951-5955	that	_	
8-157	5956-5958	we	_	
8-158	5959-5964	could	_	
8-159	5965-5976	distinguish	_	
8-160	5977-5980	two	_	
8-161	5981-5988	genetic	_	
8-162	5989-5997	subtypes	_	
8-163	5998-6000	in	_	
8-164	6001-6014	schizophrenia	_	
8-165	6014-6015	,	_	
8-166	6016-6019	one	_	
8-167	6020-6024	with	_	
8-168	6025-6029	RDVs	_	
8-169	6030-6033	and	_	
8-170	6034-6037	one	_	
8-171	6038-6045	without	_	
8-172	6046-6050	RDVs	_	
8-173	6050-6051	,	_	
8-174	6052-6054	as	_	
8-175	6055-6062	related	_	
8-176	6063-6065	to	_	
8-177	6066-6077	hippocampal	_	
8-178	6078-6091	developmental	_	
8-179	6092-6100	function	_	
8-180	6100-6101	.	_	

#Text=On the basis of these considerations, the second specific aim consisted of measuring especially rsFC (as controlled for by structural volume) of the hippocampus in the same patients using brain magnetic resonance imaging (MRI), and to explore the relationship among genes, rsFC of the hippocampus and related neurocognitive functions. We hypothesized different hippocampal rsFC patterns in those schizophrenic patients with RDVs when compared with the ones without RDVs. To further underline hippocampal involvement, we included cognitive measures like spatial and logical memory that have been shown to be associated with specifically hippocampal function. We hypothesized that schizophrenic patients with RDVs may have different memory-related cognitive functions relative to schizophrenic patients without RDVs.
9-1	6102-6104	On	_	
9-2	6105-6108	the	_	
9-3	6109-6114	basis	_	
9-4	6115-6117	of	_	
9-5	6118-6123	these	_	
9-6	6124-6138	considerations	_	
9-7	6138-6139	,	_	
9-8	6140-6143	the	_	
9-9	6144-6150	second	_	
9-10	6151-6159	specific	_	
9-11	6160-6163	aim	_	
9-12	6164-6173	consisted	_	
9-13	6174-6176	of	_	
9-14	6177-6186	measuring	_	
9-15	6187-6197	especially	_	
9-16	6198-6202	rsFC	_	
9-17	6203-6204	(	_	
9-18	6204-6206	as	_	
9-19	6207-6217	controlled	_	
9-20	6218-6221	for	_	
9-21	6222-6224	by	_	
9-22	6225-6235	structural	_	
9-23	6236-6242	volume	_	
9-24	6242-6243	)	_	
9-25	6244-6246	of	_	
9-26	6247-6250	the	_	
9-27	6251-6262	hippocampus	_	
9-28	6263-6265	in	_	
9-29	6266-6269	the	_	
9-30	6270-6274	same	_	
9-31	6275-6283	patients	_	
9-32	6284-6289	using	_	
9-33	6290-6295	brain	_	
9-34	6296-6304	magnetic	_	
9-35	6305-6314	resonance	_	
9-36	6315-6322	imaging	_	
9-37	6323-6324	(	_	
9-38	6324-6327	MRI	_	
9-39	6327-6328	)	_	
9-40	6328-6329	,	_	
9-41	6330-6333	and	_	
9-42	6334-6336	to	_	
9-43	6337-6344	explore	_	
9-44	6345-6348	the	_	
9-45	6349-6361	relationship	_	
9-46	6362-6367	among	_	
9-47	6368-6373	genes	_	
9-48	6373-6374	,	_	
9-49	6375-6379	rsFC	_	
9-50	6380-6382	of	_	
9-51	6383-6386	the	_	
9-52	6387-6398	hippocampus	_	
9-53	6399-6402	and	_	
9-54	6403-6410	related	_	
9-55	6411-6425	neurocognitive	_	
9-56	6426-6435	functions	_	
9-57	6435-6436	.	_	
9-58	6437-6439	We	_	
9-59	6440-6452	hypothesized	_	
9-60	6453-6462	different	_	
9-61	6463-6474	hippocampal	_	
9-62	6475-6479	rsFC	_	
9-63	6480-6488	patterns	_	
9-64	6489-6491	in	_	
9-65	6492-6497	those	_	
9-66	6498-6511	schizophrenic	_	
9-67	6512-6520	patients	_	
9-68	6521-6525	with	_	
9-69	6526-6530	RDVs	_	
9-70	6531-6535	when	_	
9-71	6536-6544	compared	_	
9-72	6545-6549	with	_	
9-73	6550-6553	the	_	
9-74	6554-6558	ones	_	
9-75	6559-6566	without	_	
9-76	6567-6571	RDVs	_	
9-77	6571-6572	.	_	
9-78	6573-6575	To	_	
9-79	6576-6583	further	_	
9-80	6584-6593	underline	_	
9-81	6594-6605	hippocampal	_	
9-82	6606-6617	involvement	_	
9-83	6617-6618	,	_	
9-84	6619-6621	we	_	
9-85	6622-6630	included	_	
9-86	6631-6640	cognitive	_	
9-87	6641-6649	measures	_	
9-88	6650-6654	like	_	
9-89	6655-6662	spatial	_	
9-90	6663-6666	and	_	
9-91	6667-6674	logical	_	
9-92	6675-6681	memory	_	
9-93	6682-6686	that	_	
9-94	6687-6691	have	_	
9-95	6692-6696	been	_	
9-96	6697-6702	shown	_	
9-97	6703-6705	to	_	
9-98	6706-6708	be	_	
9-99	6709-6719	associated	_	
9-100	6720-6724	with	_	
9-101	6725-6737	specifically	_	
9-102	6738-6749	hippocampal	_	
9-103	6750-6758	function	_	
9-104	6758-6759	.	_	
9-105	6760-6762	We	_	
9-106	6763-6775	hypothesized	_	
9-107	6776-6780	that	_	
9-108	6781-6794	schizophrenic	_	
9-109	6795-6803	patients	_	
9-110	6804-6808	with	_	
9-111	6809-6813	RDVs	_	
9-112	6814-6817	may	_	
9-113	6818-6822	have	_	
9-114	6823-6832	different	_	
9-115	6833-6847	memory-related	_	
9-116	6848-6857	cognitive	_	
9-117	6858-6867	functions	_	
9-118	6868-6876	relative	_	
9-119	6877-6879	to	_	
9-120	6880-6893	schizophrenic	_	
9-121	6894-6902	patients	_	
9-122	6903-6910	without	_	
9-123	6911-6915	RDVs	_	
9-124	6915-6916	.	_	

#Text=There are several unique advantages in the present study. First, this is the first investigation, to our knowledge, to study the contribution of RDVs to the imaging and neurocognitive phenotype of schizophrenia. Second, we recruited first-episode treatment-naive patients with schizophrenia to rule out the confounding factors of chronicity of the illness and treatment effects on neuroimaging and neurocognitive assessments. Third, extending limits on the power to identifying specific loci responsible for the disorder, we improve the definition of the phenotype and/or reducing the phenotypic complexity of schizophrenia for genetic studies by combining the latter with cognitive (for example, neuropsychological) and neural (for example, neuroimaging measures) that are more closely related to the phenotype.
10-1	6917-6922	There	_	
10-2	6923-6926	are	_	
10-3	6927-6934	several	_	
10-4	6935-6941	unique	_	
10-5	6942-6952	advantages	_	
10-6	6953-6955	in	_	
10-7	6956-6959	the	_	
10-8	6960-6967	present	_	
10-9	6968-6973	study	_	
10-10	6973-6974	.	_	
10-11	6975-6980	First	_	
10-12	6980-6981	,	_	
10-13	6982-6986	this	_	
10-14	6987-6989	is	_	
10-15	6990-6993	the	_	
10-16	6994-6999	first	_	
10-17	7000-7013	investigation	_	
10-18	7013-7014	,	_	
10-19	7015-7017	to	_	
10-20	7018-7021	our	_	
10-21	7022-7031	knowledge	_	
10-22	7031-7032	,	_	
10-23	7033-7035	to	_	
10-24	7036-7041	study	_	
10-25	7042-7045	the	_	
10-26	7046-7058	contribution	_	
10-27	7059-7061	of	_	
10-28	7062-7066	RDVs	_	
10-29	7067-7069	to	_	
10-30	7070-7073	the	_	
10-31	7074-7081	imaging	_	
10-32	7082-7085	and	_	
10-33	7086-7100	neurocognitive	_	
10-34	7101-7110	phenotype	_	
10-35	7111-7113	of	_	
10-36	7114-7127	schizophrenia	_	
10-37	7127-7128	.	_	
10-38	7129-7135	Second	_	
10-39	7135-7136	,	_	
10-40	7137-7139	we	_	
10-41	7140-7149	recruited	_	
10-42	7150-7163	first-episode	_	
10-43	7164-7179	treatment-naive	_	
10-44	7180-7188	patients	_	
10-45	7189-7193	with	_	
10-46	7194-7207	schizophrenia	_	
10-47	7208-7210	to	_	
10-48	7211-7215	rule	_	
10-49	7216-7219	out	_	
10-50	7220-7223	the	_	
10-51	7224-7235	confounding	_	
10-52	7236-7243	factors	_	
10-53	7244-7246	of	_	
10-54	7247-7257	chronicity	_	
10-55	7258-7260	of	_	
10-56	7261-7264	the	_	
10-57	7265-7272	illness	_	
10-58	7273-7276	and	_	
10-59	7277-7286	treatment	_	
10-60	7287-7294	effects	_	
10-61	7295-7297	on	_	
10-62	7298-7310	neuroimaging	_	
10-63	7311-7314	and	_	
10-64	7315-7329	neurocognitive	_	
10-65	7330-7341	assessments	_	
10-66	7341-7342	.	_	
10-67	7343-7348	Third	_	
10-68	7348-7349	,	_	
10-69	7350-7359	extending	_	
10-70	7360-7366	limits	_	
10-71	7367-7369	on	_	
10-72	7370-7373	the	_	
10-73	7374-7379	power	_	
10-74	7380-7382	to	_	
10-75	7383-7394	identifying	_	
10-76	7395-7403	specific	_	
10-77	7404-7408	loci	_	
10-78	7409-7420	responsible	_	
10-79	7421-7424	for	_	
10-80	7425-7428	the	_	
10-81	7429-7437	disorder	_	
10-82	7437-7438	,	_	
10-83	7439-7441	we	_	
10-84	7442-7449	improve	_	
10-85	7450-7453	the	_	
10-86	7454-7464	definition	_	
10-87	7465-7467	of	_	
10-88	7468-7471	the	_	
10-89	7472-7481	phenotype	_	
10-90	7482-7485	and	_	
10-91	7485-7486	/	_	
10-92	7486-7488	or	_	
10-93	7489-7497	reducing	_	
10-94	7498-7501	the	_	
10-95	7502-7512	phenotypic	_	
10-96	7513-7523	complexity	_	
10-97	7524-7526	of	_	
10-98	7527-7540	schizophrenia	_	
10-99	7541-7544	for	_	
10-100	7545-7552	genetic	_	
10-101	7553-7560	studies	_	
10-102	7561-7563	by	_	
10-103	7564-7573	combining	_	
10-104	7574-7577	the	_	
10-105	7578-7584	latter	_	
10-106	7585-7589	with	_	
10-107	7590-7599	cognitive	_	
10-108	7600-7601	(	_	
10-109	7601-7604	for	_	
10-110	7605-7612	example	_	
10-111	7612-7613	,	_	
10-112	7614-7632	neuropsychological	_	
10-113	7632-7633	)	_	
10-114	7634-7637	and	_	
10-115	7638-7644	neural	_	
10-116	7645-7646	(	_	
10-117	7646-7649	for	_	
10-118	7650-7657	example	_	
10-119	7657-7658	,	_	
10-120	7659-7671	neuroimaging	_	
10-121	7672-7680	measures	_	
10-122	7680-7681	)	_	
10-123	7682-7686	that	_	
10-124	7687-7690	are	_	
10-125	7691-7695	more	_	
10-126	7696-7703	closely	_	
10-127	7704-7711	related	_	
10-128	7712-7714	to	_	
10-129	7715-7718	the	_	
10-130	7719-7728	phenotype	_	
10-131	7728-7729	.	_	

#Text=Materials and methods
11-1	7730-7739	Materials	_	
11-2	7740-7743	and	_	
11-3	7744-7751	methods	_	

#Text=Samples
12-1	7752-7759	Samples	_	

#Text=There were total 234 participants including 97 first-episode treatment-naive patients with schizophrenia and 137 healthy controls. Patients with schizophrenia were recruited at the Mental Health Centre of the West China Hospital, Sichuan University, China. Healthy volunteers were recruited from the community. The study was approved by the ethical committee in West China Hospital of Sichuan University. All participants were Han Chinese and provided written informed consent for their participation in this study.
13-1	7760-7765	There	_	
13-2	7766-7770	were	_	
13-3	7771-7776	total	_	
13-4	7777-7780	234	_	
13-5	7781-7793	participants	_	
13-6	7794-7803	including	_	
13-7	7804-7806	97	_	
13-8	7807-7820	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
13-9	7821-7836	treatment-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
13-10	7837-7845	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[1]	
13-11	7846-7850	with	_	
13-12	7851-7864	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
13-13	7865-7868	and	_	
13-14	7869-7872	137	_	
13-15	7873-7880	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
13-16	7881-7889	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
13-17	7889-7890	.	_	
13-18	7891-7899	Patients	_	
13-19	7900-7904	with	_	
13-20	7905-7918	schizophrenia	_	
13-21	7919-7923	were	_	
13-22	7924-7933	recruited	_	
13-23	7934-7936	at	_	
13-24	7937-7940	the	_	
13-25	7941-7947	Mental	_	
13-26	7948-7954	Health	_	
13-27	7955-7961	Centre	_	
13-28	7962-7964	of	_	
13-29	7965-7968	the	_	
13-30	7969-7973	West	_	
13-31	7974-7979	China	_	
13-32	7980-7988	Hospital	_	
13-33	7988-7989	,	_	
13-34	7990-7997	Sichuan	_	
13-35	7998-8008	University	_	
13-36	8008-8009	,	_	
13-37	8010-8015	China	_	
13-38	8015-8016	.	_	
13-39	8017-8024	Healthy	_	
13-40	8025-8035	volunteers	_	
13-41	8036-8040	were	_	
13-42	8041-8050	recruited	_	
13-43	8051-8055	from	_	
13-44	8056-8059	the	_	
13-45	8060-8069	community	_	
13-46	8069-8070	.	_	
13-47	8071-8074	The	_	
13-48	8075-8080	study	_	
13-49	8081-8084	was	_	
13-50	8085-8093	approved	_	
13-51	8094-8096	by	_	
13-52	8097-8100	the	_	
13-53	8101-8108	ethical	_	
13-54	8109-8118	committee	_	
13-55	8119-8121	in	_	
13-56	8122-8126	West	_	
13-57	8127-8132	China	_	
13-58	8133-8141	Hospital	_	
13-59	8142-8144	of	_	
13-60	8145-8152	Sichuan	_	
13-61	8153-8163	University	_	
13-62	8163-8164	.	_	
13-63	8165-8168	All	_	
13-64	8169-8181	participants	_	
13-65	8182-8186	were	_	
13-66	8187-8190	Han	_	
13-67	8191-8198	Chinese	_	
13-68	8199-8202	and	_	
13-69	8203-8211	provided	_	
13-70	8212-8219	written	_	
13-71	8220-8228	informed	_	
13-72	8229-8236	consent	_	
13-73	8237-8240	for	_	
13-74	8241-8246	their	_	
13-75	8247-8260	participation	_	
13-76	8261-8263	in	_	
13-77	8264-8268	this	_	
13-78	8269-8274	study	_	
13-79	8274-8275	.	_	

#Text=Clinical and memory assessments
14-1	8276-8284	Clinical	_	
14-2	8285-8288	and	_	
14-3	8289-8295	memory	_	
14-4	8296-8307	assessments	_	

#Text=All patients were interviewed by a trained psychiatrist using the Structured Clinical Interview for the DSM-IV (SCID). DSM-IV criteria for schizophrenia were used for diagnosis. Those who were initially diagnosed with schizophrenia from psychosis due to the illness duration (less than 6 months) were followed up for at least 6 months to meet the DSM-IV criteria for schizophrenia. Psychopathology associated with schizophrenia was evaluated using the positive and negative syndrome scale. Healthy controls were screened with the SCID-P non-patient version for the lifetime absence of psychiatric illnesses. Subjects with the existence of organic brain disorders, alcohol or drug abuse, pregnancy or any severe physical illness, such as brain tumor or epilepsy, were excluded from the study.
15-1	8308-8311	All	_	
15-2	8312-8320	patients	_	
15-3	8321-8325	were	_	
15-4	8326-8337	interviewed	_	
15-5	8338-8340	by	_	
15-6	8341-8342	a	_	
15-7	8343-8350	trained	_	
15-8	8351-8363	psychiatrist	_	
15-9	8364-8369	using	_	
15-10	8370-8373	the	_	
15-11	8374-8384	Structured	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-12	8385-8393	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-13	8394-8403	Interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-14	8404-8407	for	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-15	8408-8411	the	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-16	8412-8418	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-17	8419-8420	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-18	8420-8424	SCID	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-19	8424-8425	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[3]	
15-20	8425-8426	.	_	
15-21	8427-8433	DSM-IV	_	
15-22	8434-8442	criteria	_	
15-23	8443-8446	for	_	
15-24	8447-8460	schizophrenia	_	
15-25	8461-8465	were	_	
15-26	8466-8470	used	_	
15-27	8471-8474	for	_	
15-28	8475-8484	diagnosis	_	
15-29	8484-8485	.	_	
15-30	8486-8491	Those	_	
15-31	8492-8495	who	_	
15-32	8496-8500	were	_	
15-33	8501-8510	initially	_	
15-34	8511-8520	diagnosed	_	
15-35	8521-8525	with	_	
15-36	8526-8539	schizophrenia	_	
15-37	8540-8544	from	_	
15-38	8545-8554	psychosis	_	
15-39	8555-8558	due	_	
15-40	8559-8561	to	_	
15-41	8562-8565	the	_	
15-42	8566-8573	illness	_	
15-43	8574-8582	duration	_	
15-44	8583-8584	(	_	
15-45	8584-8588	less	_	
15-46	8589-8593	than	_	
15-47	8594-8595	6	_	
15-48	8596-8602	months	_	
15-49	8602-8603	)	_	
15-50	8604-8608	were	_	
15-51	8609-8617	followed	_	
15-52	8618-8620	up	_	
15-53	8621-8624	for	_	
15-54	8625-8627	at	_	
15-55	8628-8633	least	_	
15-56	8634-8635	6	_	
15-57	8636-8642	months	_	
15-58	8643-8645	to	_	
15-59	8646-8650	meet	_	
15-60	8651-8654	the	_	
15-61	8655-8661	DSM-IV	_	
15-62	8662-8670	criteria	_	
15-63	8671-8674	for	_	
15-64	8675-8688	schizophrenia	_	
15-65	8688-8689	.	_	
15-66	8690-8705	Psychopathology	_	
15-67	8706-8716	associated	_	
15-68	8717-8721	with	_	
15-69	8722-8735	schizophrenia	_	
15-70	8736-8739	was	_	
15-71	8740-8749	evaluated	_	
15-72	8750-8755	using	_	
15-73	8756-8759	the	_	
15-74	8760-8768	positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[4]	
15-75	8769-8772	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[4]	
15-76	8773-8781	negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[4]	
15-77	8782-8790	syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[4]	
15-78	8791-8796	scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[4]	
15-79	8796-8797	.	_	
15-80	8798-8805	Healthy	_	
15-81	8806-8814	controls	_	
15-82	8815-8819	were	_	
15-83	8820-8828	screened	_	
15-84	8829-8833	with	_	
15-85	8834-8837	the	_	
15-86	8838-8844	SCID-P	_	
15-87	8845-8856	non-patient	_	
15-88	8857-8864	version	_	
15-89	8865-8868	for	_	
15-90	8869-8872	the	_	
15-91	8873-8881	lifetime	_	
15-92	8882-8889	absence	_	
15-93	8890-8892	of	_	
15-94	8893-8904	psychiatric	_	
15-95	8905-8914	illnesses	_	
15-96	8914-8915	.	_	
15-97	8916-8924	Subjects	_	
15-98	8925-8929	with	_	
15-99	8930-8933	the	_	
15-100	8934-8943	existence	_	
15-101	8944-8946	of	_	
15-102	8947-8954	organic	_	
15-103	8955-8960	brain	_	
15-104	8961-8970	disorders	_	
15-105	8970-8971	,	_	
15-106	8972-8979	alcohol	_	
15-107	8980-8982	or	_	
15-108	8983-8987	drug	_	
15-109	8988-8993	abuse	_	
15-110	8993-8994	,	_	
15-111	8995-9004	pregnancy	_	
15-112	9005-9007	or	_	
15-113	9008-9011	any	_	
15-114	9012-9018	severe	_	
15-115	9019-9027	physical	_	
15-116	9028-9035	illness	_	
15-117	9035-9036	,	_	
15-118	9037-9041	such	_	
15-119	9042-9044	as	_	
15-120	9045-9050	brain	_	
15-121	9051-9056	tumor	_	
15-122	9057-9059	or	_	
15-123	9060-9068	epilepsy	_	
15-124	9068-9069	,	_	
15-125	9070-9074	were	_	
15-126	9075-9083	excluded	_	
15-127	9084-9088	from	_	
15-128	9089-9092	the	_	
15-129	9093-9098	study	_	
15-130	9098-9099	.	_	

#Text=Schizophrenic patients and healthy controls completed SWM test in the Cambridge Neuropsychological Test Automated Battery (CANTAB; http://www.cantab.com) and immediate and delayed (30â€‰min) logical memory subtest of the Wechsler Memory Scale, respectively.
16-1	9100-9113	Schizophrenic	_	
16-2	9114-9122	patients	_	
16-3	9123-9126	and	_	
16-4	9127-9134	healthy	_	
16-5	9135-9143	controls	_	
16-6	9144-9153	completed	_	
16-7	9154-9157	SWM	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-8	9158-9162	test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-9	9163-9165	in	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-10	9166-9169	the	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-11	9170-9179	Cambridge	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-12	9180-9198	Neuropsychological	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-13	9199-9203	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-14	9204-9213	Automated	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-15	9214-9221	Battery	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[5]	
16-16	9222-9223	(	_	
16-17	9223-9229	CANTAB	_	
16-18	9229-9230	;	_	
16-19	9231-9235	http	_	
16-20	9235-9236	:	_	
16-21	9236-9237	/	_	
16-22	9237-9238	/	_	
16-23	9238-9252	www.cantab.com	_	
16-24	9252-9253	)	_	
16-25	9254-9257	and	_	
16-26	9258-9267	immediate	_	
16-27	9268-9271	and	_	
16-28	9272-9279	delayed	_	
16-29	9280-9281	(	_	
16-30	9281-9283	30	_	
16-31	9284-9287	min	_	
16-32	9287-9288	)	_	
16-33	9289-9296	logical	_	
16-34	9297-9303	memory	_	
16-35	9304-9311	subtest	_	
16-36	9312-9314	of	_	
16-37	9315-9318	the	_	
16-38	9319-9327	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[6]	
16-39	9328-9334	Memory	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[6]	
16-40	9335-9340	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[6]	
16-41	9340-9341	,	_	
16-42	9342-9354	respectively	_	
16-43	9354-9355	.	_	

#Text=MRI data acquisition
17-1	9356-9359	MRI	_	
17-2	9360-9364	data	_	
17-3	9365-9376	acquisition	_	

#Text=Overall, 74 healthy controls and 74 patients with schizophrenia underwent structural MRI scans on a Signa 3.0-T scanner (General Electric, Medical Systems, Milwaukee, WI, USA), whereas 65 healthy controls and 55 patients were scanned to obtain brain resting-state functional MRI in the Department of Radiology at West China Hospital. Detailed procedures of scanning are presented in Supplementary Information, sections 7 and 8.
18-1	9377-9384	Overall	_	
18-2	9384-9385	,	_	
18-3	9386-9388	74	_	
18-4	9389-9396	healthy	_	
18-5	9397-9405	controls	_	
18-6	9406-9409	and	_	
18-7	9410-9412	74	_	
18-8	9413-9421	patients	_	
18-9	9422-9426	with	_	
18-10	9427-9440	schizophrenia	_	
18-11	9441-9450	underwent	_	
18-12	9451-9461	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
18-13	9462-9465	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
18-14	9466-9471	scans	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[7]	
18-15	9472-9474	on	_	
18-16	9475-9476	a	_	
18-17	9477-9482	Signa	_	
18-18	9483-9486	3.0	_	
18-19	9486-9487	-	_	
18-20	9487-9488	T	_	
18-21	9489-9496	scanner	_	
18-22	9497-9498	(	_	
18-23	9498-9505	General	_	
18-24	9506-9514	Electric	_	
18-25	9514-9515	,	_	
18-26	9516-9523	Medical	_	
18-27	9524-9531	Systems	_	
18-28	9531-9532	,	_	
18-29	9533-9542	Milwaukee	_	
18-30	9542-9543	,	_	
18-31	9544-9546	WI	_	
18-32	9546-9547	,	_	
18-33	9548-9551	USA	_	
18-34	9551-9552	)	_	
18-35	9552-9553	,	_	
18-36	9554-9561	whereas	_	
18-37	9562-9564	65	_	
18-38	9565-9572	healthy	_	
18-39	9573-9581	controls	_	
18-40	9582-9585	and	_	
18-41	9586-9588	55	_	
18-42	9589-9597	patients	_	
18-43	9598-9602	were	_	
18-44	9603-9610	scanned	_	
18-45	9611-9613	to	_	
18-46	9614-9620	obtain	_	
18-47	9621-9626	brain	_	
18-48	9627-9640	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
18-49	9641-9651	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
18-50	9652-9655	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]	
18-51	9656-9658	in	_	
18-52	9659-9662	the	_	
18-53	9663-9673	Department	_	
18-54	9674-9676	of	_	
18-55	9677-9686	Radiology	_	
18-56	9687-9689	at	_	
18-57	9690-9694	West	_	
18-58	9695-9700	China	_	
18-59	9701-9709	Hospital	_	
18-60	9709-9710	.	_	
18-61	9711-9719	Detailed	_	
18-62	9720-9730	procedures	_	
18-63	9731-9733	of	_	
18-64	9734-9742	scanning	_	
18-65	9743-9746	are	_	
18-66	9747-9756	presented	_	
18-67	9757-9759	in	_	
18-68	9760-9773	Supplementary	_	
18-69	9774-9785	Information	_	
18-70	9785-9786	,	_	
18-71	9787-9795	sections	_	
18-72	9796-9797	7	_	
18-73	9798-9801	and	_	
18-74	9802-9803	8	_	
18-75	9803-9804	.	_	

#Text=Sequencing and variant calling
19-1	9805-9815	Sequencing	_	
19-2	9816-9819	and	_	
19-3	9820-9827	variant	_	
19-4	9828-9835	calling	_	

#Text=All samples were sequenced using the TruSeq Exome Enrichment Kit (San Diego, CA, USA) optimized for IlluminaHiSeq2000 sequencing. The pipeline of raw data processing and variants calling is present in Supplementary Figure 2, which includes using Burrows-Wheeler Alignment tool alignment reads to the reference human genome (hg19); Picard tools (http://picard.sourceforge.net/) to collect quality statistics and fix read group problem; GATK for IN/DEL alignment; Samtools (http://samtools.sourceforge.net/) to filter out low-quality reads; and GATK to perform SNP and INDEL calling. Validation of selected variants was conducted by Sanger sequencing.
20-1	9836-9839	All	_	
20-2	9840-9847	samples	_	
20-3	9848-9852	were	_	
20-4	9853-9862	sequenced	_	
20-5	9863-9868	using	_	
20-6	9869-9872	the	_	
20-7	9873-9879	TruSeq	_	
20-8	9880-9885	Exome	_	
20-9	9886-9896	Enrichment	_	
20-10	9897-9900	Kit	_	
20-11	9901-9902	(	_	
20-12	9902-9905	San	_	
20-13	9906-9911	Diego	_	
20-14	9911-9912	,	_	
20-15	9913-9915	CA	_	
20-16	9915-9916	,	_	
20-17	9917-9920	USA	_	
20-18	9920-9921	)	_	
20-19	9922-9931	optimized	_	
20-20	9932-9935	for	_	
20-21	9936-9953	IlluminaHiSeq2000	_	
20-22	9954-9964	sequencing	_	
20-23	9964-9965	.	_	
20-24	9966-9969	The	_	
20-25	9970-9978	pipeline	_	
20-26	9979-9981	of	_	
20-27	9982-9985	raw	_	
20-28	9986-9990	data	_	
20-29	9991-10001	processing	_	
20-30	10002-10005	and	_	
20-31	10006-10014	variants	_	
20-32	10015-10022	calling	_	
20-33	10023-10025	is	_	
20-34	10026-10033	present	_	
20-35	10034-10036	in	_	
20-36	10037-10050	Supplementary	_	
20-37	10051-10057	Figure	_	
20-38	10058-10059	2	_	
20-39	10059-10060	,	_	
20-40	10061-10066	which	_	
20-41	10067-10075	includes	_	
20-42	10076-10081	using	_	
20-43	10082-10097	Burrows-Wheeler	_	
20-44	10098-10107	Alignment	_	
20-45	10108-10112	tool	_	
20-46	10113-10122	alignment	_	
20-47	10123-10128	reads	_	
20-48	10129-10131	to	_	
20-49	10132-10135	the	_	
20-50	10136-10145	reference	_	
20-51	10146-10151	human	_	
20-52	10152-10158	genome	_	
20-53	10159-10160	(	_	
20-54	10160-10164	hg19	_	
20-55	10164-10165	)	_	
20-56	10165-10166	;	_	
20-57	10167-10173	Picard	_	
20-58	10174-10179	tools	_	
20-59	10180-10181	(	_	
20-60	10181-10185	http	_	
20-61	10185-10186	:	_	
20-62	10186-10187	/	_	
20-63	10187-10188	/	_	
20-64	10188-10210	picard.sourceforge.net	_	
20-65	10210-10211	/	_	
20-66	10211-10212	)	_	
20-67	10213-10215	to	_	
20-68	10216-10223	collect	_	
20-69	10224-10231	quality	_	
20-70	10232-10242	statistics	_	
20-71	10243-10246	and	_	
20-72	10247-10250	fix	_	
20-73	10251-10255	read	_	
20-74	10256-10261	group	_	
20-75	10262-10269	problem	_	
20-76	10269-10270	;	_	
20-77	10271-10275	GATK	_	
20-78	10276-10279	for	_	
20-79	10280-10282	IN	_	
20-80	10282-10283	/	_	
20-81	10283-10286	DEL	_	
20-82	10287-10296	alignment	_	
20-83	10296-10297	;	_	
20-84	10298-10306	Samtools	_	
20-85	10307-10308	(	_	
20-86	10308-10312	http	_	
20-87	10312-10313	:	_	
20-88	10313-10314	/	_	
20-89	10314-10315	/	_	
20-90	10315-10339	samtools.sourceforge.net	_	
20-91	10339-10340	/	_	
20-92	10340-10341	)	_	
20-93	10342-10344	to	_	
20-94	10345-10351	filter	_	
20-95	10352-10355	out	_	
20-96	10356-10367	low-quality	_	
20-97	10368-10373	reads	_	
20-98	10373-10374	;	_	
20-99	10375-10378	and	_	
20-100	10379-10383	GATK	_	
20-101	10384-10386	to	_	
20-102	10387-10394	perform	_	
20-103	10395-10398	SNP	_	
20-104	10399-10402	and	_	
20-105	10403-10408	INDEL	_	
20-106	10409-10416	calling	_	
20-107	10416-10417	.	_	
20-108	10418-10428	Validation	_	
20-109	10429-10431	of	_	
20-110	10432-10440	selected	_	
20-111	10441-10449	variants	_	
20-112	10450-10453	was	_	
20-113	10454-10463	conducted	_	
20-114	10464-10466	by	_	
20-115	10467-10473	Sanger	_	
20-116	10474-10484	sequencing	_	
20-117	10484-10485	.	_	

#Text=Data analysis
21-1	10486-10490	Data	_	
21-2	10491-10499	analysis	_	

#Text=We use PLINK and KGGSeq (http://statgenpro.psychiatry.hku.hk/limx/kggseq/doc/UserManual.html) to perform individual and variants' quality control. We use software KGGSeq to integrate databases to annotate the minor allele frequency of variants, including Hapmap and 1000 Genome. The cutoff frequency was set at 0.1% for rare variance. Methods implemented in PLINK/Seq (http://atgu.mgh.harvard.edu/plinkseq/) were employed for single site and gene-based association analysis. After filtering, we performed GO enrichment analysis in 2895 mutations within 2442 genes in cases and 4484 mutations within 3481 genes in controls using GeneMANIA (http://www.genemania.org/).The results of enrichment indicated that two GO (GO: 0006281 and GO:0007049) only present in cases. We identified more mutations in controls (that is, 2895 mutations within 2442 genes in schizophrenic patients and 4484 mutations within 3481 genes in healthy controls) mainly because, in present study, the sample size in controls (134) is bigger than cases (94). The bigger sample size in controls provides the higher chance to identify mutations. The weighted gene coexpression network analysis (WGCNA) was used for expression profile, all of which was carried out by the WGCNA R package. All of Brain expression data from different points in life were acquired from a published study (The Human Brain Transcriptome). Sample size and statistical power were conducted by the statistical software, Exome Power Calculation (http://darth.ssg.uab.edu:8080/epc/).
22-1	10500-10502	We	_	
22-2	10503-10506	use	_	
22-3	10507-10512	PLINK	_	
22-4	10513-10516	and	_	
22-5	10517-10523	KGGSeq	_	
22-6	10524-10525	(	_	
22-7	10525-10529	http	_	
22-8	10529-10530	:	_	
22-9	10530-10531	/	_	
22-10	10531-10532	/	_	
22-11	10532-10560	statgenpro.psychiatry.hku.hk	_	
22-12	10560-10561	/	_	
22-13	10561-10565	limx	_	
22-14	10565-10566	/	_	
22-15	10566-10572	kggseq	_	
22-16	10572-10573	/	_	
22-17	10573-10576	doc	_	
22-18	10576-10577	/	_	
22-19	10577-10592	UserManual.html	_	
22-20	10592-10593	)	_	
22-21	10594-10596	to	_	
22-22	10597-10604	perform	_	
22-23	10605-10615	individual	_	
22-24	10616-10619	and	_	
22-25	10620-10628	variants	_	
22-26	10628-10629	'	_	
22-27	10630-10637	quality	_	
22-28	10638-10645	control	_	
22-29	10645-10646	.	_	
22-30	10647-10649	We	_	
22-31	10650-10653	use	_	
22-32	10654-10662	software	_	
22-33	10663-10669	KGGSeq	_	
22-34	10670-10672	to	_	
22-35	10673-10682	integrate	_	
22-36	10683-10692	databases	_	
22-37	10693-10695	to	_	
22-38	10696-10704	annotate	_	
22-39	10705-10708	the	_	
22-40	10709-10714	minor	_	
22-41	10715-10721	allele	_	
22-42	10722-10731	frequency	_	
22-43	10732-10734	of	_	
22-44	10735-10743	variants	_	
22-45	10743-10744	,	_	
22-46	10745-10754	including	_	
22-47	10755-10761	Hapmap	_	
22-48	10762-10765	and	_	
22-49	10766-10770	1000	_	
22-50	10771-10777	Genome	_	
22-51	10777-10778	.	_	
22-52	10779-10782	The	_	
22-53	10783-10789	cutoff	_	
22-54	10790-10799	frequency	_	
22-55	10800-10803	was	_	
22-56	10804-10807	set	_	
22-57	10808-10810	at	_	
22-58	10811-10815	0.1%	_	
22-59	10816-10819	for	_	
22-60	10820-10824	rare	_	
22-61	10825-10833	variance	_	
22-62	10833-10834	.	_	
22-63	10835-10842	Methods	_	
22-64	10843-10854	implemented	_	
22-65	10855-10857	in	_	
22-66	10858-10863	PLINK	_	
22-67	10863-10864	/	_	
22-68	10864-10867	Seq	_	
22-69	10868-10869	(	_	
22-70	10869-10873	http	_	
22-71	10873-10874	:	_	
22-72	10874-10875	/	_	
22-73	10875-10876	/	_	
22-74	10876-10896	atgu.mgh.harvard.edu	_	
22-75	10896-10897	/	_	
22-76	10897-10905	plinkseq	_	
22-77	10905-10906	/	_	
22-78	10906-10907	)	_	
22-79	10908-10912	were	_	
22-80	10913-10921	employed	_	
22-81	10922-10925	for	_	
22-82	10926-10932	single	_	
22-83	10933-10937	site	_	
22-84	10938-10941	and	_	
22-85	10942-10952	gene-based	_	
22-86	10953-10964	association	_	
22-87	10965-10973	analysis	_	
22-88	10973-10974	.	_	
22-89	10975-10980	After	_	
22-90	10981-10990	filtering	_	
22-91	10990-10991	,	_	
22-92	10992-10994	we	_	
22-93	10995-11004	performed	_	
22-94	11005-11007	GO	_	
22-95	11008-11018	enrichment	_	
22-96	11019-11027	analysis	_	
22-97	11028-11030	in	_	
22-98	11031-11035	2895	_	
22-99	11036-11045	mutations	_	
22-100	11046-11052	within	_	
22-101	11053-11057	2442	_	
22-102	11058-11063	genes	_	
22-103	11064-11066	in	_	
22-104	11067-11072	cases	_	
22-105	11073-11076	and	_	
22-106	11077-11081	4484	_	
22-107	11082-11091	mutations	_	
22-108	11092-11098	within	_	
22-109	11099-11103	3481	_	
22-110	11104-11109	genes	_	
22-111	11110-11112	in	_	
22-112	11113-11121	controls	_	
22-113	11122-11127	using	_	
22-114	11128-11137	GeneMANIA	_	
22-115	11138-11139	(	_	
22-116	11139-11143	http	_	
22-117	11143-11144	:	_	
22-118	11144-11145	/	_	
22-119	11145-11146	/	_	
22-120	11146-11163	www.genemania.org	_	
22-121	11163-11164	/	_	
22-122	11164-11165	)	_	
22-123	11165-11166	.	_	
22-124	11166-11169	The	_	
22-125	11170-11177	results	_	
22-126	11178-11180	of	_	
22-127	11181-11191	enrichment	_	
22-128	11192-11201	indicated	_	
22-129	11202-11206	that	_	
22-130	11207-11210	two	_	
22-131	11211-11213	GO	_	
22-132	11214-11215	(	_	
22-133	11215-11217	GO	_	
22-134	11217-11218	:	_	
22-135	11219-11226	0006281	_	
22-136	11227-11230	and	_	
22-137	11231-11233	GO	_	
22-138	11233-11234	:	_	
22-139	11234-11241	0007049	_	
22-140	11241-11242	)	_	
22-141	11243-11247	only	_	
22-142	11248-11255	present	_	
22-143	11256-11258	in	_	
22-144	11259-11264	cases	_	
22-145	11264-11265	.	_	
22-146	11266-11268	We	_	
22-147	11269-11279	identified	_	
22-148	11280-11284	more	_	
22-149	11285-11294	mutations	_	
22-150	11295-11297	in	_	
22-151	11298-11306	controls	_	
22-152	11307-11308	(	_	
22-153	11308-11312	that	_	
22-154	11313-11315	is	_	
22-155	11315-11316	,	_	
22-156	11317-11321	2895	_	
22-157	11322-11331	mutations	_	
22-158	11332-11338	within	_	
22-159	11339-11343	2442	_	
22-160	11344-11349	genes	_	
22-161	11350-11352	in	_	
22-162	11353-11366	schizophrenic	_	
22-163	11367-11375	patients	_	
22-164	11376-11379	and	_	
22-165	11380-11384	4484	_	
22-166	11385-11394	mutations	_	
22-167	11395-11401	within	_	
22-168	11402-11406	3481	_	
22-169	11407-11412	genes	_	
22-170	11413-11415	in	_	
22-171	11416-11423	healthy	_	
22-172	11424-11432	controls	_	
22-173	11432-11433	)	_	
22-174	11434-11440	mainly	_	
22-175	11441-11448	because	_	
22-176	11448-11449	,	_	
22-177	11450-11452	in	_	
22-178	11453-11460	present	_	
22-179	11461-11466	study	_	
22-180	11466-11467	,	_	
22-181	11468-11471	the	_	
22-182	11472-11478	sample	_	
22-183	11479-11483	size	_	
22-184	11484-11486	in	_	
22-185	11487-11495	controls	_	
22-186	11496-11497	(	_	
22-187	11497-11500	134	_	
22-188	11500-11501	)	_	
22-189	11502-11504	is	_	
22-190	11505-11511	bigger	_	
22-191	11512-11516	than	_	
22-192	11517-11522	cases	_	
22-193	11523-11524	(	_	
22-194	11524-11526	94	_	
22-195	11526-11527	)	_	
22-196	11527-11528	.	_	
22-197	11529-11532	The	_	
22-198	11533-11539	bigger	_	
22-199	11540-11546	sample	_	
22-200	11547-11551	size	_	
22-201	11552-11554	in	_	
22-202	11555-11563	controls	_	
22-203	11564-11572	provides	_	
22-204	11573-11576	the	_	
22-205	11577-11583	higher	_	
22-206	11584-11590	chance	_	
22-207	11591-11593	to	_	
22-208	11594-11602	identify	_	
22-209	11603-11612	mutations	_	
22-210	11612-11613	.	_	
22-211	11614-11617	The	_	
22-212	11618-11626	weighted	_	
22-213	11627-11631	gene	_	
22-214	11632-11644	coexpression	_	
22-215	11645-11652	network	_	
22-216	11653-11661	analysis	_	
22-217	11662-11663	(	_	
22-218	11663-11668	WGCNA	_	
22-219	11668-11669	)	_	
22-220	11670-11673	was	_	
22-221	11674-11678	used	_	
22-222	11679-11682	for	_	
22-223	11683-11693	expression	_	
22-224	11694-11701	profile	_	
22-225	11701-11702	,	_	
22-226	11703-11706	all	_	
22-227	11707-11709	of	_	
22-228	11710-11715	which	_	
22-229	11716-11719	was	_	
22-230	11720-11727	carried	_	
22-231	11728-11731	out	_	
22-232	11732-11734	by	_	
22-233	11735-11738	the	_	
22-234	11739-11744	WGCNA	_	
22-235	11745-11746	R	_	
22-236	11747-11754	package	_	
22-237	11754-11755	.	_	
22-238	11756-11759	All	_	
22-239	11760-11762	of	_	
22-240	11763-11768	Brain	_	
22-241	11769-11779	expression	_	
22-242	11780-11784	data	_	
22-243	11785-11789	from	_	
22-244	11790-11799	different	_	
22-245	11800-11806	points	_	
22-246	11807-11809	in	_	
22-247	11810-11814	life	_	
22-248	11815-11819	were	_	
22-249	11820-11828	acquired	_	
22-250	11829-11833	from	_	
22-251	11834-11835	a	_	
22-252	11836-11845	published	_	
22-253	11846-11851	study	_	
22-254	11852-11853	(	_	
22-255	11853-11856	The	_	
22-256	11857-11862	Human	_	
22-257	11863-11868	Brain	_	
22-258	11869-11882	Transcriptome	_	
22-259	11882-11883	)	_	
22-260	11883-11884	.	_	
22-261	11885-11891	Sample	_	
22-262	11892-11896	size	_	
22-263	11897-11900	and	_	
22-264	11901-11912	statistical	_	
22-265	11913-11918	power	_	
22-266	11919-11923	were	_	
22-267	11924-11933	conducted	_	
22-268	11934-11936	by	_	
22-269	11937-11940	the	_	
22-270	11941-11952	statistical	_	
22-271	11953-11961	software	_	
22-272	11961-11962	,	_	
22-273	11963-11968	Exome	_	
22-274	11969-11974	Power	_	
22-275	11975-11986	Calculation	_	
22-276	11987-11988	(	_	
22-277	11988-11992	http	_	
22-278	11992-11993	:	_	
22-279	11993-11994	/	_	
22-280	11994-11995	/	_	
22-281	11995-12012	darth.ssg.uab.edu	_	
22-282	12012-12013	:	_	
22-283	12013-12017	8080	_	
22-284	12017-12018	/	_	
22-285	12018-12021	epc	_	
22-286	12021-12022	/	_	
22-287	12022-12023	)	_	
22-288	12023-12024	.	_	

#Text=rsFC of bilateral hippocampus and six hippocampal subregions was calculated by seed-to-voxel analysis using Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm) and data-processing assistant for resting-state functional MRI from resting-state functional MRI (Supplementary material). The time courses averaged over all voxels of each hippocampus and six hippocampal subregions were extracted. Pearson's correlation coefficients (r) between time courses of left/right hippocampus and all other voxels were calculated and transformed to Fisher's z-scores to derive rsFC maps. Thus, 67â€‰349 pairs of functional connectivity were calculated between right hippocampus and the other voxels of the brain, whereas 67â€‰370 pairs of functional connectivity were computed between left hippocampus and the other voxels of the brain. Statistical tests on the functional connectivity maps of hippocampus between patients with schizophrenia and healthy controls were performed using analysis of covariance with sex, age and education years, and volume of hippocampus as covariates in SPM8. The significant threshold was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations. Subsequently, the mean Z-value of each cluster with a significant functional connectivity (FC) difference was extracted and were compared by analysis of variance followed by post hoc test (least significant difference) in SPSS 18.0, across patients with RDVs, patients without RDVs and healthy controls (SPSS, Chicago, IL, USA), significant level of P values were set at less than 0.05. Analysis of covariance followed by post hoc test were applied to test the differences of functional connectivity and memory functions among patients with RDVs, patients without RDVs and healthy controls. Partial correlation analysis was used to analyze the relationship between the functional connectivities of bilateral hippocampus (and six hippocampal subregions) and cognitive, that is, memory functions, with age, sex and education years (and structural hippocampal volume) as covariance (Supplementary material). Furthermore, Fisher's Z-transformation was used to transform the correlation coefficients(r value) to Z-score, and Z-test was used for testing the differences of correlations between groups. Corrections for multiple comparisons were applied as appropriate.
23-1	12025-12029	rsFC	_	
23-2	12030-12032	of	_	
23-3	12033-12042	bilateral	_	
23-4	12043-12054	hippocampus	_	
23-5	12055-12058	and	_	
23-6	12059-12062	six	_	
23-7	12063-12074	hippocampal	_	
23-8	12075-12085	subregions	_	
23-9	12086-12089	was	_	
23-10	12090-12100	calculated	_	
23-11	12101-12103	by	_	
23-12	12104-12117	seed-to-voxel	_	
23-13	12118-12126	analysis	_	
23-14	12127-12132	using	_	
23-15	12133-12144	Statistical	_	
23-16	12145-12155	Parametric	_	
23-17	12156-12163	Mapping	_	
23-18	12164-12165	(	_	
23-19	12165-12169	SPM8	_	
23-20	12169-12170	,	_	
23-21	12171-12175	http	_	
23-22	12175-12176	:	_	
23-23	12176-12177	/	_	
23-24	12177-12178	/	_	
23-25	12178-12199	www.fil.ion.ucl.ac.uk	_	
23-26	12199-12200	/	_	
23-27	12200-12203	spm	_	
23-28	12203-12204	)	_	
23-29	12205-12208	and	_	
23-30	12209-12224	data-processing	_	
23-31	12225-12234	assistant	_	
23-32	12235-12238	for	_	
23-33	12239-12252	resting-state	_	
23-34	12253-12263	functional	_	
23-35	12264-12267	MRI	_	
23-36	12268-12272	from	_	
23-37	12273-12286	resting-state	_	
23-38	12287-12297	functional	_	
23-39	12298-12301	MRI	_	
23-40	12302-12303	(	_	
23-41	12303-12316	Supplementary	_	
23-42	12317-12325	material	_	
23-43	12325-12326	)	_	
23-44	12326-12327	.	_	
23-45	12328-12331	The	_	
23-46	12332-12336	time	_	
23-47	12337-12344	courses	_	
23-48	12345-12353	averaged	_	
23-49	12354-12358	over	_	
23-50	12359-12362	all	_	
23-51	12363-12369	voxels	_	
23-52	12370-12372	of	_	
23-53	12373-12377	each	_	
23-54	12378-12389	hippocampus	_	
23-55	12390-12393	and	_	
23-56	12394-12397	six	_	
23-57	12398-12409	hippocampal	_	
23-58	12410-12420	subregions	_	
23-59	12421-12425	were	_	
23-60	12426-12435	extracted	_	
23-61	12435-12436	.	_	
23-62	12437-12446	Pearson's	_	
23-63	12447-12458	correlation	_	
23-64	12459-12471	coefficients	_	
23-65	12472-12473	(	_	
23-66	12473-12474	r	_	
23-67	12474-12475	)	_	
23-68	12476-12483	between	_	
23-69	12484-12488	time	_	
23-70	12489-12496	courses	_	
23-71	12497-12499	of	_	
23-72	12500-12504	left	_	
23-73	12504-12505	/	_	
23-74	12505-12510	right	_	
23-75	12511-12522	hippocampus	_	
23-76	12523-12526	and	_	
23-77	12527-12530	all	_	
23-78	12531-12536	other	_	
23-79	12537-12543	voxels	_	
23-80	12544-12548	were	_	
23-81	12549-12559	calculated	_	
23-82	12560-12563	and	_	
23-83	12564-12575	transformed	_	
23-84	12576-12578	to	_	
23-85	12579-12587	Fisher's	_	
23-86	12588-12596	z-scores	_	
23-87	12597-12599	to	_	
23-88	12600-12606	derive	_	
23-89	12607-12611	rsFC	_	
23-90	12612-12616	maps	_	
23-91	12616-12617	.	_	
23-92	12618-12622	Thus	_	
23-93	12622-12623	,	_	
23-94	12624-12626	67	_	
23-95	12627-12630	349	_	
23-96	12631-12636	pairs	_	
23-97	12637-12639	of	_	
23-98	12640-12650	functional	_	
23-99	12651-12663	connectivity	_	
23-100	12664-12668	were	_	
23-101	12669-12679	calculated	_	
23-102	12680-12687	between	_	
23-103	12688-12693	right	_	
23-104	12694-12705	hippocampus	_	
23-105	12706-12709	and	_	
23-106	12710-12713	the	_	
23-107	12714-12719	other	_	
23-108	12720-12726	voxels	_	
23-109	12727-12729	of	_	
23-110	12730-12733	the	_	
23-111	12734-12739	brain	_	
23-112	12739-12740	,	_	
23-113	12741-12748	whereas	_	
23-114	12749-12751	67	_	
23-115	12752-12755	370	_	
23-116	12756-12761	pairs	_	
23-117	12762-12764	of	_	
23-118	12765-12775	functional	_	
23-119	12776-12788	connectivity	_	
23-120	12789-12793	were	_	
23-121	12794-12802	computed	_	
23-122	12803-12810	between	_	
23-123	12811-12815	left	_	
23-124	12816-12827	hippocampus	_	
23-125	12828-12831	and	_	
23-126	12832-12835	the	_	
23-127	12836-12841	other	_	
23-128	12842-12848	voxels	_	
23-129	12849-12851	of	_	
23-130	12852-12855	the	_	
23-131	12856-12861	brain	_	
23-132	12861-12862	.	_	
23-133	12863-12874	Statistical	_	
23-134	12875-12880	tests	_	
23-135	12881-12883	on	_	
23-136	12884-12887	the	_	
23-137	12888-12898	functional	_	
23-138	12899-12911	connectivity	_	
23-139	12912-12916	maps	_	
23-140	12917-12919	of	_	
23-141	12920-12931	hippocampus	_	
23-142	12932-12939	between	_	
23-143	12940-12948	patients	_	
23-144	12949-12953	with	_	
23-145	12954-12967	schizophrenia	_	
23-146	12968-12971	and	_	
23-147	12972-12979	healthy	_	
23-148	12980-12988	controls	_	
23-149	12989-12993	were	_	
23-150	12994-13003	performed	_	
23-151	13004-13009	using	_	
23-152	13010-13018	analysis	_	
23-153	13019-13021	of	_	
23-154	13022-13032	covariance	_	
23-155	13033-13037	with	_	
23-156	13038-13041	sex	_	
23-157	13041-13042	,	_	
23-158	13043-13046	age	_	
23-159	13047-13050	and	_	
23-160	13051-13060	education	_	
23-161	13061-13066	years	_	
23-162	13066-13067	,	_	
23-163	13068-13071	and	_	
23-164	13072-13078	volume	_	
23-165	13079-13081	of	_	
23-166	13082-13093	hippocampus	_	
23-167	13094-13096	as	_	
23-168	13097-13107	covariates	_	
23-169	13108-13110	in	_	
23-170	13111-13115	SPM8	_	
23-171	13115-13116	.	_	
23-172	13117-13120	The	_	
23-173	13121-13132	significant	_	
23-174	13133-13142	threshold	_	
23-175	13143-13146	was	_	
23-176	13147-13150	set	_	
23-177	13151-13153	at	_	
23-178	13154-13155	P	_	
23-179	13155-13156	<	_	
23-180	13156-13160	0.05	_	
23-181	13160-13161	,	_	
23-182	13162-13171	corrected	_	
23-183	13172-13175	for	_	
23-184	13176-13184	multiple	_	
23-185	13185-13196	comparisons	_	
23-186	13197-13202	based	_	
23-187	13203-13205	on	_	
23-188	13206-13211	Monte	_	
23-189	13212-13217	Carlo	_	
23-190	13218-13229	simulations	_	
23-191	13229-13230	.	_	
23-192	13231-13243	Subsequently	_	
23-193	13243-13244	,	_	
23-194	13245-13248	the	_	
23-195	13249-13253	mean	_	
23-196	13254-13261	Z-value	_	
23-197	13262-13264	of	_	
23-198	13265-13269	each	_	
23-199	13270-13277	cluster	_	
23-200	13278-13282	with	_	
23-201	13283-13284	a	_	
23-202	13285-13296	significant	_	
23-203	13297-13307	functional	_	
23-204	13308-13320	connectivity	_	
23-205	13321-13322	(	_	
23-206	13322-13324	FC	_	
23-207	13324-13325	)	_	
23-208	13326-13336	difference	_	
23-209	13337-13340	was	_	
23-210	13341-13350	extracted	_	
23-211	13351-13354	and	_	
23-212	13355-13359	were	_	
23-213	13360-13368	compared	_	
23-214	13369-13371	by	_	
23-215	13372-13380	analysis	_	
23-216	13381-13383	of	_	
23-217	13384-13392	variance	_	
23-218	13393-13401	followed	_	
23-219	13402-13404	by	_	
23-220	13405-13409	post	_	
23-221	13410-13413	hoc	_	
23-222	13414-13418	test	_	
23-223	13419-13420	(	_	
23-224	13420-13425	least	_	
23-225	13426-13437	significant	_	
23-226	13438-13448	difference	_	
23-227	13448-13449	)	_	
23-228	13450-13452	in	_	
23-229	13453-13457	SPSS	_	
23-230	13458-13462	18.0	_	
23-231	13462-13463	,	_	
23-232	13464-13470	across	_	
23-233	13471-13479	patients	_	
23-234	13480-13484	with	_	
23-235	13485-13489	RDVs	_	
23-236	13489-13490	,	_	
23-237	13491-13499	patients	_	
23-238	13500-13507	without	_	
23-239	13508-13512	RDVs	_	
23-240	13513-13516	and	_	
23-241	13517-13524	healthy	_	
23-242	13525-13533	controls	_	
23-243	13534-13535	(	_	
23-244	13535-13539	SPSS	_	
23-245	13539-13540	,	_	
23-246	13541-13548	Chicago	_	
23-247	13548-13549	,	_	
23-248	13550-13552	IL	_	
23-249	13552-13553	,	_	
23-250	13554-13557	USA	_	
23-251	13557-13558	)	_	
23-252	13558-13559	,	_	
23-253	13560-13571	significant	_	
23-254	13572-13577	level	_	
23-255	13578-13580	of	_	
23-256	13581-13582	P	_	
23-257	13583-13589	values	_	
23-258	13590-13594	were	_	
23-259	13595-13598	set	_	
23-260	13599-13601	at	_	
23-261	13602-13606	less	_	
23-262	13607-13611	than	_	
23-263	13612-13616	0.05	_	
23-264	13616-13617	.	_	
23-265	13618-13626	Analysis	_	
23-266	13627-13629	of	_	
23-267	13630-13640	covariance	_	
23-268	13641-13649	followed	_	
23-269	13650-13652	by	_	
23-270	13653-13657	post	_	
23-271	13658-13661	hoc	_	
23-272	13662-13666	test	_	
23-273	13667-13671	were	_	
23-274	13672-13679	applied	_	
23-275	13680-13682	to	_	
23-276	13683-13687	test	_	
23-277	13688-13691	the	_	
23-278	13692-13703	differences	_	
23-279	13704-13706	of	_	
23-280	13707-13717	functional	_	
23-281	13718-13730	connectivity	_	
23-282	13731-13734	and	_	
23-283	13735-13741	memory	_	
23-284	13742-13751	functions	_	
23-285	13752-13757	among	_	
23-286	13758-13766	patients	_	
23-287	13767-13771	with	_	
23-288	13772-13776	RDVs	_	
23-289	13776-13777	,	_	
23-290	13778-13786	patients	_	
23-291	13787-13794	without	_	
23-292	13795-13799	RDVs	_	
23-293	13800-13803	and	_	
23-294	13804-13811	healthy	_	
23-295	13812-13820	controls	_	
23-296	13820-13821	.	_	
23-297	13822-13829	Partial	_	
23-298	13830-13841	correlation	_	
23-299	13842-13850	analysis	_	
23-300	13851-13854	was	_	
23-301	13855-13859	used	_	
23-302	13860-13862	to	_	
23-303	13863-13870	analyze	_	
23-304	13871-13874	the	_	
23-305	13875-13887	relationship	_	
23-306	13888-13895	between	_	
23-307	13896-13899	the	_	
23-308	13900-13910	functional	_	
23-309	13911-13925	connectivities	_	
23-310	13926-13928	of	_	
23-311	13929-13938	bilateral	_	
23-312	13939-13950	hippocampus	_	
23-313	13951-13952	(	_	
23-314	13952-13955	and	_	
23-315	13956-13959	six	_	
23-316	13960-13971	hippocampal	_	
23-317	13972-13982	subregions	_	
23-318	13982-13983	)	_	
23-319	13984-13987	and	_	
23-320	13988-13997	cognitive	_	
23-321	13997-13998	,	_	
23-322	13999-14003	that	_	
23-323	14004-14006	is	_	
23-324	14006-14007	,	_	
23-325	14008-14014	memory	_	
23-326	14015-14024	functions	_	
23-327	14024-14025	,	_	
23-328	14026-14030	with	_	
23-329	14031-14034	age	_	
23-330	14034-14035	,	_	
23-331	14036-14039	sex	_	
23-332	14040-14043	and	_	
23-333	14044-14053	education	_	
23-334	14054-14059	years	_	
23-335	14060-14061	(	_	
23-336	14061-14064	and	_	
23-337	14065-14075	structural	_	
23-338	14076-14087	hippocampal	_	
23-339	14088-14094	volume	_	
23-340	14094-14095	)	_	
23-341	14096-14098	as	_	
23-342	14099-14109	covariance	_	
23-343	14110-14111	(	_	
23-344	14111-14124	Supplementary	_	
23-345	14125-14133	material	_	
23-346	14133-14134	)	_	
23-347	14134-14135	.	_	
23-348	14136-14147	Furthermore	_	
23-349	14147-14148	,	_	
23-350	14149-14157	Fisher's	_	
23-351	14158-14174	Z-transformation	_	
23-352	14175-14178	was	_	
23-353	14179-14183	used	_	
23-354	14184-14186	to	_	
23-355	14187-14196	transform	_	
23-356	14197-14200	the	_	
23-357	14201-14212	correlation	_	
23-358	14213-14225	coefficients	_	
23-359	14225-14226	(	_	
23-360	14226-14227	r	_	
23-361	14228-14233	value	_	
23-362	14233-14234	)	_	
23-363	14235-14237	to	_	
23-364	14238-14245	Z-score	_	
23-365	14245-14246	,	_	
23-366	14247-14250	and	_	
23-367	14251-14257	Z-test	_	
23-368	14258-14261	was	_	
23-369	14262-14266	used	_	
23-370	14267-14270	for	_	
23-371	14271-14278	testing	_	
23-372	14279-14282	the	_	
23-373	14283-14294	differences	_	
23-374	14295-14297	of	_	
23-375	14298-14310	correlations	_	
23-376	14311-14318	between	_	
23-377	14319-14325	groups	_	
23-378	14325-14326	.	_	
23-379	14327-14338	Corrections	_	
23-380	14339-14342	for	_	
23-381	14343-14351	multiple	_	
23-382	14352-14363	comparisons	_	
23-383	14364-14368	were	_	
23-384	14369-14376	applied	_	
23-385	14377-14379	as	_	
23-386	14380-14391	appropriate	_	
23-387	14391-14392	.	_	

#Text=Results
24-1	14393-14400	Results	_	

#Text=Genetic investigation of single nucleotide variants and In/Dels
25-1	14401-14408	Genetic	_	
25-2	14409-14422	investigation	_	
25-3	14423-14425	of	_	
25-4	14426-14432	single	_	
25-5	14433-14443	nucleotide	_	
25-6	14444-14452	variants	_	
25-7	14453-14456	and	_	
25-8	14457-14459	In	_	
25-9	14459-14460	/	_	
25-10	14460-14464	Dels	_	

#Text=In the current study, 234 subjects (97 patients with first-episode treatment-naive schizophrenia and 137 healthy controls) were collected for exome sequencing to identify those alleles, genes or gene networks that harbor rare coding variants of moderate or large effect on risk for schizophrenia (Supplementary Information, sections 1). Six samples were removed with low quality along with likely contamination after quality control and variant calling (Supplementary Information, sections 2 and 3). Quality control of all variants was conducted by in-house software KGGSeq. The final data set comprised 94 schizophrenic cases and 134 controls. Detailed demographic and clinical information, as well as summary for sequencing quality, was shown in Table 1. There were no significant differences in age, sex distribution and years of education (Table 1).
26-1	14465-14467	In	_	
26-2	14468-14471	the	_	
26-3	14472-14479	current	_	
26-4	14480-14485	study	_	
26-5	14485-14486	,	_	
26-6	14487-14490	234	_	
26-7	14491-14499	subjects	_	
26-8	14500-14501	(	_	
26-9	14501-14503	97	_	
26-10	14504-14512	patients	_	
26-11	14513-14517	with	_	
26-12	14518-14531	first-episode	_	
26-13	14532-14547	treatment-naive	_	
26-14	14548-14561	schizophrenia	_	
26-15	14562-14565	and	_	
26-16	14566-14569	137	_	
26-17	14570-14577	healthy	_	
26-18	14578-14586	controls	_	
26-19	14586-14587	)	_	
26-20	14588-14592	were	_	
26-21	14593-14602	collected	_	
26-22	14603-14606	for	_	
26-23	14607-14612	exome	_	
26-24	14613-14623	sequencing	_	
26-25	14624-14626	to	_	
26-26	14627-14635	identify	_	
26-27	14636-14641	those	_	
26-28	14642-14649	alleles	_	
26-29	14649-14650	,	_	
26-30	14651-14656	genes	_	
26-31	14657-14659	or	_	
26-32	14660-14664	gene	_	
26-33	14665-14673	networks	_	
26-34	14674-14678	that	_	
26-35	14679-14685	harbor	_	
26-36	14686-14690	rare	_	
26-37	14691-14697	coding	_	
26-38	14698-14706	variants	_	
26-39	14707-14709	of	_	
26-40	14710-14718	moderate	_	
26-41	14719-14721	or	_	
26-42	14722-14727	large	_	
26-43	14728-14734	effect	_	
26-44	14735-14737	on	_	
26-45	14738-14742	risk	_	
26-46	14743-14746	for	_	
26-47	14747-14760	schizophrenia	_	
26-48	14761-14762	(	_	
26-49	14762-14775	Supplementary	_	
26-50	14776-14787	Information	_	
26-51	14787-14788	,	_	
26-52	14789-14797	sections	_	
26-53	14798-14799	1	_	
26-54	14799-14800	)	_	
26-55	14800-14801	.	_	
26-56	14802-14805	Six	_	
26-57	14806-14813	samples	_	
26-58	14814-14818	were	_	
26-59	14819-14826	removed	_	
26-60	14827-14831	with	_	
26-61	14832-14835	low	_	
26-62	14836-14843	quality	_	
26-63	14844-14849	along	_	
26-64	14850-14854	with	_	
26-65	14855-14861	likely	_	
26-66	14862-14875	contamination	_	
26-67	14876-14881	after	_	
26-68	14882-14889	quality	_	
26-69	14890-14897	control	_	
26-70	14898-14901	and	_	
26-71	14902-14909	variant	_	
26-72	14910-14917	calling	_	
26-73	14918-14919	(	_	
26-74	14919-14932	Supplementary	_	
26-75	14933-14944	Information	_	
26-76	14944-14945	,	_	
26-77	14946-14954	sections	_	
26-78	14955-14956	2	_	
26-79	14957-14960	and	_	
26-80	14961-14962	3	_	
26-81	14962-14963	)	_	
26-82	14963-14964	.	_	
26-83	14965-14972	Quality	_	
26-84	14973-14980	control	_	
26-85	14981-14983	of	_	
26-86	14984-14987	all	_	
26-87	14988-14996	variants	_	
26-88	14997-15000	was	_	
26-89	15001-15010	conducted	_	
26-90	15011-15013	by	_	
26-91	15014-15022	in-house	_	
26-92	15023-15031	software	_	
26-93	15032-15038	KGGSeq	_	
26-94	15038-15039	.	_	
26-95	15040-15043	The	_	
26-96	15044-15049	final	_	
26-97	15050-15054	data	_	
26-98	15055-15058	set	_	
26-99	15059-15068	comprised	_	
26-100	15069-15071	94	_	
26-101	15072-15085	schizophrenic	_	
26-102	15086-15091	cases	_	
26-103	15092-15095	and	_	
26-104	15096-15099	134	_	
26-105	15100-15108	controls	_	
26-106	15108-15109	.	_	
26-107	15110-15118	Detailed	_	
26-108	15119-15130	demographic	_	
26-109	15131-15134	and	_	
26-110	15135-15143	clinical	_	
26-111	15144-15155	information	_	
26-112	15155-15156	,	_	
26-113	15157-15159	as	_	
26-114	15160-15164	well	_	
26-115	15165-15167	as	_	
26-116	15168-15175	summary	_	
26-117	15176-15179	for	_	
26-118	15180-15190	sequencing	_	
26-119	15191-15198	quality	_	
26-120	15198-15199	,	_	
26-121	15200-15203	was	_	
26-122	15204-15209	shown	_	
26-123	15210-15212	in	_	
26-124	15213-15218	Table	_	
26-125	15219-15220	1	_	
26-126	15220-15221	.	_	
26-127	15222-15227	There	_	
26-128	15228-15232	were	_	
26-129	15233-15235	no	_	
26-130	15236-15247	significant	_	
26-131	15248-15259	differences	_	
26-132	15260-15262	in	_	
26-133	15263-15266	age	_	
26-134	15266-15267	,	_	
26-135	15268-15271	sex	_	
26-136	15272-15284	distribution	_	
26-137	15285-15288	and	_	
26-138	15289-15294	years	_	
26-139	15295-15297	of	_	
26-140	15298-15307	education	_	
26-141	15308-15309	(	_	
26-142	15309-15314	Table	_	
26-143	15315-15316	1	_	
26-144	15316-15317	)	_	
26-145	15317-15318	.	_	

#Text=On average, we obtained 7.67â€‰Gb of mappable sequence data per individual after exome enrichment, targeting ~62â€‰Mb from exons and their flanking regions. In all, 99.75% of the reads were properly aligned to the reference genome. Our median read depth is ~45 Ã—, which is higher than the estimated average depth (33 Ã—) required for highly accurate downstream heterozygous variant detection. In addition, 88.60% of the captured target exons were covered by high-quality genotype calls at least 10 times to ensure good detection sensitivity. Technical sequencing metrics, including total coverage, proportion of deeply covered targets and initial mapping reads, indicated no difference between schizophrenic patients and healthy controls (Table 2).
27-1	15319-15321	On	_	
27-2	15322-15329	average	_	
27-3	15329-15330	,	_	
27-4	15331-15333	we	_	
27-5	15334-15342	obtained	_	
27-6	15343-15347	7.67	_	
27-7	15348-15350	Gb	_	
27-8	15351-15353	of	_	
27-9	15354-15362	mappable	_	
27-10	15363-15371	sequence	_	
27-11	15372-15376	data	_	
27-12	15377-15380	per	_	
27-13	15381-15391	individual	_	
27-14	15392-15397	after	_	
27-15	15398-15403	exome	_	
27-16	15404-15414	enrichment	_	
27-17	15414-15415	,	_	
27-18	15416-15425	targeting	_	
27-19	15426-15427	~	_	
27-20	15427-15429	62	_	
27-21	15430-15432	Mb	_	
27-22	15433-15437	from	_	
27-23	15438-15443	exons	_	
27-24	15444-15447	and	_	
27-25	15448-15453	their	_	
27-26	15454-15462	flanking	_	
27-27	15463-15470	regions	_	
27-28	15470-15471	.	_	
27-29	15472-15474	In	_	
27-30	15475-15478	all	_	
27-31	15478-15479	,	_	
27-32	15480-15486	99.75%	_	
27-33	15487-15489	of	_	
27-34	15490-15493	the	_	
27-35	15494-15499	reads	_	
27-36	15500-15504	were	_	
27-37	15505-15513	properly	_	
27-38	15514-15521	aligned	_	
27-39	15522-15524	to	_	
27-40	15525-15528	the	_	
27-41	15529-15538	reference	_	
27-42	15539-15545	genome	_	
27-43	15545-15546	.	_	
27-44	15547-15550	Our	_	
27-45	15551-15557	median	_	
27-46	15558-15562	read	_	
27-47	15563-15568	depth	_	
27-48	15569-15571	is	_	
27-49	15572-15573	~	_	
27-50	15573-15575	45	_	
27-51	15576-15577	Ã—	_	
27-52	15577-15578	,	_	
27-53	15579-15584	which	_	
27-54	15585-15587	is	_	
27-55	15588-15594	higher	_	
27-56	15595-15599	than	_	
27-57	15600-15603	the	_	
27-58	15604-15613	estimated	_	
27-59	15614-15621	average	_	
27-60	15622-15627	depth	_	
27-61	15628-15629	(	_	
27-62	15629-15631	33	_	
27-63	15632-15633	Ã—	_	
27-64	15633-15634	)	_	
27-65	15635-15643	required	_	
27-66	15644-15647	for	_	
27-67	15648-15654	highly	_	
27-68	15655-15663	accurate	_	
27-69	15664-15674	downstream	_	
27-70	15675-15687	heterozygous	_	
27-71	15688-15695	variant	_	
27-72	15696-15705	detection	_	
27-73	15705-15706	.	_	
27-74	15707-15709	In	_	
27-75	15710-15718	addition	_	
27-76	15718-15719	,	_	
27-77	15720-15726	88.60%	_	
27-78	15727-15729	of	_	
27-79	15730-15733	the	_	
27-80	15734-15742	captured	_	
27-81	15743-15749	target	_	
27-82	15750-15755	exons	_	
27-83	15756-15760	were	_	
27-84	15761-15768	covered	_	
27-85	15769-15771	by	_	
27-86	15772-15784	high-quality	_	
27-87	15785-15793	genotype	_	
27-88	15794-15799	calls	_	
27-89	15800-15802	at	_	
27-90	15803-15808	least	_	
27-91	15809-15811	10	_	
27-92	15812-15817	times	_	
27-93	15818-15820	to	_	
27-94	15821-15827	ensure	_	
27-95	15828-15832	good	_	
27-96	15833-15842	detection	_	
27-97	15843-15854	sensitivity	_	
27-98	15854-15855	.	_	
27-99	15856-15865	Technical	_	
27-100	15866-15876	sequencing	_	
27-101	15877-15884	metrics	_	
27-102	15884-15885	,	_	
27-103	15886-15895	including	_	
27-104	15896-15901	total	_	
27-105	15902-15910	coverage	_	
27-106	15910-15911	,	_	
27-107	15912-15922	proportion	_	
27-108	15923-15925	of	_	
27-109	15926-15932	deeply	_	
27-110	15933-15940	covered	_	
27-111	15941-15948	targets	_	
27-112	15949-15952	and	_	
27-113	15953-15960	initial	_	
27-114	15961-15968	mapping	_	
27-115	15969-15974	reads	_	
27-116	15974-15975	,	_	
27-117	15976-15985	indicated	_	
27-118	15986-15988	no	_	
27-119	15989-15999	difference	_	
27-120	16000-16007	between	_	
27-121	16008-16021	schizophrenic	_	
27-122	16022-16030	patients	_	
27-123	16031-16034	and	_	
27-124	16035-16042	healthy	_	
27-125	16043-16051	controls	_	
27-126	16052-16053	(	_	
27-127	16053-16058	Table	_	
27-128	16059-16060	2	_	
27-129	16060-16061	)	_	
27-130	16061-16062	.	_	

#Text=Importantly, we found that schizophrenic patients enriched significantly more nonsynonymous and coding variants than controls (Table 2, P<0.001). Allele counts between schizophrenic cases and healthy subjects did not show significant difference after adjustment (Supplementary Information, section 4). We performed two series of gene-based tests: a one-sided burden test of an increased rare allele rate in cases (https://atgu.mgh.harvard.edu/plinkseq/) and the CALPHA test. Both tests indicated that gene NRK (Nik Related Kinase, NM_198465, chrX: 105132399...105199499) had increased rare allele rate in cases (Pâ©½1.0 Ã— 10âˆ’6). However, even according to the most stringent Bofferroni correction (0.05/20000=2.5 Ã— 10âˆ’6, 20â€‰000 are the total gene number; the results of NRK gene still present significant statistical difference. Nine rare variants within NRK present in 13 schizophrenic patients, but not in healthy controls (Supplementary Table 1).
28-1	16063-16074	Importantly	_	
28-2	16074-16075	,	_	
28-3	16076-16078	we	_	
28-4	16079-16084	found	_	
28-5	16085-16089	that	_	
28-6	16090-16103	schizophrenic	_	
28-7	16104-16112	patients	_	
28-8	16113-16121	enriched	_	
28-9	16122-16135	significantly	_	
28-10	16136-16140	more	_	
28-11	16141-16154	nonsynonymous	_	
28-12	16155-16158	and	_	
28-13	16159-16165	coding	_	
28-14	16166-16174	variants	_	
28-15	16175-16179	than	_	
28-16	16180-16188	controls	_	
28-17	16189-16190	(	_	
28-18	16190-16195	Table	_	
28-19	16196-16197	2	_	
28-20	16197-16198	,	_	
28-21	16199-16200	P	_	
28-22	16200-16201	<	_	
28-23	16201-16206	0.001	_	
28-24	16206-16207	)	_	
28-25	16207-16208	.	_	
28-26	16209-16215	Allele	_	
28-27	16216-16222	counts	_	
28-28	16223-16230	between	_	
28-29	16231-16244	schizophrenic	_	
28-30	16245-16250	cases	_	
28-31	16251-16254	and	_	
28-32	16255-16262	healthy	_	
28-33	16263-16271	subjects	_	
28-34	16272-16275	did	_	
28-35	16276-16279	not	_	
28-36	16280-16284	show	_	
28-37	16285-16296	significant	_	
28-38	16297-16307	difference	_	
28-39	16308-16313	after	_	
28-40	16314-16324	adjustment	_	
28-41	16325-16326	(	_	
28-42	16326-16339	Supplementary	_	
28-43	16340-16351	Information	_	
28-44	16351-16352	,	_	
28-45	16353-16360	section	_	
28-46	16361-16362	4	_	
28-47	16362-16363	)	_	
28-48	16363-16364	.	_	
28-49	16365-16367	We	_	
28-50	16368-16377	performed	_	
28-51	16378-16381	two	_	
28-52	16382-16388	series	_	
28-53	16389-16391	of	_	
28-54	16392-16402	gene-based	_	
28-55	16403-16408	tests	_	
28-56	16408-16409	:	_	
28-57	16410-16411	a	_	
28-58	16412-16421	one-sided	_	
28-59	16422-16428	burden	_	
28-60	16429-16433	test	_	
28-61	16434-16436	of	_	
28-62	16437-16439	an	_	
28-63	16440-16449	increased	_	
28-64	16450-16454	rare	_	
28-65	16455-16461	allele	_	
28-66	16462-16466	rate	_	
28-67	16467-16469	in	_	
28-68	16470-16475	cases	_	
28-69	16476-16477	(	_	
28-70	16477-16482	https	_	
28-71	16482-16483	:	_	
28-72	16483-16484	/	_	
28-73	16484-16485	/	_	
28-74	16485-16505	atgu.mgh.harvard.edu	_	
28-75	16505-16506	/	_	
28-76	16506-16514	plinkseq	_	
28-77	16514-16515	/	_	
28-78	16515-16516	)	_	
28-79	16517-16520	and	_	
28-80	16521-16524	the	_	
28-81	16525-16531	CALPHA	_	
28-82	16532-16536	test	_	
28-83	16536-16537	.	_	
28-84	16538-16542	Both	_	
28-85	16543-16548	tests	_	
28-86	16549-16558	indicated	_	
28-87	16559-16563	that	_	
28-88	16564-16568	gene	_	
28-89	16569-16572	NRK	_	
28-90	16573-16574	(	_	
28-91	16574-16577	Nik	_	
28-92	16578-16585	Related	_	
28-93	16586-16592	Kinase	_	
28-94	16592-16593	,	_	
28-95	16594-16596	NM	_	
28-96	16596-16597	_	_	
28-97	16597-16603	198465	_	
28-98	16603-16604	,	_	
28-99	16605-16609	chrX	_	
28-100	16609-16610	:	_	
28-101	16611-16620	105132399	_	
28-102	16620-16621	.	_	
28-103	16621-16622	.	_	
28-104	16622-16632	.105199499	_	
28-105	16632-16633	)	_	
28-106	16634-16637	had	_	
28-107	16638-16647	increased	_	
28-108	16648-16652	rare	_	
28-109	16653-16659	allele	_	
28-110	16660-16664	rate	_	
28-111	16665-16667	in	_	
28-112	16668-16673	cases	_	
28-113	16674-16675	(	_	
28-114	16675-16676	P	_	
28-115	16676-16677	â©½	_	
28-116	16677-16680	1.0	_	
28-117	16681-16682	Ã—	_	
28-118	16683-16685	10	_	
28-119	16685-16686	âˆ’	_	
28-120	16686-16687	6	_	
28-121	16687-16688	)	_	
28-122	16688-16689	.	_	
28-123	16690-16697	However	_	
28-124	16697-16698	,	_	
28-125	16699-16703	even	_	
28-126	16704-16713	according	_	
28-127	16714-16716	to	_	
28-128	16717-16720	the	_	
28-129	16721-16725	most	_	
28-130	16726-16735	stringent	_	
28-131	16736-16746	Bofferroni	_	
28-132	16747-16757	correction	_	
28-133	16758-16759	(	_	
28-134	16759-16763	0.05	_	
28-135	16763-16764	/	_	
28-136	16764-16769	20000	_	
28-137	16769-16770	=	_	
28-138	16770-16773	2.5	_	
28-139	16774-16775	Ã—	_	
28-140	16776-16778	10	_	
28-141	16778-16779	âˆ’	_	
28-142	16779-16780	6	_	
28-143	16780-16781	,	_	
28-144	16782-16784	20	_	
28-145	16785-16788	000	_	
28-146	16789-16792	are	_	
28-147	16793-16796	the	_	
28-148	16797-16802	total	_	
28-149	16803-16807	gene	_	
28-150	16808-16814	number	_	
28-151	16814-16815	;	_	
28-152	16816-16819	the	_	
28-153	16820-16827	results	_	
28-154	16828-16830	of	_	
28-155	16831-16834	NRK	_	
28-156	16835-16839	gene	_	
28-157	16840-16845	still	_	
28-158	16846-16853	present	_	
28-159	16854-16865	significant	_	
28-160	16866-16877	statistical	_	
28-161	16878-16888	difference	_	
28-162	16888-16889	.	_	
28-163	16890-16894	Nine	_	
28-164	16895-16899	rare	_	
28-165	16900-16908	variants	_	
28-166	16909-16915	within	_	
28-167	16916-16919	NRK	_	
28-168	16920-16927	present	_	
28-169	16928-16930	in	_	
28-170	16931-16933	13	_	
28-171	16934-16947	schizophrenic	_	
28-172	16948-16956	patients	_	
28-173	16956-16957	,	_	
28-174	16958-16961	but	_	
28-175	16962-16965	not	_	
28-176	16966-16968	in	_	
28-177	16969-16976	healthy	_	
28-178	16977-16985	controls	_	
28-179	16986-16987	(	_	
28-180	16987-17000	Supplementary	_	
28-181	17001-17006	Table	_	
28-182	17007-17008	1	_	
28-183	17008-17009	)	_	
28-184	17009-17010	.	_	

#Text=NRK is a protein-coding gene, which is associated with hypermobility syndrome, hyperinsulinemic and hypoglycemia. GO annotations related to this gene include protein serine/threonine kinase activity and small GTPase regulator activity. Previous studies did not denote any association between NRK and schizophrenia; however, an important paralog of this gene is TAOK2, which is essential for dendrite morphogenesis and has been associated with autism spectrum disorder.
29-1	17011-17014	NRK	_	
29-2	17015-17017	is	_	
29-3	17018-17019	a	_	
29-4	17020-17034	protein-coding	_	
29-5	17035-17039	gene	_	
29-6	17039-17040	,	_	
29-7	17041-17046	which	_	
29-8	17047-17049	is	_	
29-9	17050-17060	associated	_	
29-10	17061-17065	with	_	
29-11	17066-17079	hypermobility	_	
29-12	17080-17088	syndrome	_	
29-13	17088-17089	,	_	
29-14	17090-17106	hyperinsulinemic	_	
29-15	17107-17110	and	_	
29-16	17111-17123	hypoglycemia	_	
29-17	17123-17124	.	_	
29-18	17125-17127	GO	_	
29-19	17128-17139	annotations	_	
29-20	17140-17147	related	_	
29-21	17148-17150	to	_	
29-22	17151-17155	this	_	
29-23	17156-17160	gene	_	
29-24	17161-17168	include	_	
29-25	17169-17176	protein	_	
29-26	17177-17183	serine	_	
29-27	17183-17184	/	_	
29-28	17184-17193	threonine	_	
29-29	17194-17200	kinase	_	
29-30	17201-17209	activity	_	
29-31	17210-17213	and	_	
29-32	17214-17219	small	_	
29-33	17220-17226	GTPase	_	
29-34	17227-17236	regulator	_	
29-35	17237-17245	activity	_	
29-36	17245-17246	.	_	
29-37	17247-17255	Previous	_	
29-38	17256-17263	studies	_	
29-39	17264-17267	did	_	
29-40	17268-17271	not	_	
29-41	17272-17278	denote	_	
29-42	17279-17282	any	_	
29-43	17283-17294	association	_	
29-44	17295-17302	between	_	
29-45	17303-17306	NRK	_	
29-46	17307-17310	and	_	
29-47	17311-17324	schizophrenia	_	
29-48	17324-17325	;	_	
29-49	17326-17333	however	_	
29-50	17333-17334	,	_	
29-51	17335-17337	an	_	
29-52	17338-17347	important	_	
29-53	17348-17355	paralog	_	
29-54	17356-17358	of	_	
29-55	17359-17363	this	_	
29-56	17364-17368	gene	_	
29-57	17369-17371	is	_	
29-58	17372-17377	TAOK2	_	
29-59	17377-17378	,	_	
29-60	17379-17384	which	_	
29-61	17385-17387	is	_	
29-62	17388-17397	essential	_	
29-63	17398-17401	for	_	
29-64	17402-17410	dendrite	_	
29-65	17411-17424	morphogenesis	_	
29-66	17425-17428	and	_	
29-67	17429-17432	has	_	
29-68	17433-17437	been	_	
29-69	17438-17448	associated	_	
29-70	17449-17453	with	_	
29-71	17454-17460	autism	_	
29-72	17461-17469	spectrum	_	
29-73	17470-17478	disorder	_	
29-74	17478-17479	.	_	

#Text=Next, we adopted an alternative strategy in which we studied RDVs. Previous reports have shown that RDVs have a higher likelihood of having a role in schizophrenia (Supplementary Information, section 5). After applying several filters (Supplementary Figure 1), 2895 mutations within 2442 genes in schizophrenic patients and 4484 mutations within 3481 genes in healthy controls were investigated with GO enrichment at the gene-based level using GeneMANIA. There were 505 and 952 pathway (or GO) terms enriched in cases and controls separately, but 56 RDVs in 42 genes within two pathways of DNA repair (GO: 0006281, 31 RDVs in 20 genes) and cell cycle (GO: 0007049, 25 RDVs in 22 genes) were present only in 39 schizophrenic patients (Supplementary Table 2 and Table 3), which also indicated a significant q-value. There are 60 control-only categories that were not statistical significant. In the present study, we focused on pathways damaged in cases only. We identified the developmental expression profile of 22 genes in cell cycle pathway and 20 genes in DNA repair pathway (Supplementary Information, section 6), which show high expression during the stage of brain development before birth, with a sharp decrease in expression after birth in hippocampus. The expression profile obtained by WGCNA is presented in Figure 1.
30-1	17480-17484	Next	_	
30-2	17484-17485	,	_	
30-3	17486-17488	we	_	
30-4	17489-17496	adopted	_	
30-5	17497-17499	an	_	
30-6	17500-17511	alternative	_	
30-7	17512-17520	strategy	_	
30-8	17521-17523	in	_	
30-9	17524-17529	which	_	
30-10	17530-17532	we	_	
30-11	17533-17540	studied	_	
30-12	17541-17545	RDVs	_	
30-13	17545-17546	.	_	
30-14	17547-17555	Previous	_	
30-15	17556-17563	reports	_	
30-16	17564-17568	have	_	
30-17	17569-17574	shown	_	
30-18	17575-17579	that	_	
30-19	17580-17584	RDVs	_	
30-20	17585-17589	have	_	
30-21	17590-17591	a	_	
30-22	17592-17598	higher	_	
30-23	17599-17609	likelihood	_	
30-24	17610-17612	of	_	
30-25	17613-17619	having	_	
30-26	17620-17621	a	_	
30-27	17622-17626	role	_	
30-28	17627-17629	in	_	
30-29	17630-17643	schizophrenia	_	
30-30	17644-17645	(	_	
30-31	17645-17658	Supplementary	_	
30-32	17659-17670	Information	_	
30-33	17670-17671	,	_	
30-34	17672-17679	section	_	
30-35	17680-17681	5	_	
30-36	17681-17682	)	_	
30-37	17682-17683	.	_	
30-38	17684-17689	After	_	
30-39	17690-17698	applying	_	
30-40	17699-17706	several	_	
30-41	17707-17714	filters	_	
30-42	17715-17716	(	_	
30-43	17716-17729	Supplementary	_	
30-44	17730-17736	Figure	_	
30-45	17737-17738	1	_	
30-46	17738-17739	)	_	
30-47	17739-17740	,	_	
30-48	17741-17745	2895	_	
30-49	17746-17755	mutations	_	
30-50	17756-17762	within	_	
30-51	17763-17767	2442	_	
30-52	17768-17773	genes	_	
30-53	17774-17776	in	_	
30-54	17777-17790	schizophrenic	_	
30-55	17791-17799	patients	_	
30-56	17800-17803	and	_	
30-57	17804-17808	4484	_	
30-58	17809-17818	mutations	_	
30-59	17819-17825	within	_	
30-60	17826-17830	3481	_	
30-61	17831-17836	genes	_	
30-62	17837-17839	in	_	
30-63	17840-17847	healthy	_	
30-64	17848-17856	controls	_	
30-65	17857-17861	were	_	
30-66	17862-17874	investigated	_	
30-67	17875-17879	with	_	
30-68	17880-17882	GO	_	
30-69	17883-17893	enrichment	_	
30-70	17894-17896	at	_	
30-71	17897-17900	the	_	
30-72	17901-17911	gene-based	_	
30-73	17912-17917	level	_	
30-74	17918-17923	using	_	
30-75	17924-17933	GeneMANIA	_	
30-76	17933-17934	.	_	
30-77	17935-17940	There	_	
30-78	17941-17945	were	_	
30-79	17946-17949	505	_	
30-80	17950-17953	and	_	
30-81	17954-17957	952	_	
30-82	17958-17965	pathway	_	
30-83	17966-17967	(	_	
30-84	17967-17969	or	_	
30-85	17970-17972	GO	_	
30-86	17972-17973	)	_	
30-87	17974-17979	terms	_	
30-88	17980-17988	enriched	_	
30-89	17989-17991	in	_	
30-90	17992-17997	cases	_	
30-91	17998-18001	and	_	
30-92	18002-18010	controls	_	
30-93	18011-18021	separately	_	
30-94	18021-18022	,	_	
30-95	18023-18026	but	_	
30-96	18027-18029	56	_	
30-97	18030-18034	RDVs	_	
30-98	18035-18037	in	_	
30-99	18038-18040	42	_	
30-100	18041-18046	genes	_	
30-101	18047-18053	within	_	
30-102	18054-18057	two	_	
30-103	18058-18066	pathways	_	
30-104	18067-18069	of	_	
30-105	18070-18073	DNA	_	
30-106	18074-18080	repair	_	
30-107	18081-18082	(	_	
30-108	18082-18084	GO	_	
30-109	18084-18085	:	_	
30-110	18086-18093	0006281	_	
30-111	18093-18094	,	_	
30-112	18095-18097	31	_	
30-113	18098-18102	RDVs	_	
30-114	18103-18105	in	_	
30-115	18106-18108	20	_	
30-116	18109-18114	genes	_	
30-117	18114-18115	)	_	
30-118	18116-18119	and	_	
30-119	18120-18124	cell	_	
30-120	18125-18130	cycle	_	
30-121	18131-18132	(	_	
30-122	18132-18134	GO	_	
30-123	18134-18135	:	_	
30-124	18136-18143	0007049	_	
30-125	18143-18144	,	_	
30-126	18145-18147	25	_	
30-127	18148-18152	RDVs	_	
30-128	18153-18155	in	_	
30-129	18156-18158	22	_	
30-130	18159-18164	genes	_	
30-131	18164-18165	)	_	
30-132	18166-18170	were	_	
30-133	18171-18178	present	_	
30-134	18179-18183	only	_	
30-135	18184-18186	in	_	
30-136	18187-18189	39	_	
30-137	18190-18203	schizophrenic	_	
30-138	18204-18212	patients	_	
30-139	18213-18214	(	_	
30-140	18214-18227	Supplementary	_	
30-141	18228-18233	Table	_	
30-142	18234-18235	2	_	
30-143	18236-18239	and	_	
30-144	18240-18245	Table	_	
30-145	18246-18247	3	_	
30-146	18247-18248	)	_	
30-147	18248-18249	,	_	
30-148	18250-18255	which	_	
30-149	18256-18260	also	_	
30-150	18261-18270	indicated	_	
30-151	18271-18272	a	_	
30-152	18273-18284	significant	_	
30-153	18285-18292	q-value	_	
30-154	18292-18293	.	_	
30-155	18294-18299	There	_	
30-156	18300-18303	are	_	
30-157	18304-18306	60	_	
30-158	18307-18319	control-only	_	
30-159	18320-18330	categories	_	
30-160	18331-18335	that	_	
30-161	18336-18340	were	_	
30-162	18341-18344	not	_	
30-163	18345-18356	statistical	_	
30-164	18357-18368	significant	_	
30-165	18368-18369	.	_	
30-166	18370-18372	In	_	
30-167	18373-18376	the	_	
30-168	18377-18384	present	_	
30-169	18385-18390	study	_	
30-170	18390-18391	,	_	
30-171	18392-18394	we	_	
30-172	18395-18402	focused	_	
30-173	18403-18405	on	_	
30-174	18406-18414	pathways	_	
30-175	18415-18422	damaged	_	
30-176	18423-18425	in	_	
30-177	18426-18431	cases	_	
30-178	18432-18436	only	_	
30-179	18436-18437	.	_	
30-180	18438-18440	We	_	
30-181	18441-18451	identified	_	
30-182	18452-18455	the	_	
30-183	18456-18469	developmental	_	
30-184	18470-18480	expression	_	
30-185	18481-18488	profile	_	
30-186	18489-18491	of	_	
30-187	18492-18494	22	_	
30-188	18495-18500	genes	_	
30-189	18501-18503	in	_	
30-190	18504-18508	cell	_	
30-191	18509-18514	cycle	_	
30-192	18515-18522	pathway	_	
30-193	18523-18526	and	_	
30-194	18527-18529	20	_	
30-195	18530-18535	genes	_	
30-196	18536-18538	in	_	
30-197	18539-18542	DNA	_	
30-198	18543-18549	repair	_	
30-199	18550-18557	pathway	_	
30-200	18558-18559	(	_	
30-201	18559-18572	Supplementary	_	
30-202	18573-18584	Information	_	
30-203	18584-18585	,	_	
30-204	18586-18593	section	_	
30-205	18594-18595	6	_	
30-206	18595-18596	)	_	
30-207	18596-18597	,	_	
30-208	18598-18603	which	_	
30-209	18604-18608	show	_	
30-210	18609-18613	high	_	
30-211	18614-18624	expression	_	
30-212	18625-18631	during	_	
30-213	18632-18635	the	_	
30-214	18636-18641	stage	_	
30-215	18642-18644	of	_	
30-216	18645-18650	brain	_	
30-217	18651-18662	development	_	
30-218	18663-18669	before	_	
30-219	18670-18675	birth	_	
30-220	18675-18676	,	_	
30-221	18677-18681	with	_	
30-222	18682-18683	a	_	
30-223	18684-18689	sharp	_	
30-224	18690-18698	decrease	_	
30-225	18699-18701	in	_	
30-226	18702-18712	expression	_	
30-227	18713-18718	after	_	
30-228	18719-18724	birth	_	
30-229	18725-18727	in	_	
30-230	18728-18739	hippocampus	_	
30-231	18739-18740	.	_	
30-232	18741-18744	The	_	
30-233	18745-18755	expression	_	
30-234	18756-18763	profile	_	
30-235	18764-18772	obtained	_	
30-236	18773-18775	by	_	
30-237	18776-18781	WGCNA	_	
30-238	18782-18784	is	_	
30-239	18785-18794	presented	_	
30-240	18795-18797	in	_	
30-241	18798-18804	Figure	_	
30-242	18805-18806	1	_	
30-243	18806-18807	.	_	

#Text=Clinical characterization and hippocampal characterization in schizophrenic patients with or without RDVs
31-1	18808-18816	Clinical	_	
31-2	18817-18833	characterization	_	
31-3	18834-18837	and	_	
31-4	18838-18849	hippocampal	_	
31-5	18850-18866	characterization	_	
31-6	18867-18869	in	_	
31-7	18870-18883	schizophrenic	_	
31-8	18884-18892	patients	_	
31-9	18893-18897	with	_	
31-10	18898-18900	or	_	
31-11	18901-18908	without	_	
31-12	18909-18913	RDVs	_	

#Text=Clinical characterization
32-1	18914-18922	Clinical	_	
32-2	18923-18939	characterization	_	

#Text=Comparisons here focus on schizophrenic and healthy subjects as well as on the two genetic-based subgroups with schizophrenia, that is, patients with RDVs and those without RDVs. There were no significant differences in age and sex among patients with RDVs, patients without RDVs and healthy controls (Table 4); however, the education years in patients without RDVs are significantly lower than those in patients with RDVs and controls. In addition, there were no significant differences in the duration of illnesses and severity of clinical symptoms between the two genetic-based patient subgroups.
33-1	18940-18951	Comparisons	_	
33-2	18952-18956	here	_	
33-3	18957-18962	focus	_	
33-4	18963-18965	on	_	
33-5	18966-18979	schizophrenic	_	
33-6	18980-18983	and	_	
33-7	18984-18991	healthy	_	
33-8	18992-19000	subjects	_	
33-9	19001-19003	as	_	
33-10	19004-19008	well	_	
33-11	19009-19011	as	_	
33-12	19012-19014	on	_	
33-13	19015-19018	the	_	
33-14	19019-19022	two	_	
33-15	19023-19036	genetic-based	_	
33-16	19037-19046	subgroups	_	
33-17	19047-19051	with	_	
33-18	19052-19065	schizophrenia	_	
33-19	19065-19066	,	_	
33-20	19067-19071	that	_	
33-21	19072-19074	is	_	
33-22	19074-19075	,	_	
33-23	19076-19084	patients	_	
33-24	19085-19089	with	_	
33-25	19090-19094	RDVs	_	
33-26	19095-19098	and	_	
33-27	19099-19104	those	_	
33-28	19105-19112	without	_	
33-29	19113-19117	RDVs	_	
33-30	19117-19118	.	_	
33-31	19119-19124	There	_	
33-32	19125-19129	were	_	
33-33	19130-19132	no	_	
33-34	19133-19144	significant	_	
33-35	19145-19156	differences	_	
33-36	19157-19159	in	_	
33-37	19160-19163	age	_	
33-38	19164-19167	and	_	
33-39	19168-19171	sex	_	
33-40	19172-19177	among	_	
33-41	19178-19186	patients	_	
33-42	19187-19191	with	_	
33-43	19192-19196	RDVs	_	
33-44	19196-19197	,	_	
33-45	19198-19206	patients	_	
33-46	19207-19214	without	_	
33-47	19215-19219	RDVs	_	
33-48	19220-19223	and	_	
33-49	19224-19231	healthy	_	
33-50	19232-19240	controls	_	
33-51	19241-19242	(	_	
33-52	19242-19247	Table	_	
33-53	19248-19249	4	_	
33-54	19249-19250	)	_	
33-55	19250-19251	;	_	
33-56	19252-19259	however	_	
33-57	19259-19260	,	_	
33-58	19261-19264	the	_	
33-59	19265-19274	education	_	
33-60	19275-19280	years	_	
33-61	19281-19283	in	_	
33-62	19284-19292	patients	_	
33-63	19293-19300	without	_	
33-64	19301-19305	RDVs	_	
33-65	19306-19309	are	_	
33-66	19310-19323	significantly	_	
33-67	19324-19329	lower	_	
33-68	19330-19334	than	_	
33-69	19335-19340	those	_	
33-70	19341-19343	in	_	
33-71	19344-19352	patients	_	
33-72	19353-19357	with	_	
33-73	19358-19362	RDVs	_	
33-74	19363-19366	and	_	
33-75	19367-19375	controls	_	
33-76	19375-19376	.	_	
33-77	19377-19379	In	_	
33-78	19380-19388	addition	_	
33-79	19388-19389	,	_	
33-80	19390-19395	there	_	
33-81	19396-19400	were	_	
33-82	19401-19403	no	_	
33-83	19404-19415	significant	_	
33-84	19416-19427	differences	_	
33-85	19428-19430	in	_	
33-86	19431-19434	the	_	
33-87	19435-19443	duration	_	
33-88	19444-19446	of	_	
33-89	19447-19456	illnesses	_	
33-90	19457-19460	and	_	
33-91	19461-19469	severity	_	
33-92	19470-19472	of	_	
33-93	19473-19481	clinical	_	
33-94	19482-19490	symptoms	_	
33-95	19491-19498	between	_	
33-96	19499-19502	the	_	
33-97	19503-19506	two	_	
33-98	19507-19520	genetic-based	_	
33-99	19521-19528	patient	_	
33-100	19529-19538	subgroups	_	
33-101	19538-19539	.	_	

#Text=rsFC of hippocampus
34-1	19540-19544	rsFC	_	
34-2	19545-19547	of	_	
34-3	19548-19559	hippocampus	_	

#Text=Functional connectivity of bilateral hippocampus
35-1	19560-19570	Functional	_	
35-2	19571-19583	connectivity	_	
35-3	19584-19586	of	_	
35-4	19587-19596	bilateral	_	
35-5	19597-19608	hippocampus	_	

#Text=Using analysis of covariance with sex, age, education and the hippocampal volume as covariances, we found that left hippocampus showed significant difference in rsFC with left inferior parietal cortex (Montreal Neurological Institute (MNI) atlas coordinates: x=âˆ’36, y=âˆ’56, z=43; voxels=42), and the right cerebellar posterior lobe (MNI coordinate: x=9, y=âˆ’75, z=âˆ’45; voxels=40) between the three groups at P<0.05 (corrected for multiple comparisons based on Monte Carlo simulations; Figure 2a). Post hoc test indicated that, compared with healthy controls and patients without RDVs, patients with RDVs demonstrated increased rsFC between left hippocampus and left inferior parietal cortex, as well as decreased rsFC between left hippocampus and right cerebellum posterior lobe. In contrast, there was no significantly different rsFC between healthy controls and patients without RDVs (Figure 2b). Unlike in the left hippocampus, there were no significant rsFC differences in the right hippocampus with other brain regions among the three groups.
36-1	19609-19614	Using	_	
36-2	19615-19623	analysis	_	
36-3	19624-19626	of	_	
36-4	19627-19637	covariance	_	
36-5	19638-19642	with	_	
36-6	19643-19646	sex	_	
36-7	19646-19647	,	_	
36-8	19648-19651	age	_	
36-9	19651-19652	,	_	
36-10	19653-19662	education	_	
36-11	19663-19666	and	_	
36-12	19667-19670	the	_	
36-13	19671-19682	hippocampal	_	
36-14	19683-19689	volume	_	
36-15	19690-19692	as	_	
36-16	19693-19704	covariances	_	
36-17	19704-19705	,	_	
36-18	19706-19708	we	_	
36-19	19709-19714	found	_	
36-20	19715-19719	that	_	
36-21	19720-19724	left	_	
36-22	19725-19736	hippocampus	_	
36-23	19737-19743	showed	_	
36-24	19744-19755	significant	_	
36-25	19756-19766	difference	_	
36-26	19767-19769	in	_	
36-27	19770-19774	rsFC	_	
36-28	19775-19779	with	_	
36-29	19780-19784	left	_	
36-30	19785-19793	inferior	_	
36-31	19794-19802	parietal	_	
36-32	19803-19809	cortex	_	
36-33	19810-19811	(	_	
36-34	19811-19819	Montreal	_	
36-35	19820-19832	Neurological	_	
36-36	19833-19842	Institute	_	
36-37	19843-19844	(	_	
36-38	19844-19847	MNI	_	
36-39	19847-19848	)	_	
36-40	19849-19854	atlas	_	
36-41	19855-19866	coordinates	_	
36-42	19866-19867	:	_	
36-43	19868-19869	x	_	
36-44	19869-19870	=	_	
36-45	19870-19871	âˆ’	_	
36-46	19871-19873	36	_	
36-47	19873-19874	,	_	
36-48	19875-19876	y	_	
36-49	19876-19877	=	_	
36-50	19877-19878	âˆ’	_	
36-51	19878-19880	56	_	
36-52	19880-19881	,	_	
36-53	19882-19883	z	_	
36-54	19883-19884	=	_	
36-55	19884-19886	43	_	
36-56	19886-19887	;	_	
36-57	19888-19894	voxels	_	
36-58	19894-19895	=	_	
36-59	19895-19897	42	_	
36-60	19897-19898	)	_	
36-61	19898-19899	,	_	
36-62	19900-19903	and	_	
36-63	19904-19907	the	_	
36-64	19908-19913	right	_	
36-65	19914-19924	cerebellar	_	
36-66	19925-19934	posterior	_	
36-67	19935-19939	lobe	_	
36-68	19940-19941	(	_	
36-69	19941-19944	MNI	_	
36-70	19945-19955	coordinate	_	
36-71	19955-19956	:	_	
36-72	19957-19958	x	_	
36-73	19958-19959	=	_	
36-74	19959-19960	9	_	
36-75	19960-19961	,	_	
36-76	19962-19963	y	_	
36-77	19963-19964	=	_	
36-78	19964-19965	âˆ’	_	
36-79	19965-19967	75	_	
36-80	19967-19968	,	_	
36-81	19969-19970	z	_	
36-82	19970-19971	=	_	
36-83	19971-19972	âˆ’	_	
36-84	19972-19974	45	_	
36-85	19974-19975	;	_	
36-86	19976-19982	voxels	_	
36-87	19982-19983	=	_	
36-88	19983-19985	40	_	
36-89	19985-19986	)	_	
36-90	19987-19994	between	_	
36-91	19995-19998	the	_	
36-92	19999-20004	three	_	
36-93	20005-20011	groups	_	
36-94	20012-20014	at	_	
36-95	20015-20016	P	_	
36-96	20016-20017	<	_	
36-97	20017-20021	0.05	_	
36-98	20022-20023	(	_	
36-99	20023-20032	corrected	_	
36-100	20033-20036	for	_	
36-101	20037-20045	multiple	_	
36-102	20046-20057	comparisons	_	
36-103	20058-20063	based	_	
36-104	20064-20066	on	_	
36-105	20067-20072	Monte	_	
36-106	20073-20078	Carlo	_	
36-107	20079-20090	simulations	_	
36-108	20090-20091	;	_	
36-109	20092-20098	Figure	_	
36-110	20099-20101	2a	_	
36-111	20101-20102	)	_	
36-112	20102-20103	.	_	
36-113	20104-20108	Post	_	
36-114	20109-20112	hoc	_	
36-115	20113-20117	test	_	
36-116	20118-20127	indicated	_	
36-117	20128-20132	that	_	
36-118	20132-20133	,	_	
36-119	20134-20142	compared	_	
36-120	20143-20147	with	_	
36-121	20148-20155	healthy	_	
36-122	20156-20164	controls	_	
36-123	20165-20168	and	_	
36-124	20169-20177	patients	_	
36-125	20178-20185	without	_	
36-126	20186-20190	RDVs	_	
36-127	20190-20191	,	_	
36-128	20192-20200	patients	_	
36-129	20201-20205	with	_	
36-130	20206-20210	RDVs	_	
36-131	20211-20223	demonstrated	_	
36-132	20224-20233	increased	_	
36-133	20234-20238	rsFC	_	
36-134	20239-20246	between	_	
36-135	20247-20251	left	_	
36-136	20252-20263	hippocampus	_	
36-137	20264-20267	and	_	
36-138	20268-20272	left	_	
36-139	20273-20281	inferior	_	
36-140	20282-20290	parietal	_	
36-141	20291-20297	cortex	_	
36-142	20297-20298	,	_	
36-143	20299-20301	as	_	
36-144	20302-20306	well	_	
36-145	20307-20309	as	_	
36-146	20310-20319	decreased	_	
36-147	20320-20324	rsFC	_	
36-148	20325-20332	between	_	
36-149	20333-20337	left	_	
36-150	20338-20349	hippocampus	_	
36-151	20350-20353	and	_	
36-152	20354-20359	right	_	
36-153	20360-20370	cerebellum	_	
36-154	20371-20380	posterior	_	
36-155	20381-20385	lobe	_	
36-156	20385-20386	.	_	
36-157	20387-20389	In	_	
36-158	20390-20398	contrast	_	
36-159	20398-20399	,	_	
36-160	20400-20405	there	_	
36-161	20406-20409	was	_	
36-162	20410-20412	no	_	
36-163	20413-20426	significantly	_	
36-164	20427-20436	different	_	
36-165	20437-20441	rsFC	_	
36-166	20442-20449	between	_	
36-167	20450-20457	healthy	_	
36-168	20458-20466	controls	_	
36-169	20467-20470	and	_	
36-170	20471-20479	patients	_	
36-171	20480-20487	without	_	
36-172	20488-20492	RDVs	_	
36-173	20493-20494	(	_	
36-174	20494-20500	Figure	_	
36-175	20501-20503	2b	_	
36-176	20503-20504	)	_	
36-177	20504-20505	.	_	
36-178	20506-20512	Unlike	_	
36-179	20513-20515	in	_	
36-180	20516-20519	the	_	
36-181	20520-20524	left	_	
36-182	20525-20536	hippocampus	_	
36-183	20536-20537	,	_	
36-184	20538-20543	there	_	
36-185	20544-20548	were	_	
36-186	20549-20551	no	_	
36-187	20552-20563	significant	_	
36-188	20564-20568	rsFC	_	
36-189	20569-20580	differences	_	
36-190	20581-20583	in	_	
36-191	20584-20587	the	_	
36-192	20588-20593	right	_	
36-193	20594-20605	hippocampus	_	
36-194	20606-20610	with	_	
36-195	20611-20616	other	_	
36-196	20617-20622	brain	_	
36-197	20623-20630	regions	_	
36-198	20631-20636	among	_	
36-199	20637-20640	the	_	
36-200	20641-20646	three	_	
36-201	20647-20653	groups	_	
36-202	20653-20654	.	_	

#Text=rsFC of the six hippocampal subregions
37-1	20655-20659	rsFC	_	
37-2	20660-20662	of	_	
37-3	20663-20666	the	_	
37-4	20667-20670	six	_	
37-5	20671-20682	hippocampal	_	
37-6	20683-20693	subregions	_	

#Text=Analysis of covariance showed significant differences in rsFC between the left dentate gyrus (DG) and left inferior parietal cortex (MNI coordinate: x=âˆ’36, y=âˆ’54, z=42; voxels=77), between right DG and left inferior parietal cortex (MNI coordinate: x=âˆ’48, y=âˆ’54, z=48; voxels=46) as well as posterior cingulate cortex (MNI coordinate: x=âˆ’6, y=âˆ’33, z=30; voxels=33), between left CA and right calcarine (MNI coordinate: x=24, y=âˆ’93, z=0; voxels=68), between right CA and right calcarine (MNI coordinate: x=21, y=âˆ’93, z=3; voxels=68) as well as left fusiform (MNI coordinate: x=âˆ’27, y=âˆ’54, z=âˆ’3; voxels=32), between left SC and orbital medial frontal cortex (MNI coordinate: x=3, y=30, z=âˆ’12; voxels=37) among the three groups at P<0.05 (corrected for multiple comparisons based on Monte Carlo simulations).
38-1	20694-20702	Analysis	_	
38-2	20703-20705	of	_	
38-3	20706-20716	covariance	_	
38-4	20717-20723	showed	_	
38-5	20724-20735	significant	_	
38-6	20736-20747	differences	_	
38-7	20748-20750	in	_	
38-8	20751-20755	rsFC	_	
38-9	20756-20763	between	_	
38-10	20764-20767	the	_	
38-11	20768-20772	left	_	
38-12	20773-20780	dentate	_	
38-13	20781-20786	gyrus	_	
38-14	20787-20788	(	_	
38-15	20788-20790	DG	_	
38-16	20790-20791	)	_	
38-17	20792-20795	and	_	
38-18	20796-20800	left	_	
38-19	20801-20809	inferior	_	
38-20	20810-20818	parietal	_	
38-21	20819-20825	cortex	_	
38-22	20826-20827	(	_	
38-23	20827-20830	MNI	_	
38-24	20831-20841	coordinate	_	
38-25	20841-20842	:	_	
38-26	20843-20844	x	_	
38-27	20844-20845	=	_	
38-28	20845-20846	âˆ’	_	
38-29	20846-20848	36	_	
38-30	20848-20849	,	_	
38-31	20850-20851	y	_	
38-32	20851-20852	=	_	
38-33	20852-20853	âˆ’	_	
38-34	20853-20855	54	_	
38-35	20855-20856	,	_	
38-36	20857-20858	z	_	
38-37	20858-20859	=	_	
38-38	20859-20861	42	_	
38-39	20861-20862	;	_	
38-40	20863-20869	voxels	_	
38-41	20869-20870	=	_	
38-42	20870-20872	77	_	
38-43	20872-20873	)	_	
38-44	20873-20874	,	_	
38-45	20875-20882	between	_	
38-46	20883-20888	right	_	
38-47	20889-20891	DG	_	
38-48	20892-20895	and	_	
38-49	20896-20900	left	_	
38-50	20901-20909	inferior	_	
38-51	20910-20918	parietal	_	
38-52	20919-20925	cortex	_	
38-53	20926-20927	(	_	
38-54	20927-20930	MNI	_	
38-55	20931-20941	coordinate	_	
38-56	20941-20942	:	_	
38-57	20943-20944	x	_	
38-58	20944-20945	=	_	
38-59	20945-20946	âˆ’	_	
38-60	20946-20948	48	_	
38-61	20948-20949	,	_	
38-62	20950-20951	y	_	
38-63	20951-20952	=	_	
38-64	20952-20953	âˆ’	_	
38-65	20953-20955	54	_	
38-66	20955-20956	,	_	
38-67	20957-20958	z	_	
38-68	20958-20959	=	_	
38-69	20959-20961	48	_	
38-70	20961-20962	;	_	
38-71	20963-20969	voxels	_	
38-72	20969-20970	=	_	
38-73	20970-20972	46	_	
38-74	20972-20973	)	_	
38-75	20974-20976	as	_	
38-76	20977-20981	well	_	
38-77	20982-20984	as	_	
38-78	20985-20994	posterior	_	
38-79	20995-21004	cingulate	_	
38-80	21005-21011	cortex	_	
38-81	21012-21013	(	_	
38-82	21013-21016	MNI	_	
38-83	21017-21027	coordinate	_	
38-84	21027-21028	:	_	
38-85	21029-21030	x	_	
38-86	21030-21031	=	_	
38-87	21031-21032	âˆ’	_	
38-88	21032-21033	6	_	
38-89	21033-21034	,	_	
38-90	21035-21036	y	_	
38-91	21036-21037	=	_	
38-92	21037-21038	âˆ’	_	
38-93	21038-21040	33	_	
38-94	21040-21041	,	_	
38-95	21042-21043	z	_	
38-96	21043-21044	=	_	
38-97	21044-21046	30	_	
38-98	21046-21047	;	_	
38-99	21048-21054	voxels	_	
38-100	21054-21055	=	_	
38-101	21055-21057	33	_	
38-102	21057-21058	)	_	
38-103	21058-21059	,	_	
38-104	21060-21067	between	_	
38-105	21068-21072	left	_	
38-106	21073-21075	CA	_	
38-107	21076-21079	and	_	
38-108	21080-21085	right	_	
38-109	21086-21095	calcarine	_	
38-110	21096-21097	(	_	
38-111	21097-21100	MNI	_	
38-112	21101-21111	coordinate	_	
38-113	21111-21112	:	_	
38-114	21113-21114	x	_	
38-115	21114-21115	=	_	
38-116	21115-21117	24	_	
38-117	21117-21118	,	_	
38-118	21119-21120	y	_	
38-119	21120-21121	=	_	
38-120	21121-21122	âˆ’	_	
38-121	21122-21124	93	_	
38-122	21124-21125	,	_	
38-123	21126-21127	z	_	
38-124	21127-21128	=	_	
38-125	21128-21129	0	_	
38-126	21129-21130	;	_	
38-127	21131-21137	voxels	_	
38-128	21137-21138	=	_	
38-129	21138-21140	68	_	
38-130	21140-21141	)	_	
38-131	21141-21142	,	_	
38-132	21143-21150	between	_	
38-133	21151-21156	right	_	
38-134	21157-21159	CA	_	
38-135	21160-21163	and	_	
38-136	21164-21169	right	_	
38-137	21170-21179	calcarine	_	
38-138	21180-21181	(	_	
38-139	21181-21184	MNI	_	
38-140	21185-21195	coordinate	_	
38-141	21195-21196	:	_	
38-142	21197-21198	x	_	
38-143	21198-21199	=	_	
38-144	21199-21201	21	_	
38-145	21201-21202	,	_	
38-146	21203-21204	y	_	
38-147	21204-21205	=	_	
38-148	21205-21206	âˆ’	_	
38-149	21206-21208	93	_	
38-150	21208-21209	,	_	
38-151	21210-21211	z	_	
38-152	21211-21212	=	_	
38-153	21212-21213	3	_	
38-154	21213-21214	;	_	
38-155	21215-21221	voxels	_	
38-156	21221-21222	=	_	
38-157	21222-21224	68	_	
38-158	21224-21225	)	_	
38-159	21226-21228	as	_	
38-160	21229-21233	well	_	
38-161	21234-21236	as	_	
38-162	21237-21241	left	_	
38-163	21242-21250	fusiform	_	
38-164	21251-21252	(	_	
38-165	21252-21255	MNI	_	
38-166	21256-21266	coordinate	_	
38-167	21266-21267	:	_	
38-168	21268-21269	x	_	
38-169	21269-21270	=	_	
38-170	21270-21271	âˆ’	_	
38-171	21271-21273	27	_	
38-172	21273-21274	,	_	
38-173	21275-21276	y	_	
38-174	21276-21277	=	_	
38-175	21277-21278	âˆ’	_	
38-176	21278-21280	54	_	
38-177	21280-21281	,	_	
38-178	21282-21283	z	_	
38-179	21283-21284	=	_	
38-180	21284-21285	âˆ’	_	
38-181	21285-21286	3	_	
38-182	21286-21287	;	_	
38-183	21288-21294	voxels	_	
38-184	21294-21295	=	_	
38-185	21295-21297	32	_	
38-186	21297-21298	)	_	
38-187	21298-21299	,	_	
38-188	21300-21307	between	_	
38-189	21308-21312	left	_	
38-190	21313-21315	SC	_	
38-191	21316-21319	and	_	
38-192	21320-21327	orbital	_	
38-193	21328-21334	medial	_	
38-194	21335-21342	frontal	_	
38-195	21343-21349	cortex	_	
38-196	21350-21351	(	_	
38-197	21351-21354	MNI	_	
38-198	21355-21365	coordinate	_	
38-199	21365-21366	:	_	
38-200	21367-21368	x	_	
38-201	21368-21369	=	_	
38-202	21369-21370	3	_	
38-203	21370-21371	,	_	
38-204	21372-21373	y	_	
38-205	21373-21374	=	_	
38-206	21374-21376	30	_	
38-207	21376-21377	,	_	
38-208	21378-21379	z	_	
38-209	21379-21380	=	_	
38-210	21380-21381	âˆ’	_	
38-211	21381-21383	12	_	
38-212	21383-21384	;	_	
38-213	21385-21391	voxels	_	
38-214	21391-21392	=	_	
38-215	21392-21394	37	_	
38-216	21394-21395	)	_	
38-217	21396-21401	among	_	
38-218	21402-21405	the	_	
38-219	21406-21411	three	_	
38-220	21412-21418	groups	_	
38-221	21419-21421	at	_	
38-222	21422-21423	P	_	
38-223	21423-21424	<	_	
38-224	21424-21428	0.05	_	
38-225	21429-21430	(	_	
38-226	21430-21439	corrected	_	
38-227	21440-21443	for	_	
38-228	21444-21452	multiple	_	
38-229	21453-21464	comparisons	_	
38-230	21465-21470	based	_	
38-231	21471-21473	on	_	
38-232	21474-21479	Monte	_	
38-233	21480-21485	Carlo	_	
38-234	21486-21497	simulations	_	
38-235	21497-21498	)	_	
38-236	21498-21499	.	_	

#Text=Post hoc tests indicated that increased rsFC between left DG and left inferior parietal cortex was only found in patients with RDVs, whereas increased rsFC between right DG and left inferior parietal cortex as well as posterior cingulum was detected in both patients group. rsFC of CA was significantly decreased in patients without RDVs and a trend decreased in patients with RDVs. Decreased rsFC of left SC and orbital medial frontal cortex was found only in patients without RDVs (Table 3, Figure 3).
39-1	21500-21504	Post	_	
39-2	21505-21508	hoc	_	
39-3	21509-21514	tests	_	
39-4	21515-21524	indicated	_	
39-5	21525-21529	that	_	
39-6	21530-21539	increased	_	
39-7	21540-21544	rsFC	_	
39-8	21545-21552	between	_	
39-9	21553-21557	left	_	
39-10	21558-21560	DG	_	
39-11	21561-21564	and	_	
39-12	21565-21569	left	_	
39-13	21570-21578	inferior	_	
39-14	21579-21587	parietal	_	
39-15	21588-21594	cortex	_	
39-16	21595-21598	was	_	
39-17	21599-21603	only	_	
39-18	21604-21609	found	_	
39-19	21610-21612	in	_	
39-20	21613-21621	patients	_	
39-21	21622-21626	with	_	
39-22	21627-21631	RDVs	_	
39-23	21631-21632	,	_	
39-24	21633-21640	whereas	_	
39-25	21641-21650	increased	_	
39-26	21651-21655	rsFC	_	
39-27	21656-21663	between	_	
39-28	21664-21669	right	_	
39-29	21670-21672	DG	_	
39-30	21673-21676	and	_	
39-31	21677-21681	left	_	
39-32	21682-21690	inferior	_	
39-33	21691-21699	parietal	_	
39-34	21700-21706	cortex	_	
39-35	21707-21709	as	_	
39-36	21710-21714	well	_	
39-37	21715-21717	as	_	
39-38	21718-21727	posterior	_	
39-39	21728-21736	cingulum	_	
39-40	21737-21740	was	_	
39-41	21741-21749	detected	_	
39-42	21750-21752	in	_	
39-43	21753-21757	both	_	
39-44	21758-21766	patients	_	
39-45	21767-21772	group	_	
39-46	21772-21773	.	_	
39-47	21774-21778	rsFC	_	
39-48	21779-21781	of	_	
39-49	21782-21784	CA	_	
39-50	21785-21788	was	_	
39-51	21789-21802	significantly	_	
39-52	21803-21812	decreased	_	
39-53	21813-21815	in	_	
39-54	21816-21824	patients	_	
39-55	21825-21832	without	_	
39-56	21833-21837	RDVs	_	
39-57	21838-21841	and	_	
39-58	21842-21843	a	_	
39-59	21844-21849	trend	_	
39-60	21850-21859	decreased	_	
39-61	21860-21862	in	_	
39-62	21863-21871	patients	_	
39-63	21872-21876	with	_	
39-64	21877-21881	RDVs	_	
39-65	21881-21882	.	_	
39-66	21883-21892	Decreased	_	
39-67	21893-21897	rsFC	_	
39-68	21898-21900	of	_	
39-69	21901-21905	left	_	
39-70	21906-21908	SC	_	
39-71	21909-21912	and	_	
39-72	21913-21920	orbital	_	
39-73	21921-21927	medial	_	
39-74	21928-21935	frontal	_	
39-75	21936-21942	cortex	_	
39-76	21943-21946	was	_	
39-77	21947-21952	found	_	
39-78	21953-21957	only	_	
39-79	21958-21960	in	_	
39-80	21961-21969	patients	_	
39-81	21970-21977	without	_	
39-82	21978-21982	RDVs	_	
39-83	21983-21984	(	_	
39-84	21984-21989	Table	_	
39-85	21990-21991	3	_	
39-86	21991-21992	,	_	
39-87	21993-21999	Figure	_	
39-88	22000-22001	3	_	
39-89	22001-22002	)	_	
39-90	22002-22003	.	_	

#Text=Relationships between hippocampal rsFC and memory
40-1	22004-22017	Relationships	_	
40-2	22018-22025	between	_	
40-3	22026-22037	hippocampal	_	
40-4	22038-22042	rsFC	_	
40-5	22043-22046	and	_	
40-6	22047-22053	memory	_	

#Text=Compared with healthy controls, both patient groups showed significant impairments in SWM as well as in immediate and delayed logical memory (Supplementary Figure 4). No significant differences in these measures were observed between the two genetic-based subgroups in schizophrenic patients, that is, with and without RDVs (Supplementary Figure 4). Despite the lack of memory-related differences between the two genetic subgroups, we nevertheless observed different correlation patterns between rsFC and cognitive deficits. Errors in SWM were positively correlated to rsFC between left DG and left inferior parietal cortex in schizophrenic patients with RDVs (r=0.670, uncorrected P=0.034), whereas they were negatively correlated to rsFC between left DG and left inferior parietal cortex in healthy controls (r=âˆ’0.373, uncorrected P=0.032; Figure 4). However, after correction for multiple tests, none of correlations above remains significant statistically, probably because of the small sample size. No correlation was observed in schizophrenic patients without RDV (r=âˆ’0.102, uncorrected P=0.739).
41-1	22054-22062	Compared	_	
41-2	22063-22067	with	_	
41-3	22068-22075	healthy	_	
41-4	22076-22084	controls	_	
41-5	22084-22085	,	_	
41-6	22086-22090	both	_	
41-7	22091-22098	patient	_	
41-8	22099-22105	groups	_	
41-9	22106-22112	showed	_	
41-10	22113-22124	significant	_	
41-11	22125-22136	impairments	_	
41-12	22137-22139	in	_	
41-13	22140-22143	SWM	_	
41-14	22144-22146	as	_	
41-15	22147-22151	well	_	
41-16	22152-22154	as	_	
41-17	22155-22157	in	_	
41-18	22158-22167	immediate	_	
41-19	22168-22171	and	_	
41-20	22172-22179	delayed	_	
41-21	22180-22187	logical	_	
41-22	22188-22194	memory	_	
41-23	22195-22196	(	_	
41-24	22196-22209	Supplementary	_	
41-25	22210-22216	Figure	_	
41-26	22217-22218	4	_	
41-27	22218-22219	)	_	
41-28	22219-22220	.	_	
41-29	22221-22223	No	_	
41-30	22224-22235	significant	_	
41-31	22236-22247	differences	_	
41-32	22248-22250	in	_	
41-33	22251-22256	these	_	
41-34	22257-22265	measures	_	
41-35	22266-22270	were	_	
41-36	22271-22279	observed	_	
41-37	22280-22287	between	_	
41-38	22288-22291	the	_	
41-39	22292-22295	two	_	
41-40	22296-22309	genetic-based	_	
41-41	22310-22319	subgroups	_	
41-42	22320-22322	in	_	
41-43	22323-22336	schizophrenic	_	
41-44	22337-22345	patients	_	
41-45	22345-22346	,	_	
41-46	22347-22351	that	_	
41-47	22352-22354	is	_	
41-48	22354-22355	,	_	
41-49	22356-22360	with	_	
41-50	22361-22364	and	_	
41-51	22365-22372	without	_	
41-52	22373-22377	RDVs	_	
41-53	22378-22379	(	_	
41-54	22379-22392	Supplementary	_	
41-55	22393-22399	Figure	_	
41-56	22400-22401	4	_	
41-57	22401-22402	)	_	
41-58	22402-22403	.	_	
41-59	22404-22411	Despite	_	
41-60	22412-22415	the	_	
41-61	22416-22420	lack	_	
41-62	22421-22423	of	_	
41-63	22424-22438	memory-related	_	
41-64	22439-22450	differences	_	
41-65	22451-22458	between	_	
41-66	22459-22462	the	_	
41-67	22463-22466	two	_	
41-68	22467-22474	genetic	_	
41-69	22475-22484	subgroups	_	
41-70	22484-22485	,	_	
41-71	22486-22488	we	_	
41-72	22489-22501	nevertheless	_	
41-73	22502-22510	observed	_	
41-74	22511-22520	different	_	
41-75	22521-22532	correlation	_	
41-76	22533-22541	patterns	_	
41-77	22542-22549	between	_	
41-78	22550-22554	rsFC	_	
41-79	22555-22558	and	_	
41-80	22559-22568	cognitive	_	
41-81	22569-22577	deficits	_	
41-82	22577-22578	.	_	
41-83	22579-22585	Errors	_	
41-84	22586-22588	in	_	
41-85	22589-22592	SWM	_	
41-86	22593-22597	were	_	
41-87	22598-22608	positively	_	
41-88	22609-22619	correlated	_	
41-89	22620-22622	to	_	
41-90	22623-22627	rsFC	_	
41-91	22628-22635	between	_	
41-92	22636-22640	left	_	
41-93	22641-22643	DG	_	
41-94	22644-22647	and	_	
41-95	22648-22652	left	_	
41-96	22653-22661	inferior	_	
41-97	22662-22670	parietal	_	
41-98	22671-22677	cortex	_	
41-99	22678-22680	in	_	
41-100	22681-22694	schizophrenic	_	
41-101	22695-22703	patients	_	
41-102	22704-22708	with	_	
41-103	22709-22713	RDVs	_	
41-104	22714-22715	(	_	
41-105	22715-22716	r	_	
41-106	22716-22717	=	_	
41-107	22717-22722	0.670	_	
41-108	22722-22723	,	_	
41-109	22724-22735	uncorrected	_	
41-110	22736-22737	P	_	
41-111	22737-22738	=	_	
41-112	22738-22743	0.034	_	
41-113	22743-22744	)	_	
41-114	22744-22745	,	_	
41-115	22746-22753	whereas	_	
41-116	22754-22758	they	_	
41-117	22759-22763	were	_	
41-118	22764-22774	negatively	_	
41-119	22775-22785	correlated	_	
41-120	22786-22788	to	_	
41-121	22789-22793	rsFC	_	
41-122	22794-22801	between	_	
41-123	22802-22806	left	_	
41-124	22807-22809	DG	_	
41-125	22810-22813	and	_	
41-126	22814-22818	left	_	
41-127	22819-22827	inferior	_	
41-128	22828-22836	parietal	_	
41-129	22837-22843	cortex	_	
41-130	22844-22846	in	_	
41-131	22847-22854	healthy	_	
41-132	22855-22863	controls	_	
41-133	22864-22865	(	_	
41-134	22865-22866	r	_	
41-135	22866-22867	=	_	
41-136	22867-22868	âˆ’	_	
41-137	22868-22873	0.373	_	
41-138	22873-22874	,	_	
41-139	22875-22886	uncorrected	_	
41-140	22887-22888	P	_	
41-141	22888-22889	=	_	
41-142	22889-22894	0.032	_	
41-143	22894-22895	;	_	
41-144	22896-22902	Figure	_	
41-145	22903-22904	4	_	
41-146	22904-22905	)	_	
41-147	22905-22906	.	_	
41-148	22907-22914	However	_	
41-149	22914-22915	,	_	
41-150	22916-22921	after	_	
41-151	22922-22932	correction	_	
41-152	22933-22936	for	_	
41-153	22937-22945	multiple	_	
41-154	22946-22951	tests	_	
41-155	22951-22952	,	_	
41-156	22953-22957	none	_	
41-157	22958-22960	of	_	
41-158	22961-22973	correlations	_	
41-159	22974-22979	above	_	
41-160	22980-22987	remains	_	
41-161	22988-22999	significant	_	
41-162	23000-23013	statistically	_	
41-163	23013-23014	,	_	
41-164	23015-23023	probably	_	
41-165	23024-23031	because	_	
41-166	23032-23034	of	_	
41-167	23035-23038	the	_	
41-168	23039-23044	small	_	
41-169	23045-23051	sample	_	
41-170	23052-23056	size	_	
41-171	23056-23057	.	_	
41-172	23058-23060	No	_	
41-173	23061-23072	correlation	_	
41-174	23073-23076	was	_	
41-175	23077-23085	observed	_	
41-176	23086-23088	in	_	
41-177	23089-23102	schizophrenic	_	
41-178	23103-23111	patients	_	
41-179	23112-23119	without	_	
41-180	23120-23123	RDV	_	
41-181	23124-23125	(	_	
41-182	23125-23126	r	_	
41-183	23126-23127	=	_	
41-184	23127-23128	âˆ’	_	
41-185	23128-23133	0.102	_	
41-186	23133-23134	,	_	
41-187	23135-23146	uncorrected	_	
41-188	23147-23148	P	_	
41-189	23148-23149	=	_	
41-190	23149-23154	0.739	_	
41-191	23154-23155	)	_	
41-192	23155-23156	.	_	

#Text=We then compared the correlation coefficient between each of the two groups by using Z-test. We found that the difference in correlations was statistically significant between schizophrenic patients with RDVs and healthy controls (Z=3.331, P=8.65 Ã— 10âˆ’4), as well as between patients with RDVs and those without RDVs (Z=2.171, P=0.030) after Bonferroni correction. No significant difference was found between patients without RDVs and healthy controls (Z=0.884, P=0.377).
42-1	23157-23159	We	_	
42-2	23160-23164	then	_	
42-3	23165-23173	compared	_	
42-4	23174-23177	the	_	
42-5	23178-23189	correlation	_	
42-6	23190-23201	coefficient	_	
42-7	23202-23209	between	_	
42-8	23210-23214	each	_	
42-9	23215-23217	of	_	
42-10	23218-23221	the	_	
42-11	23222-23225	two	_	
42-12	23226-23232	groups	_	
42-13	23233-23235	by	_	
42-14	23236-23241	using	_	
42-15	23242-23248	Z-test	_	
42-16	23248-23249	.	_	
42-17	23250-23252	We	_	
42-18	23253-23258	found	_	
42-19	23259-23263	that	_	
42-20	23264-23267	the	_	
42-21	23268-23278	difference	_	
42-22	23279-23281	in	_	
42-23	23282-23294	correlations	_	
42-24	23295-23298	was	_	
42-25	23299-23312	statistically	_	
42-26	23313-23324	significant	_	
42-27	23325-23332	between	_	
42-28	23333-23346	schizophrenic	_	
42-29	23347-23355	patients	_	
42-30	23356-23360	with	_	
42-31	23361-23365	RDVs	_	
42-32	23366-23369	and	_	
42-33	23370-23377	healthy	_	
42-34	23378-23386	controls	_	
42-35	23387-23388	(	_	
42-36	23388-23389	Z	_	
42-37	23389-23390	=	_	
42-38	23390-23395	3.331	_	
42-39	23395-23396	,	_	
42-40	23397-23398	P	_	
42-41	23398-23399	=	_	
42-42	23399-23403	8.65	_	
42-43	23404-23405	Ã—	_	
42-44	23406-23408	10	_	
42-45	23408-23409	âˆ’	_	
42-46	23409-23410	4	_	
42-47	23410-23411	)	_	
42-48	23411-23412	,	_	
42-49	23413-23415	as	_	
42-50	23416-23420	well	_	
42-51	23421-23423	as	_	
42-52	23424-23431	between	_	
42-53	23432-23440	patients	_	
42-54	23441-23445	with	_	
42-55	23446-23450	RDVs	_	
42-56	23451-23454	and	_	
42-57	23455-23460	those	_	
42-58	23461-23468	without	_	
42-59	23469-23473	RDVs	_	
42-60	23474-23475	(	_	
42-61	23475-23476	Z	_	
42-62	23476-23477	=	_	
42-63	23477-23482	2.171	_	
42-64	23482-23483	,	_	
42-65	23484-23485	P	_	
42-66	23485-23486	=	_	
42-67	23486-23491	0.030	_	
42-68	23491-23492	)	_	
42-69	23493-23498	after	_	
42-70	23499-23509	Bonferroni	_	
42-71	23510-23520	correction	_	
42-72	23520-23521	.	_	
42-73	23522-23524	No	_	
42-74	23525-23536	significant	_	
42-75	23537-23547	difference	_	
42-76	23548-23551	was	_	
42-77	23552-23557	found	_	
42-78	23558-23565	between	_	
42-79	23566-23574	patients	_	
42-80	23575-23582	without	_	
42-81	23583-23587	RDVs	_	
42-82	23588-23591	and	_	
42-83	23592-23599	healthy	_	
42-84	23600-23608	controls	_	
42-85	23609-23610	(	_	
42-86	23610-23611	Z	_	
42-87	23611-23612	=	_	
42-88	23612-23617	0.884	_	
42-89	23617-23618	,	_	
42-90	23619-23620	P	_	
42-91	23620-23621	=	_	
42-92	23621-23626	0.377	_	
42-93	23626-23627	)	_	
42-94	23627-23628	.	_	

#Text=Discussion
43-1	23629-23639	Discussion	_	

#Text=Investigating a unique large sample of first-episode treatment-naive schizophrenic patients, we first identified that 56 RDVs in 42 genes within two pathways implicated in DNA repair and cell cycle were present only in a subgroup including 39 schizophrenic patients, whereas the remaining schizophrenic patients (that is, those without RDVs) as well as healthy subjects did not show these RDVs. Further analysis revealed that these genes are highly expressed during the stage of brain development before birth, with a sharp decreased expression after birth in specifically the hippocampus. Second, we identified a unique hippocampus rsFC pattern in schizophrenic patients with RDVs, that is, increased rsFC between left hippocampus (especially for left dentate gyrus) and left inferior parietal cortex, as well as decreased rsFC between the left hippocampus and cerebellum. Subsequently, we found a tentative significant correlation of altered hippocampal rsFC with spatial memory deficits in schizophrenic patients with RDVs.
44-1	23640-23653	Investigating	_	
44-2	23654-23655	a	_	
44-3	23656-23662	unique	_	
44-4	23663-23668	large	_	
44-5	23669-23675	sample	_	
44-6	23676-23678	of	_	
44-7	23679-23692	first-episode	_	
44-8	23693-23708	treatment-naive	_	
44-9	23709-23722	schizophrenic	_	
44-10	23723-23731	patients	_	
44-11	23731-23732	,	_	
44-12	23733-23735	we	_	
44-13	23736-23741	first	_	
44-14	23742-23752	identified	_	
44-15	23753-23757	that	_	
44-16	23758-23760	56	_	
44-17	23761-23765	RDVs	_	
44-18	23766-23768	in	_	
44-19	23769-23771	42	_	
44-20	23772-23777	genes	_	
44-21	23778-23784	within	_	
44-22	23785-23788	two	_	
44-23	23789-23797	pathways	_	
44-24	23798-23808	implicated	_	
44-25	23809-23811	in	_	
44-26	23812-23815	DNA	_	
44-27	23816-23822	repair	_	
44-28	23823-23826	and	_	
44-29	23827-23831	cell	_	
44-30	23832-23837	cycle	_	
44-31	23838-23842	were	_	
44-32	23843-23850	present	_	
44-33	23851-23855	only	_	
44-34	23856-23858	in	_	
44-35	23859-23860	a	_	
44-36	23861-23869	subgroup	_	
44-37	23870-23879	including	_	
44-38	23880-23882	39	_	
44-39	23883-23896	schizophrenic	_	
44-40	23897-23905	patients	_	
44-41	23905-23906	,	_	
44-42	23907-23914	whereas	_	
44-43	23915-23918	the	_	
44-44	23919-23928	remaining	_	
44-45	23929-23942	schizophrenic	_	
44-46	23943-23951	patients	_	
44-47	23952-23953	(	_	
44-48	23953-23957	that	_	
44-49	23958-23960	is	_	
44-50	23960-23961	,	_	
44-51	23962-23967	those	_	
44-52	23968-23975	without	_	
44-53	23976-23980	RDVs	_	
44-54	23980-23981	)	_	
44-55	23982-23984	as	_	
44-56	23985-23989	well	_	
44-57	23990-23992	as	_	
44-58	23993-24000	healthy	_	
44-59	24001-24009	subjects	_	
44-60	24010-24013	did	_	
44-61	24014-24017	not	_	
44-62	24018-24022	show	_	
44-63	24023-24028	these	_	
44-64	24029-24033	RDVs	_	
44-65	24033-24034	.	_	
44-66	24035-24042	Further	_	
44-67	24043-24051	analysis	_	
44-68	24052-24060	revealed	_	
44-69	24061-24065	that	_	
44-70	24066-24071	these	_	
44-71	24072-24077	genes	_	
44-72	24078-24081	are	_	
44-73	24082-24088	highly	_	
44-74	24089-24098	expressed	_	
44-75	24099-24105	during	_	
44-76	24106-24109	the	_	
44-77	24110-24115	stage	_	
44-78	24116-24118	of	_	
44-79	24119-24124	brain	_	
44-80	24125-24136	development	_	
44-81	24137-24143	before	_	
44-82	24144-24149	birth	_	
44-83	24149-24150	,	_	
44-84	24151-24155	with	_	
44-85	24156-24157	a	_	
44-86	24158-24163	sharp	_	
44-87	24164-24173	decreased	_	
44-88	24174-24184	expression	_	
44-89	24185-24190	after	_	
44-90	24191-24196	birth	_	
44-91	24197-24199	in	_	
44-92	24200-24212	specifically	_	
44-93	24213-24216	the	_	
44-94	24217-24228	hippocampus	_	
44-95	24228-24229	.	_	
44-96	24230-24236	Second	_	
44-97	24236-24237	,	_	
44-98	24238-24240	we	_	
44-99	24241-24251	identified	_	
44-100	24252-24253	a	_	
44-101	24254-24260	unique	_	
44-102	24261-24272	hippocampus	_	
44-103	24273-24277	rsFC	_	
44-104	24278-24285	pattern	_	
44-105	24286-24288	in	_	
44-106	24289-24302	schizophrenic	_	
44-107	24303-24311	patients	_	
44-108	24312-24316	with	_	
44-109	24317-24321	RDVs	_	
44-110	24321-24322	,	_	
44-111	24323-24327	that	_	
44-112	24328-24330	is	_	
44-113	24330-24331	,	_	
44-114	24332-24341	increased	_	
44-115	24342-24346	rsFC	_	
44-116	24347-24354	between	_	
44-117	24355-24359	left	_	
44-118	24360-24371	hippocampus	_	
44-119	24372-24373	(	_	
44-120	24373-24383	especially	_	
44-121	24384-24387	for	_	
44-122	24388-24392	left	_	
44-123	24393-24400	dentate	_	
44-124	24401-24406	gyrus	_	
44-125	24406-24407	)	_	
44-126	24408-24411	and	_	
44-127	24412-24416	left	_	
44-128	24417-24425	inferior	_	
44-129	24426-24434	parietal	_	
44-130	24435-24441	cortex	_	
44-131	24441-24442	,	_	
44-132	24443-24445	as	_	
44-133	24446-24450	well	_	
44-134	24451-24453	as	_	
44-135	24454-24463	decreased	_	
44-136	24464-24468	rsFC	_	
44-137	24469-24476	between	_	
44-138	24477-24480	the	_	
44-139	24481-24485	left	_	
44-140	24486-24497	hippocampus	_	
44-141	24498-24501	and	_	
44-142	24502-24512	cerebellum	_	
44-143	24512-24513	.	_	
44-144	24514-24526	Subsequently	_	
44-145	24526-24527	,	_	
44-146	24528-24530	we	_	
44-147	24531-24536	found	_	
44-148	24537-24538	a	_	
44-149	24539-24548	tentative	_	
44-150	24549-24560	significant	_	
44-151	24561-24572	correlation	_	
44-152	24573-24575	of	_	
44-153	24576-24583	altered	_	
44-154	24584-24595	hippocampal	_	
44-155	24596-24600	rsFC	_	
44-156	24601-24605	with	_	
44-157	24606-24613	spatial	_	
44-158	24614-24620	memory	_	
44-159	24621-24629	deficits	_	
44-160	24630-24632	in	_	
44-161	24633-24646	schizophrenic	_	
44-162	24647-24655	patients	_	
44-163	24656-24660	with	_	
44-164	24661-24665	RDVs	_	
44-165	24665-24666	.	_	

#Text=Schizophrenic patients harbor more than threefolds rare DNA mutations, especially in those with early onset of illness. More de novo mutations were found recently at genomic hotspots, including chromosomes 1q21.1, 15q13.3, 16p13.1 and 22q11.2. Studies in larger sample sets demonstrated a polygenic burden that increases the risk for schizophrenia, those genes primarily comprising many ultrarare nonsense mutations distributed across many genes, which mainly involved in neurodevelopment pathways. Considering the low frequency and larger effect sizes of rare DNA mutations in current studies, we focused here on the case-unique RDVs, and found that these variants enriched in two pathways, for example, cell cycle regulation and DNA repair. Our finding in current study supported that disturbances of cell cycle regulation and DNA repair in post-mitotic neurons have been implicated in development of psychotic disorders.
45-1	24667-24680	Schizophrenic	_	
45-2	24681-24689	patients	_	
45-3	24690-24696	harbor	_	
45-4	24697-24701	more	_	
45-5	24702-24706	than	_	
45-6	24707-24717	threefolds	_	
45-7	24718-24722	rare	_	
45-8	24723-24726	DNA	_	
45-9	24727-24736	mutations	_	
45-10	24736-24737	,	_	
45-11	24738-24748	especially	_	
45-12	24749-24751	in	_	
45-13	24752-24757	those	_	
45-14	24758-24762	with	_	
45-15	24763-24768	early	_	
45-16	24769-24774	onset	_	
45-17	24775-24777	of	_	
45-18	24778-24785	illness	_	
45-19	24785-24786	.	_	
45-20	24787-24791	More	_	
45-21	24792-24794	de	_	
45-22	24795-24799	novo	_	
45-23	24800-24809	mutations	_	
45-24	24810-24814	were	_	
45-25	24815-24820	found	_	
45-26	24821-24829	recently	_	
45-27	24830-24832	at	_	
45-28	24833-24840	genomic	_	
45-29	24841-24849	hotspots	_	
45-30	24849-24850	,	_	
45-31	24851-24860	including	_	
45-32	24861-24872	chromosomes	_	
45-33	24873-24879	1q21.1	_	
45-34	24879-24880	,	_	
45-35	24881-24888	15q13.3	_	
45-36	24888-24889	,	_	
45-37	24890-24897	16p13.1	_	
45-38	24898-24901	and	_	
45-39	24902-24909	22q11.2	_	
45-40	24909-24910	.	_	
45-41	24911-24918	Studies	_	
45-42	24919-24921	in	_	
45-43	24922-24928	larger	_	
45-44	24929-24935	sample	_	
45-45	24936-24940	sets	_	
45-46	24941-24953	demonstrated	_	
45-47	24954-24955	a	_	
45-48	24956-24965	polygenic	_	
45-49	24966-24972	burden	_	
45-50	24973-24977	that	_	
45-51	24978-24987	increases	_	
45-52	24988-24991	the	_	
45-53	24992-24996	risk	_	
45-54	24997-25000	for	_	
45-55	25001-25014	schizophrenia	_	
45-56	25014-25015	,	_	
45-57	25016-25021	those	_	
45-58	25022-25027	genes	_	
45-59	25028-25037	primarily	_	
45-60	25038-25048	comprising	_	
45-61	25049-25053	many	_	
45-62	25054-25063	ultrarare	_	
45-63	25064-25072	nonsense	_	
45-64	25073-25082	mutations	_	
45-65	25083-25094	distributed	_	
45-66	25095-25101	across	_	
45-67	25102-25106	many	_	
45-68	25107-25112	genes	_	
45-69	25112-25113	,	_	
45-70	25114-25119	which	_	
45-71	25120-25126	mainly	_	
45-72	25127-25135	involved	_	
45-73	25136-25138	in	_	
45-74	25139-25155	neurodevelopment	_	
45-75	25156-25164	pathways	_	
45-76	25164-25165	.	_	
45-77	25166-25177	Considering	_	
45-78	25178-25181	the	_	
45-79	25182-25185	low	_	
45-80	25186-25195	frequency	_	
45-81	25196-25199	and	_	
45-82	25200-25206	larger	_	
45-83	25207-25213	effect	_	
45-84	25214-25219	sizes	_	
45-85	25220-25222	of	_	
45-86	25223-25227	rare	_	
45-87	25228-25231	DNA	_	
45-88	25232-25241	mutations	_	
45-89	25242-25244	in	_	
45-90	25245-25252	current	_	
45-91	25253-25260	studies	_	
45-92	25260-25261	,	_	
45-93	25262-25264	we	_	
45-94	25265-25272	focused	_	
45-95	25273-25277	here	_	
45-96	25278-25280	on	_	
45-97	25281-25284	the	_	
45-98	25285-25296	case-unique	_	
45-99	25297-25301	RDVs	_	
45-100	25301-25302	,	_	
45-101	25303-25306	and	_	
45-102	25307-25312	found	_	
45-103	25313-25317	that	_	
45-104	25318-25323	these	_	
45-105	25324-25332	variants	_	
45-106	25333-25341	enriched	_	
45-107	25342-25344	in	_	
45-108	25345-25348	two	_	
45-109	25349-25357	pathways	_	
45-110	25357-25358	,	_	
45-111	25359-25362	for	_	
45-112	25363-25370	example	_	
45-113	25370-25371	,	_	
45-114	25372-25376	cell	_	
45-115	25377-25382	cycle	_	
45-116	25383-25393	regulation	_	
45-117	25394-25397	and	_	
45-118	25398-25401	DNA	_	
45-119	25402-25408	repair	_	
45-120	25408-25409	.	_	
45-121	25410-25413	Our	_	
45-122	25414-25421	finding	_	
45-123	25422-25424	in	_	
45-124	25425-25432	current	_	
45-125	25433-25438	study	_	
45-126	25439-25448	supported	_	
45-127	25449-25453	that	_	
45-128	25454-25466	disturbances	_	
45-129	25467-25469	of	_	
45-130	25470-25474	cell	_	
45-131	25475-25480	cycle	_	
45-132	25481-25491	regulation	_	
45-133	25492-25495	and	_	
45-134	25496-25499	DNA	_	
45-135	25500-25506	repair	_	
45-136	25507-25509	in	_	
45-137	25510-25522	post-mitotic	_	
45-138	25523-25530	neurons	_	
45-139	25531-25535	have	_	
45-140	25536-25540	been	_	
45-141	25541-25551	implicated	_	
45-142	25552-25554	in	_	
45-143	25555-25566	development	_	
45-144	25567-25569	of	_	
45-145	25570-25579	psychotic	_	
45-146	25580-25589	disorders	_	
45-147	25589-25590	.	_	

#Text=Importantly, most of the genes enrichment in these two pathways was detected to be highly expressed in the hippocampus in the fetal stage, with the expression level sharply decreasing after birth. On the basis of this finding, we could hypothesize that individuals possessing mutations in these two particular pathways may be more prone to develop schizophrenia later on because of the critical gene expressions during their fetal development. More interestingly, such hypothesis genetically specifies and conforms well with the neurodevelopmental model that emphasizes insults as early as late-first or early-second trimester as central for pathological activation of neural circuits in schizophrenia
46-1	25591-25602	Importantly	_	
46-2	25602-25603	,	_	
46-3	25604-25608	most	_	
46-4	25609-25611	of	_	
46-5	25612-25615	the	_	
46-6	25616-25621	genes	_	
46-7	25622-25632	enrichment	_	
46-8	25633-25635	in	_	
46-9	25636-25641	these	_	
46-10	25642-25645	two	_	
46-11	25646-25654	pathways	_	
46-12	25655-25658	was	_	
46-13	25659-25667	detected	_	
46-14	25668-25670	to	_	
46-15	25671-25673	be	_	
46-16	25674-25680	highly	_	
46-17	25681-25690	expressed	_	
46-18	25691-25693	in	_	
46-19	25694-25697	the	_	
46-20	25698-25709	hippocampus	_	
46-21	25710-25712	in	_	
46-22	25713-25716	the	_	
46-23	25717-25722	fetal	_	
46-24	25723-25728	stage	_	
46-25	25728-25729	,	_	
46-26	25730-25734	with	_	
46-27	25735-25738	the	_	
46-28	25739-25749	expression	_	
46-29	25750-25755	level	_	
46-30	25756-25763	sharply	_	
46-31	25764-25774	decreasing	_	
46-32	25775-25780	after	_	
46-33	25781-25786	birth	_	
46-34	25786-25787	.	_	
46-35	25788-25790	On	_	
46-36	25791-25794	the	_	
46-37	25795-25800	basis	_	
46-38	25801-25803	of	_	
46-39	25804-25808	this	_	
46-40	25809-25816	finding	_	
46-41	25816-25817	,	_	
46-42	25818-25820	we	_	
46-43	25821-25826	could	_	
46-44	25827-25838	hypothesize	_	
46-45	25839-25843	that	_	
46-46	25844-25855	individuals	_	
46-47	25856-25866	possessing	_	
46-48	25867-25876	mutations	_	
46-49	25877-25879	in	_	
46-50	25880-25885	these	_	
46-51	25886-25889	two	_	
46-52	25890-25900	particular	_	
46-53	25901-25909	pathways	_	
46-54	25910-25913	may	_	
46-55	25914-25916	be	_	
46-56	25917-25921	more	_	
46-57	25922-25927	prone	_	
46-58	25928-25930	to	_	
46-59	25931-25938	develop	_	
46-60	25939-25952	schizophrenia	_	
46-61	25953-25958	later	_	
46-62	25959-25961	on	_	
46-63	25962-25969	because	_	
46-64	25970-25972	of	_	
46-65	25973-25976	the	_	
46-66	25977-25985	critical	_	
46-67	25986-25990	gene	_	
46-68	25991-26002	expressions	_	
46-69	26003-26009	during	_	
46-70	26010-26015	their	_	
46-71	26016-26021	fetal	_	
46-72	26022-26033	development	_	
46-73	26033-26034	.	_	
46-74	26035-26039	More	_	
46-75	26040-26053	interestingly	_	
46-76	26053-26054	,	_	
46-77	26055-26059	such	_	
46-78	26060-26070	hypothesis	_	
46-79	26071-26082	genetically	_	
46-80	26083-26092	specifies	_	
46-81	26093-26096	and	_	
46-82	26097-26105	conforms	_	
46-83	26106-26110	well	_	
46-84	26111-26115	with	_	
46-85	26116-26119	the	_	
46-86	26120-26138	neurodevelopmental	_	
46-87	26139-26144	model	_	
46-88	26145-26149	that	_	
46-89	26150-26160	emphasizes	_	
46-90	26161-26168	insults	_	
46-91	26169-26171	as	_	
46-92	26172-26177	early	_	
46-93	26178-26180	as	_	
46-94	26181-26191	late-first	_	
46-95	26192-26194	or	_	
46-96	26195-26207	early-second	_	
46-97	26208-26217	trimester	_	
46-98	26218-26220	as	_	
46-99	26221-26228	central	_	
46-100	26229-26232	for	_	
46-101	26233-26245	pathological	_	
46-102	26246-26256	activation	_	
46-103	26257-26259	of	_	
46-104	26260-26266	neural	_	
46-105	26267-26275	circuits	_	
46-106	26276-26278	in	_	
46-107	26279-26292	schizophrenia	_	

#Text=Our finding of the RDVs in these two pathways hints upon alterations in cell cycle regulation and the DNA repair in schizophrenic patients during embryogenesis, although the underlying mechanisms are still in explicit. Study from Katsel et al. suggested abnormal patterns of cell cycle gene and protein expression in schizophrenia, which may contribute to the oligodendroglial deficits observed in schizophrenia. This could lead to changes in brain development and make the brain more susceptible to environmental risk factors, with downstream effects on neural progenitor proliferation and differentiation.
47-1	26293-26296	Our	_	
47-2	26297-26304	finding	_	
47-3	26305-26307	of	_	
47-4	26308-26311	the	_	
47-5	26312-26316	RDVs	_	
47-6	26317-26319	in	_	
47-7	26320-26325	these	_	
47-8	26326-26329	two	_	
47-9	26330-26338	pathways	_	
47-10	26339-26344	hints	_	
47-11	26345-26349	upon	_	
47-12	26350-26361	alterations	_	
47-13	26362-26364	in	_	
47-14	26365-26369	cell	_	
47-15	26370-26375	cycle	_	
47-16	26376-26386	regulation	_	
47-17	26387-26390	and	_	
47-18	26391-26394	the	_	
47-19	26395-26398	DNA	_	
47-20	26399-26405	repair	_	
47-21	26406-26408	in	_	
47-22	26409-26422	schizophrenic	_	
47-23	26423-26431	patients	_	
47-24	26432-26438	during	_	
47-25	26439-26452	embryogenesis	_	
47-26	26452-26453	,	_	
47-27	26454-26462	although	_	
47-28	26463-26466	the	_	
47-29	26467-26477	underlying	_	
47-30	26478-26488	mechanisms	_	
47-31	26489-26492	are	_	
47-32	26493-26498	still	_	
47-33	26499-26501	in	_	
47-34	26502-26510	explicit	_	
47-35	26510-26511	.	_	
47-36	26512-26517	Study	_	
47-37	26518-26522	from	_	
47-38	26523-26529	Katsel	_	
47-39	26530-26532	et	_	
47-40	26533-26535	al	_	
47-41	26535-26536	.	_	
47-42	26537-26546	suggested	_	
47-43	26547-26555	abnormal	_	
47-44	26556-26564	patterns	_	
47-45	26565-26567	of	_	
47-46	26568-26572	cell	_	
47-47	26573-26578	cycle	_	
47-48	26579-26583	gene	_	
47-49	26584-26587	and	_	
47-50	26588-26595	protein	_	
47-51	26596-26606	expression	_	
47-52	26607-26609	in	_	
47-53	26610-26623	schizophrenia	_	
47-54	26623-26624	,	_	
47-55	26625-26630	which	_	
47-56	26631-26634	may	_	
47-57	26635-26645	contribute	_	
47-58	26646-26648	to	_	
47-59	26649-26652	the	_	
47-60	26653-26669	oligodendroglial	_	
47-61	26670-26678	deficits	_	
47-62	26679-26687	observed	_	
47-63	26688-26690	in	_	
47-64	26691-26704	schizophrenia	_	
47-65	26704-26705	.	_	
47-66	26706-26710	This	_	
47-67	26711-26716	could	_	
47-68	26717-26721	lead	_	
47-69	26722-26724	to	_	
47-70	26725-26732	changes	_	
47-71	26733-26735	in	_	
47-72	26736-26741	brain	_	
47-73	26742-26753	development	_	
47-74	26754-26757	and	_	
47-75	26758-26762	make	_	
47-76	26763-26766	the	_	
47-77	26767-26772	brain	_	
47-78	26773-26777	more	_	
47-79	26778-26789	susceptible	_	
47-80	26790-26792	to	_	
47-81	26793-26806	environmental	_	
47-82	26807-26811	risk	_	
47-83	26812-26819	factors	_	
47-84	26819-26820	,	_	
47-85	26821-26825	with	_	
47-86	26826-26836	downstream	_	
47-87	26837-26844	effects	_	
47-88	26845-26847	on	_	
47-89	26848-26854	neural	_	
47-90	26855-26865	progenitor	_	
47-91	26866-26879	proliferation	_	
47-92	26880-26883	and	_	
47-93	26884-26899	differentiation	_	
47-94	26899-26900	.	_	

#Text=In the present study, we detected aberrant functional connectivity of left hippocampus with inferior parietal lobe, posterior cingulate cortex, visual cortex and medial frontal gyrus in schizophrenic patients with RDVs. In contrast, schizophrenic patients without RDVs did not show such pattern. This suggests that the aberrant resting-state functional connections of left hippocampus in schizophrenia might likely be of neurodevelopmental origin (rather than of neurodegenerative origin or affected by antipsychotics with the latter being excluded here anyway because of the fact that our sample of treatment-naive). Most interesting, we found that increased functional connectivity of left hippocampus (especially for the dentate gyrus) with left inferior parietal cortex and decreased FC between left hippocampus and cerebellum were only found in schizophrenic patients with RDVs. This further underlines the neurodevelopmental impact of RDV on phenotypic makers like the left hippocampal rsFC and its high relevance for schizophrenia. The exact mechanisms mediating the transition from early prenatal RDVs' occurrence to hippocampal rsFC abnormalities during the later outbreak of schizophrenia remain unclear though.
48-1	26901-26903	In	_	
48-2	26904-26907	the	_	
48-3	26908-26915	present	_	
48-4	26916-26921	study	_	
48-5	26921-26922	,	_	
48-6	26923-26925	we	_	
48-7	26926-26934	detected	_	
48-8	26935-26943	aberrant	_	
48-9	26944-26954	functional	_	
48-10	26955-26967	connectivity	_	
48-11	26968-26970	of	_	
48-12	26971-26975	left	_	
48-13	26976-26987	hippocampus	_	
48-14	26988-26992	with	_	
48-15	26993-27001	inferior	_	
48-16	27002-27010	parietal	_	
48-17	27011-27015	lobe	_	
48-18	27015-27016	,	_	
48-19	27017-27026	posterior	_	
48-20	27027-27036	cingulate	_	
48-21	27037-27043	cortex	_	
48-22	27043-27044	,	_	
48-23	27045-27051	visual	_	
48-24	27052-27058	cortex	_	
48-25	27059-27062	and	_	
48-26	27063-27069	medial	_	
48-27	27070-27077	frontal	_	
48-28	27078-27083	gyrus	_	
48-29	27084-27086	in	_	
48-30	27087-27100	schizophrenic	_	
48-31	27101-27109	patients	_	
48-32	27110-27114	with	_	
48-33	27115-27119	RDVs	_	
48-34	27119-27120	.	_	
48-35	27121-27123	In	_	
48-36	27124-27132	contrast	_	
48-37	27132-27133	,	_	
48-38	27134-27147	schizophrenic	_	
48-39	27148-27156	patients	_	
48-40	27157-27164	without	_	
48-41	27165-27169	RDVs	_	
48-42	27170-27173	did	_	
48-43	27174-27177	not	_	
48-44	27178-27182	show	_	
48-45	27183-27187	such	_	
48-46	27188-27195	pattern	_	
48-47	27195-27196	.	_	
48-48	27197-27201	This	_	
48-49	27202-27210	suggests	_	
48-50	27211-27215	that	_	
48-51	27216-27219	the	_	
48-52	27220-27228	aberrant	_	
48-53	27229-27242	resting-state	_	
48-54	27243-27253	functional	_	
48-55	27254-27265	connections	_	
48-56	27266-27268	of	_	
48-57	27269-27273	left	_	
48-58	27274-27285	hippocampus	_	
48-59	27286-27288	in	_	
48-60	27289-27302	schizophrenia	_	
48-61	27303-27308	might	_	
48-62	27309-27315	likely	_	
48-63	27316-27318	be	_	
48-64	27319-27321	of	_	
48-65	27322-27340	neurodevelopmental	_	
48-66	27341-27347	origin	_	
48-67	27348-27349	(	_	
48-68	27349-27355	rather	_	
48-69	27356-27360	than	_	
48-70	27361-27363	of	_	
48-71	27364-27381	neurodegenerative	_	
48-72	27382-27388	origin	_	
48-73	27389-27391	or	_	
48-74	27392-27400	affected	_	
48-75	27401-27403	by	_	
48-76	27404-27418	antipsychotics	_	
48-77	27419-27423	with	_	
48-78	27424-27427	the	_	
48-79	27428-27434	latter	_	
48-80	27435-27440	being	_	
48-81	27441-27449	excluded	_	
48-82	27450-27454	here	_	
48-83	27455-27461	anyway	_	
48-84	27462-27469	because	_	
48-85	27470-27472	of	_	
48-86	27473-27476	the	_	
48-87	27477-27481	fact	_	
48-88	27482-27486	that	_	
48-89	27487-27490	our	_	
48-90	27491-27497	sample	_	
48-91	27498-27500	of	_	
48-92	27501-27516	treatment-naive	_	
48-93	27516-27517	)	_	
48-94	27517-27518	.	_	
48-95	27519-27523	Most	_	
48-96	27524-27535	interesting	_	
48-97	27535-27536	,	_	
48-98	27537-27539	we	_	
48-99	27540-27545	found	_	
48-100	27546-27550	that	_	
48-101	27551-27560	increased	_	
48-102	27561-27571	functional	_	
48-103	27572-27584	connectivity	_	
48-104	27585-27587	of	_	
48-105	27588-27592	left	_	
48-106	27593-27604	hippocampus	_	
48-107	27605-27606	(	_	
48-108	27606-27616	especially	_	
48-109	27617-27620	for	_	
48-110	27621-27624	the	_	
48-111	27625-27632	dentate	_	
48-112	27633-27638	gyrus	_	
48-113	27638-27639	)	_	
48-114	27640-27644	with	_	
48-115	27645-27649	left	_	
48-116	27650-27658	inferior	_	
48-117	27659-27667	parietal	_	
48-118	27668-27674	cortex	_	
48-119	27675-27678	and	_	
48-120	27679-27688	decreased	_	
48-121	27689-27691	FC	_	
48-122	27692-27699	between	_	
48-123	27700-27704	left	_	
48-124	27705-27716	hippocampus	_	
48-125	27717-27720	and	_	
48-126	27721-27731	cerebellum	_	
48-127	27732-27736	were	_	
48-128	27737-27741	only	_	
48-129	27742-27747	found	_	
48-130	27748-27750	in	_	
48-131	27751-27764	schizophrenic	_	
48-132	27765-27773	patients	_	
48-133	27774-27778	with	_	
48-134	27779-27783	RDVs	_	
48-135	27783-27784	.	_	
48-136	27785-27789	This	_	
48-137	27790-27797	further	_	
48-138	27798-27808	underlines	_	
48-139	27809-27812	the	_	
48-140	27813-27831	neurodevelopmental	_	
48-141	27832-27838	impact	_	
48-142	27839-27841	of	_	
48-143	27842-27845	RDV	_	
48-144	27846-27848	on	_	
48-145	27849-27859	phenotypic	_	
48-146	27860-27866	makers	_	
48-147	27867-27871	like	_	
48-148	27872-27875	the	_	
48-149	27876-27880	left	_	
48-150	27881-27892	hippocampal	_	
48-151	27893-27897	rsFC	_	
48-152	27898-27901	and	_	
48-153	27902-27905	its	_	
48-154	27906-27910	high	_	
48-155	27911-27920	relevance	_	
48-156	27921-27924	for	_	
48-157	27925-27938	schizophrenia	_	
48-158	27938-27939	.	_	
48-159	27940-27943	The	_	
48-160	27944-27949	exact	_	
48-161	27950-27960	mechanisms	_	
48-162	27961-27970	mediating	_	
48-163	27971-27974	the	_	
48-164	27975-27985	transition	_	
48-165	27986-27990	from	_	
48-166	27991-27996	early	_	
48-167	27997-28005	prenatal	_	
48-168	28006-28010	RDVs	_	
48-169	28010-28011	'	_	
48-170	28012-28022	occurrence	_	
48-171	28023-28025	to	_	
48-172	28026-28037	hippocampal	_	
48-173	28038-28042	rsFC	_	
48-174	28043-28056	abnormalities	_	
48-175	28057-28063	during	_	
48-176	28064-28067	the	_	
48-177	28068-28073	later	_	
48-178	28074-28082	outbreak	_	
48-179	28083-28085	of	_	
48-180	28086-28099	schizophrenia	_	
48-181	28100-28106	remain	_	
48-182	28107-28114	unclear	_	
48-183	28115-28121	though	_	
48-184	28121-28122	.	_	

#Text=Increased functional connectivity between left dentate gyrus and left inferior parietal cortex was correlated with more errors of SWM in schizophrenic patients with RDVs, whereas no such correlation was found in schizophrenic patients without RDVs (and opposite, that is, negative) and in healthy subjects. The dentate gyrus has been regarded as one of a few brain structures owning high rates of adult neurogenesis and has a critical role in resolving new memories and spatial memory. A recent study demonstrated that the inferior parietal cortex is involved in spatial perception and spatial orientation in particular and spatial functions in general (the â€˜where'). In addition, the inferior parietal cortex is also the target of output from hippocampus. The findings in the present study thus provided direct evidence that aberrant increased FC of left dentate gyrus with inferior parietal cortex might contribute to the severity of SWM deficits in schizophrenic patients with RDVs. Above all, our results provide a link among RDVs, dentate gyrus dysfunctional resting-state connectivity and SWM deficits in a genetic-based neurodevelopmental subgroup of patients with schizophrenia.
49-1	28123-28132	Increased	_	
49-2	28133-28143	functional	_	
49-3	28144-28156	connectivity	_	
49-4	28157-28164	between	_	
49-5	28165-28169	left	_	
49-6	28170-28177	dentate	_	
49-7	28178-28183	gyrus	_	
49-8	28184-28187	and	_	
49-9	28188-28192	left	_	
49-10	28193-28201	inferior	_	
49-11	28202-28210	parietal	_	
49-12	28211-28217	cortex	_	
49-13	28218-28221	was	_	
49-14	28222-28232	correlated	_	
49-15	28233-28237	with	_	
49-16	28238-28242	more	_	
49-17	28243-28249	errors	_	
49-18	28250-28252	of	_	
49-19	28253-28256	SWM	_	
49-20	28257-28259	in	_	
49-21	28260-28273	schizophrenic	_	
49-22	28274-28282	patients	_	
49-23	28283-28287	with	_	
49-24	28288-28292	RDVs	_	
49-25	28292-28293	,	_	
49-26	28294-28301	whereas	_	
49-27	28302-28304	no	_	
49-28	28305-28309	such	_	
49-29	28310-28321	correlation	_	
49-30	28322-28325	was	_	
49-31	28326-28331	found	_	
49-32	28332-28334	in	_	
49-33	28335-28348	schizophrenic	_	
49-34	28349-28357	patients	_	
49-35	28358-28365	without	_	
49-36	28366-28370	RDVs	_	
49-37	28371-28372	(	_	
49-38	28372-28375	and	_	
49-39	28376-28384	opposite	_	
49-40	28384-28385	,	_	
49-41	28386-28390	that	_	
49-42	28391-28393	is	_	
49-43	28393-28394	,	_	
49-44	28395-28403	negative	_	
49-45	28403-28404	)	_	
49-46	28405-28408	and	_	
49-47	28409-28411	in	_	
49-48	28412-28419	healthy	_	
49-49	28420-28428	subjects	_	
49-50	28428-28429	.	_	
49-51	28430-28433	The	_	
49-52	28434-28441	dentate	_	
49-53	28442-28447	gyrus	_	
49-54	28448-28451	has	_	
49-55	28452-28456	been	_	
49-56	28457-28465	regarded	_	
49-57	28466-28468	as	_	
49-58	28469-28472	one	_	
49-59	28473-28475	of	_	
49-60	28476-28477	a	_	
49-61	28478-28481	few	_	
49-62	28482-28487	brain	_	
49-63	28488-28498	structures	_	
49-64	28499-28505	owning	_	
49-65	28506-28510	high	_	
49-66	28511-28516	rates	_	
49-67	28517-28519	of	_	
49-68	28520-28525	adult	_	
49-69	28526-28538	neurogenesis	_	
49-70	28539-28542	and	_	
49-71	28543-28546	has	_	
49-72	28547-28548	a	_	
49-73	28549-28557	critical	_	
49-74	28558-28562	role	_	
49-75	28563-28565	in	_	
49-76	28566-28575	resolving	_	
49-77	28576-28579	new	_	
49-78	28580-28588	memories	_	
49-79	28589-28592	and	_	
49-80	28593-28600	spatial	_	
49-81	28601-28607	memory	_	
49-82	28607-28608	.	_	
49-83	28609-28610	A	_	
49-84	28611-28617	recent	_	
49-85	28618-28623	study	_	
49-86	28624-28636	demonstrated	_	
49-87	28637-28641	that	_	
49-88	28642-28645	the	_	
49-89	28646-28654	inferior	_	
49-90	28655-28663	parietal	_	
49-91	28664-28670	cortex	_	
49-92	28671-28673	is	_	
49-93	28674-28682	involved	_	
49-94	28683-28685	in	_	
49-95	28686-28693	spatial	_	
49-96	28694-28704	perception	_	
49-97	28705-28708	and	_	
49-98	28709-28716	spatial	_	
49-99	28717-28728	orientation	_	
49-100	28729-28731	in	_	
49-101	28732-28742	particular	_	
49-102	28743-28746	and	_	
49-103	28747-28754	spatial	_	
49-104	28755-28764	functions	_	
49-105	28765-28767	in	_	
49-106	28768-28775	general	_	
49-107	28776-28777	(	_	
49-108	28777-28780	the	_	
49-109	28781-28782	â€˜	_	
49-110	28782-28787	where	_	
49-111	28787-28788	'	_	
49-112	28788-28789	)	_	
49-113	28789-28790	.	_	
49-114	28791-28793	In	_	
49-115	28794-28802	addition	_	
49-116	28802-28803	,	_	
49-117	28804-28807	the	_	
49-118	28808-28816	inferior	_	
49-119	28817-28825	parietal	_	
49-120	28826-28832	cortex	_	
49-121	28833-28835	is	_	
49-122	28836-28840	also	_	
49-123	28841-28844	the	_	
49-124	28845-28851	target	_	
49-125	28852-28854	of	_	
49-126	28855-28861	output	_	
49-127	28862-28866	from	_	
49-128	28867-28878	hippocampus	_	
49-129	28878-28879	.	_	
49-130	28880-28883	The	_	
49-131	28884-28892	findings	_	
49-132	28893-28895	in	_	
49-133	28896-28899	the	_	
49-134	28900-28907	present	_	
49-135	28908-28913	study	_	
49-136	28914-28918	thus	_	
49-137	28919-28927	provided	_	
49-138	28928-28934	direct	_	
49-139	28935-28943	evidence	_	
49-140	28944-28948	that	_	
49-141	28949-28957	aberrant	_	
49-142	28958-28967	increased	_	
49-143	28968-28970	FC	_	
49-144	28971-28973	of	_	
49-145	28974-28978	left	_	
49-146	28979-28986	dentate	_	
49-147	28987-28992	gyrus	_	
49-148	28993-28997	with	_	
49-149	28998-29006	inferior	_	
49-150	29007-29015	parietal	_	
49-151	29016-29022	cortex	_	
49-152	29023-29028	might	_	
49-153	29029-29039	contribute	_	
49-154	29040-29042	to	_	
49-155	29043-29046	the	_	
49-156	29047-29055	severity	_	
49-157	29056-29058	of	_	
49-158	29059-29062	SWM	_	
49-159	29063-29071	deficits	_	
49-160	29072-29074	in	_	
49-161	29075-29088	schizophrenic	_	
49-162	29089-29097	patients	_	
49-163	29098-29102	with	_	
49-164	29103-29107	RDVs	_	
49-165	29107-29108	.	_	
49-166	29109-29114	Above	_	
49-167	29115-29118	all	_	
49-168	29118-29119	,	_	
49-169	29120-29123	our	_	
49-170	29124-29131	results	_	
49-171	29132-29139	provide	_	
49-172	29140-29141	a	_	
49-173	29142-29146	link	_	
49-174	29147-29152	among	_	
49-175	29153-29157	RDVs	_	
49-176	29157-29158	,	_	
49-177	29159-29166	dentate	_	
49-178	29167-29172	gyrus	_	
49-179	29173-29186	dysfunctional	_	
49-180	29187-29200	resting-state	_	
49-181	29201-29213	connectivity	_	
49-182	29214-29217	and	_	
49-183	29218-29221	SWM	_	
49-184	29222-29230	deficits	_	
49-185	29231-29233	in	_	
49-186	29234-29235	a	_	
49-187	29236-29249	genetic-based	_	
49-188	29250-29268	neurodevelopmental	_	
49-189	29269-29277	subgroup	_	
49-190	29278-29280	of	_	
49-191	29281-29289	patients	_	
49-192	29290-29294	with	_	
49-193	29295-29308	schizophrenia	_	
49-194	29308-29309	.	_	

#Text=However, several limitations must be born in mind when interpreting our results. First, the sample size of the present study is relatively small for genetic study, which might be lack of the power to detect significant association signal between cases and controls. However, we adopt an alternative strategy for filtering rare variants and then enrich to find two special pathways. Second, not all the subjects underwent the memory test in both the two-patient groups, which could have affected the results of correlation analysis between imaging and cognitive data. Fortunately, there were no significant differences in clinical profiles between patients with RDVs who underwent cognitive tests and those who did not within both groups. Third, considering the small sample size of patients who underwent the cognitive tasks, the correlation analysis between neuroimaging and neurocognition remained uncorrected for multiple comparisons, which might lead to false-positive results.
50-1	29310-29317	However	_	
50-2	29317-29318	,	_	
50-3	29319-29326	several	_	
50-4	29327-29338	limitations	_	
50-5	29339-29343	must	_	
50-6	29344-29346	be	_	
50-7	29347-29351	born	_	
50-8	29352-29354	in	_	
50-9	29355-29359	mind	_	
50-10	29360-29364	when	_	
50-11	29365-29377	interpreting	_	
50-12	29378-29381	our	_	
50-13	29382-29389	results	_	
50-14	29389-29390	.	_	
50-15	29391-29396	First	_	
50-16	29396-29397	,	_	
50-17	29398-29401	the	_	
50-18	29402-29408	sample	_	
50-19	29409-29413	size	_	
50-20	29414-29416	of	_	
50-21	29417-29420	the	_	
50-22	29421-29428	present	_	
50-23	29429-29434	study	_	
50-24	29435-29437	is	_	
50-25	29438-29448	relatively	_	
50-26	29449-29454	small	_	
50-27	29455-29458	for	_	
50-28	29459-29466	genetic	_	
50-29	29467-29472	study	_	
50-30	29472-29473	,	_	
50-31	29474-29479	which	_	
50-32	29480-29485	might	_	
50-33	29486-29488	be	_	
50-34	29489-29493	lack	_	
50-35	29494-29496	of	_	
50-36	29497-29500	the	_	
50-37	29501-29506	power	_	
50-38	29507-29509	to	_	
50-39	29510-29516	detect	_	
50-40	29517-29528	significant	_	
50-41	29529-29540	association	_	
50-42	29541-29547	signal	_	
50-43	29548-29555	between	_	
50-44	29556-29561	cases	_	
50-45	29562-29565	and	_	
50-46	29566-29574	controls	_	
50-47	29574-29575	.	_	
50-48	29576-29583	However	_	
50-49	29583-29584	,	_	
50-50	29585-29587	we	_	
50-51	29588-29593	adopt	_	
50-52	29594-29596	an	_	
50-53	29597-29608	alternative	_	
50-54	29609-29617	strategy	_	
50-55	29618-29621	for	_	
50-56	29622-29631	filtering	_	
50-57	29632-29636	rare	_	
50-58	29637-29645	variants	_	
50-59	29646-29649	and	_	
50-60	29650-29654	then	_	
50-61	29655-29661	enrich	_	
50-62	29662-29664	to	_	
50-63	29665-29669	find	_	
50-64	29670-29673	two	_	
50-65	29674-29681	special	_	
50-66	29682-29690	pathways	_	
50-67	29690-29691	.	_	
50-68	29692-29698	Second	_	
50-69	29698-29699	,	_	
50-70	29700-29703	not	_	
50-71	29704-29707	all	_	
50-72	29708-29711	the	_	
50-73	29712-29720	subjects	_	
50-74	29721-29730	underwent	_	
50-75	29731-29734	the	_	
50-76	29735-29741	memory	_	
50-77	29742-29746	test	_	
50-78	29747-29749	in	_	
50-79	29750-29754	both	_	
50-80	29755-29758	the	_	
50-81	29759-29770	two-patient	_	
50-82	29771-29777	groups	_	
50-83	29777-29778	,	_	
50-84	29779-29784	which	_	
50-85	29785-29790	could	_	
50-86	29791-29795	have	_	
50-87	29796-29804	affected	_	
50-88	29805-29808	the	_	
50-89	29809-29816	results	_	
50-90	29817-29819	of	_	
50-91	29820-29831	correlation	_	
50-92	29832-29840	analysis	_	
50-93	29841-29848	between	_	
50-94	29849-29856	imaging	_	
50-95	29857-29860	and	_	
50-96	29861-29870	cognitive	_	
50-97	29871-29875	data	_	
50-98	29875-29876	.	_	
50-99	29877-29888	Fortunately	_	
50-100	29888-29889	,	_	
50-101	29890-29895	there	_	
50-102	29896-29900	were	_	
50-103	29901-29903	no	_	
50-104	29904-29915	significant	_	
50-105	29916-29927	differences	_	
50-106	29928-29930	in	_	
50-107	29931-29939	clinical	_	
50-108	29940-29948	profiles	_	
50-109	29949-29956	between	_	
50-110	29957-29965	patients	_	
50-111	29966-29970	with	_	
50-112	29971-29975	RDVs	_	
50-113	29976-29979	who	_	
50-114	29980-29989	underwent	_	
50-115	29990-29999	cognitive	_	
50-116	30000-30005	tests	_	
50-117	30006-30009	and	_	
50-118	30010-30015	those	_	
50-119	30016-30019	who	_	
50-120	30020-30023	did	_	
50-121	30024-30027	not	_	
50-122	30028-30034	within	_	
50-123	30035-30039	both	_	
50-124	30040-30046	groups	_	
50-125	30046-30047	.	_	
50-126	30048-30053	Third	_	
50-127	30053-30054	,	_	
50-128	30055-30066	considering	_	
50-129	30067-30070	the	_	
50-130	30071-30076	small	_	
50-131	30077-30083	sample	_	
50-132	30084-30088	size	_	
50-133	30089-30091	of	_	
50-134	30092-30100	patients	_	
50-135	30101-30104	who	_	
50-136	30105-30114	underwent	_	
50-137	30115-30118	the	_	
50-138	30119-30128	cognitive	_	
50-139	30129-30134	tasks	_	
50-140	30134-30135	,	_	
50-141	30136-30139	the	_	
50-142	30140-30151	correlation	_	
50-143	30152-30160	analysis	_	
50-144	30161-30168	between	_	
50-145	30169-30181	neuroimaging	_	
50-146	30182-30185	and	_	
50-147	30186-30200	neurocognition	_	
50-148	30201-30209	remained	_	
50-149	30210-30221	uncorrected	_	
50-150	30222-30225	for	_	
50-151	30226-30234	multiple	_	
50-152	30235-30246	comparisons	_	
50-153	30246-30247	,	_	
50-154	30248-30253	which	_	
50-155	30254-30259	might	_	
50-156	30260-30264	lead	_	
50-157	30265-30267	to	_	
50-158	30268-30282	false-positive	_	
50-159	30283-30290	results	_	
50-160	30290-30291	.	_	

#Text=In sum, to our knowledge, our findings demonstrate for the first time the presence of genes implicated in DNA repair and cell cycle pathways and related specifically to hippocampal development in a subgroup of first-episode treatment-naive schizophrenic patients. Importantly, the presence of these genes directly had an impact on or modulated phenotypic expression as hippocampal rsFC and related spatial memory function in this subgroup. Hence, our findings bridge the gap from genes regulating hippocampal development before birth to corresponding phenotypical markers like rsFC of hippocampus and associated cognitive, that is, SWM function at the outbreak of first-episode schizophrenia.
51-1	30292-30294	In	_	
51-2	30295-30298	sum	_	
51-3	30298-30299	,	_	
51-4	30300-30302	to	_	
51-5	30303-30306	our	_	
51-6	30307-30316	knowledge	_	
51-7	30316-30317	,	_	
51-8	30318-30321	our	_	
51-9	30322-30330	findings	_	
51-10	30331-30342	demonstrate	_	
51-11	30343-30346	for	_	
51-12	30347-30350	the	_	
51-13	30351-30356	first	_	
51-14	30357-30361	time	_	
51-15	30362-30365	the	_	
51-16	30366-30374	presence	_	
51-17	30375-30377	of	_	
51-18	30378-30383	genes	_	
51-19	30384-30394	implicated	_	
51-20	30395-30397	in	_	
51-21	30398-30401	DNA	_	
51-22	30402-30408	repair	_	
51-23	30409-30412	and	_	
51-24	30413-30417	cell	_	
51-25	30418-30423	cycle	_	
51-26	30424-30432	pathways	_	
51-27	30433-30436	and	_	
51-28	30437-30444	related	_	
51-29	30445-30457	specifically	_	
51-30	30458-30460	to	_	
51-31	30461-30472	hippocampal	_	
51-32	30473-30484	development	_	
51-33	30485-30487	in	_	
51-34	30488-30489	a	_	
51-35	30490-30498	subgroup	_	
51-36	30499-30501	of	_	
51-37	30502-30515	first-episode	_	
51-38	30516-30531	treatment-naive	_	
51-39	30532-30545	schizophrenic	_	
51-40	30546-30554	patients	_	
51-41	30554-30555	.	_	
51-42	30556-30567	Importantly	_	
51-43	30567-30568	,	_	
51-44	30569-30572	the	_	
51-45	30573-30581	presence	_	
51-46	30582-30584	of	_	
51-47	30585-30590	these	_	
51-48	30591-30596	genes	_	
51-49	30597-30605	directly	_	
51-50	30606-30609	had	_	
51-51	30610-30612	an	_	
51-52	30613-30619	impact	_	
51-53	30620-30622	on	_	
51-54	30623-30625	or	_	
51-55	30626-30635	modulated	_	
51-56	30636-30646	phenotypic	_	
51-57	30647-30657	expression	_	
51-58	30658-30660	as	_	
51-59	30661-30672	hippocampal	_	
51-60	30673-30677	rsFC	_	
51-61	30678-30681	and	_	
51-62	30682-30689	related	_	
51-63	30690-30697	spatial	_	
51-64	30698-30704	memory	_	
51-65	30705-30713	function	_	
51-66	30714-30716	in	_	
51-67	30717-30721	this	_	
51-68	30722-30730	subgroup	_	
51-69	30730-30731	.	_	
51-70	30732-30737	Hence	_	
51-71	30737-30738	,	_	
51-72	30739-30742	our	_	
51-73	30743-30751	findings	_	
51-74	30752-30758	bridge	_	
51-75	30759-30762	the	_	
51-76	30763-30766	gap	_	
51-77	30767-30771	from	_	
51-78	30772-30777	genes	_	
51-79	30778-30788	regulating	_	
51-80	30789-30800	hippocampal	_	
51-81	30801-30812	development	_	
51-82	30813-30819	before	_	
51-83	30820-30825	birth	_	
51-84	30826-30828	to	_	
51-85	30829-30842	corresponding	_	
51-86	30843-30855	phenotypical	_	
51-87	30856-30863	markers	_	
51-88	30864-30868	like	_	
51-89	30869-30873	rsFC	_	
51-90	30874-30876	of	_	
51-91	30877-30888	hippocampus	_	
51-92	30889-30892	and	_	
51-93	30893-30903	associated	_	
51-94	30904-30913	cognitive	_	
51-95	30913-30914	,	_	
51-96	30915-30919	that	_	
51-97	30920-30922	is	_	
51-98	30922-30923	,	_	
51-99	30924-30927	SWM	_	
51-100	30928-30936	function	_	
51-101	30937-30939	at	_	
51-102	30940-30943	the	_	
51-103	30944-30952	outbreak	_	
51-104	30953-30955	of	_	
51-105	30956-30969	first-episode	_	
51-106	30970-30983	schizophrenia	_	
51-107	30983-30984	.	_	

#Text=Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
52-1	30985-30998	Supplementary	_	
52-2	30999-31010	Information	_	
52-3	31011-31022	accompanies	_	
52-4	31023-31026	the	_	
52-5	31027-31032	paper	_	
52-6	31033-31035	on	_	
52-7	31036-31039	the	_	
52-8	31040-31053	Translational	_	
52-9	31054-31064	Psychiatry	_	
52-10	31065-31072	website	_	
52-11	31073-31074	(	_	
52-12	31074-31078	http	_	
52-13	31078-31079	:	_	
52-14	31079-31080	/	_	
52-15	31080-31081	/	_	
52-16	31081-31095	www.nature.com	_	
52-17	31095-31096	/	_	
52-18	31096-31098	tp	_	
52-19	31098-31099	)	_	

#Text=The authors declare no conflict of interest.
53-1	31100-31103	The	_	
53-2	31104-31111	authors	_	
53-3	31112-31119	declare	_	
53-4	31120-31122	no	_	
53-5	31123-31131	conflict	_	
53-6	31132-31134	of	_	
53-7	31135-31143	interest	_	
53-8	31143-31144	.	_	

#Text=Genes, environment and schizophrenia
54-1	31145-31150	Genes	_	
54-2	31150-31151	,	_	
54-3	31152-31163	environment	_	
54-4	31164-31167	and	_	
54-5	31168-31181	schizophrenia	_	

#Text=Implications of normal brain development for the pathogenesis of schizophrenia
55-1	31182-31194	Implications	_	
55-2	31195-31197	of	_	
55-3	31198-31204	normal	_	
55-4	31205-31210	brain	_	
55-5	31211-31222	development	_	
55-6	31223-31226	for	_	
55-7	31227-31230	the	_	
55-8	31231-31243	pathogenesis	_	
55-9	31244-31246	of	_	
55-10	31247-31260	schizophrenia	_	

#Text=Is schizophrenia a neurodevelopmental disorder
56-1	31261-31263	Is	_	
56-2	31264-31277	schizophrenia	_	
56-3	31278-31279	a	_	
56-4	31280-31298	neurodevelopmental	_	
56-5	31299-31307	disorder	_	

#Text=The heritability of schizophrenia and schizoaffective disorder: a family study
57-1	31308-31311	The	_	
57-2	31312-31324	heritability	_	
57-3	31325-31327	of	_	
57-4	31328-31341	schizophrenia	_	
57-5	31342-31345	and	_	
57-6	31346-31361	schizoaffective	_	
57-7	31362-31370	disorder	_	
57-8	31370-31371	:	_	
57-9	31372-31373	a	_	
57-10	31374-31380	family	_	
57-11	31381-31386	study	_	

#Text=The Roscommon family study: I. Methods, diagnosis of probands, and risk of schizophrenia in relatives
58-1	31387-31390	The	_	
58-2	31391-31400	Roscommon	_	
58-3	31401-31407	family	_	
58-4	31408-31413	study	_	
58-5	31413-31414	:	_	
58-6	31415-31416	I	_	
58-7	31416-31417	.	_	
58-8	31418-31425	Methods	_	
58-9	31425-31426	,	_	
58-10	31427-31436	diagnosis	_	
58-11	31437-31439	of	_	
58-12	31440-31448	probands	_	
58-13	31448-31449	,	_	
58-14	31450-31453	and	_	
58-15	31454-31458	risk	_	
58-16	31459-31461	of	_	
58-17	31462-31475	schizophrenia	_	
58-18	31476-31478	in	_	
58-19	31479-31488	relatives	_	

#Text=Gottesman II. The genetic epidemiology of schizophrenia and the design of linkage studies
59-1	31489-31498	Gottesman	_	
59-2	31499-31501	II	_	
59-3	31501-31502	.	_	
59-4	31503-31506	The	_	
59-5	31507-31514	genetic	_	
59-6	31515-31527	epidemiology	_	
59-7	31528-31530	of	_	
59-8	31531-31544	schizophrenia	_	
59-9	31545-31548	and	_	
59-10	31549-31552	the	_	
59-11	31553-31559	design	_	
59-12	31560-31562	of	_	
59-13	31563-31570	linkage	_	
59-14	31571-31578	studies	_	

#Text=Biological insights from 108 schizophrenia-associated genetic loci
60-1	31579-31589	Biological	_	
60-2	31590-31598	insights	_	
60-3	31599-31603	from	_	
60-4	31604-31607	108	_	
60-5	31608-31632	schizophrenia-associated	_	
60-6	31633-31640	genetic	_	
60-7	31641-31645	loci	_	

#Text=Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network
61-1	31646-31653	Spatial	_	
61-2	31654-31657	and	_	
61-3	31658-31666	temporal	_	
61-4	31667-31674	mapping	_	
61-5	31675-31677	of	_	
61-6	31678-31680	de	_	
61-7	31681-31685	novo	_	
61-8	31686-31695	mutations	_	
61-9	31696-31698	in	_	
61-10	31699-31712	schizophrenia	_	
61-11	31713-31715	to	_	
61-12	31716-31717	a	_	
61-13	31718-31723	fetal	_	
61-14	31724-31734	prefrontal	_	
61-15	31735-31743	cortical	_	
61-16	31744-31751	network	_	

#Text=De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia
62-1	31752-31754	De	_	
62-2	31755-31759	novo	_	
62-3	31760-31763	CNV	_	
62-4	31764-31772	analysis	_	
62-5	31773-31783	implicates	_	
62-6	31784-31792	specific	_	
62-7	31793-31806	abnormalities	_	
62-8	31807-31809	of	_	
62-9	31810-31822	postsynaptic	_	
62-10	31823-31833	signalling	_	
62-11	31834-31843	complexes	_	
62-12	31844-31846	in	_	
62-13	31847-31850	the	_	
62-14	31851-31863	pathogenesis	_	
62-15	31864-31866	of	_	
62-16	31867-31880	schizophrenia	_	

#Text=High frequencies of de novo CNVs in bipolar disorder and schizophrenia
63-1	31881-31885	High	_	
63-2	31886-31897	frequencies	_	
63-3	31898-31900	of	_	
63-4	31901-31903	de	_	
63-5	31904-31908	novo	_	
63-6	31909-31913	CNVs	_	
63-7	31914-31916	in	_	
63-8	31917-31924	bipolar	_	
63-9	31925-31933	disorder	_	
63-10	31934-31937	and	_	
63-11	31938-31951	schizophrenia	_	

#Text=De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia
64-1	31952-31954	De	_	
64-2	31955-31959	novo	_	
64-3	31960-31964	gene	_	
64-4	31965-31974	mutations	_	
64-5	31975-31984	highlight	_	
64-6	31985-31993	patterns	_	
64-7	31994-31996	of	_	
64-8	31997-32004	genetic	_	
64-9	32005-32008	and	_	
64-10	32009-32015	neural	_	
64-11	32016-32026	complexity	_	
64-12	32027-32029	in	_	
64-13	32030-32043	schizophrenia	_	

#Text=De novo mutations in schizophrenia implicate synaptic networks
65-1	32044-32046	De	_	
65-2	32047-32051	novo	_	
65-3	32052-32061	mutations	_	
65-4	32062-32064	in	_	
65-5	32065-32078	schizophrenia	_	
65-6	32079-32088	implicate	_	
65-7	32089-32097	synaptic	_	
65-8	32098-32106	networks	_	

#Text=A polygenic burden of rare disruptive mutations in schizophrenia
66-1	32107-32108	A	_	
66-2	32109-32118	polygenic	_	
66-3	32119-32125	burden	_	
66-4	32126-32128	of	_	
66-5	32129-32133	rare	_	
66-6	32134-32144	disruptive	_	
66-7	32145-32154	mutations	_	
66-8	32155-32157	in	_	
66-9	32158-32171	schizophrenia	_	

#Text=Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia
67-1	32172-32176	Rare	_	
67-2	32177-32187	structural	_	
67-3	32188-32196	variants	_	
67-4	32197-32204	disrupt	_	
67-5	32205-32213	multiple	_	
67-6	32214-32219	genes	_	
67-7	32220-32222	in	_	
67-8	32223-32241	neurodevelopmental	_	
67-9	32242-32250	pathways	_	
67-10	32251-32253	in	_	
67-11	32254-32267	schizophrenia	_	

#Text=De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability
68-1	32268-32270	De	_	
68-2	32271-32275	novo	_	
68-3	32276-32285	mutations	_	
68-4	32286-32288	in	_	
68-5	32289-32302	schizophrenia	_	
68-6	32303-32312	implicate	_	
68-7	32313-32322	chromatin	_	
68-8	32323-32333	remodeling	_	
68-9	32334-32337	and	_	
68-10	32338-32345	support	_	
68-11	32346-32347	a	_	
68-12	32348-32355	genetic	_	
68-13	32356-32363	overlap	_	
68-14	32364-32368	with	_	
68-15	32369-32375	autism	_	
68-16	32376-32379	and	_	
68-17	32380-32392	intellectual	_	
68-18	32393-32403	disability	_	

#Text=The hippocampal formation in schizophrenia
69-1	32404-32407	The	_	
69-2	32408-32419	hippocampal	_	
69-3	32420-32429	formation	_	
69-4	32430-32432	in	_	
69-5	32433-32446	schizophrenia	_	

#Text=Neuroimaging studies of the hippocampus in schizophrenia
70-1	32447-32459	Neuroimaging	_	
70-2	32460-32467	studies	_	
70-3	32468-32470	of	_	
70-4	32471-32474	the	_	
70-5	32475-32486	hippocampus	_	
70-6	32487-32489	in	_	
70-7	32490-32503	schizophrenia	_	

#Text=The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications
71-1	32504-32507	The	_	
71-2	32508-32519	hippocampus	_	
71-3	32520-32522	in	_	
71-4	32523-32536	schizophrenia	_	
71-5	32536-32537	:	_	
71-6	32538-32539	a	_	
71-7	32540-32546	review	_	
71-8	32547-32549	of	_	
71-9	32550-32553	the	_	
71-10	32554-32571	neuropathological	_	
71-11	32572-32580	evidence	_	
71-12	32581-32584	and	_	
71-13	32585-32588	its	_	
71-14	32589-32607	pathophysiological	_	
71-15	32608-32620	implications	_	

#Text=Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia
72-1	32621-32628	Altered	_	
72-2	32629-32642	resting-state	_	
72-3	32643-32653	functional	_	
72-4	32654-32666	connectivity	_	
72-5	32667-32670	and	_	
72-6	32671-32681	anatomical	_	
72-7	32682-32694	connectivity	_	
72-8	32695-32697	of	_	
72-9	32698-32709	hippocampus	_	
72-10	32710-32712	in	_	
72-11	32713-32726	schizophrenia	_	

#Text=Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state
73-1	32727-32737	Functional	_	
73-2	32738-32749	integration	_	
73-3	32750-32757	between	_	
73-4	32758-32761	the	_	
73-5	32762-32771	posterior	_	
73-6	32772-32783	hippocampus	_	
73-7	32784-32787	and	_	
73-8	32788-32798	prefrontal	_	
73-9	32799-32805	cortex	_	
73-10	32806-32808	is	_	
73-11	32809-32817	impaired	_	
73-12	32818-32820	in	_	
73-13	32821-32825	both	_	
73-14	32826-32831	first	_	
73-15	32832-32839	episode	_	
73-16	32840-32853	schizophrenia	_	
73-17	32854-32857	and	_	
73-18	32858-32861	the	_	
73-19	32862-32864	at	_	
73-20	32865-32869	risk	_	
73-21	32870-32876	mental	_	
73-22	32877-32882	state	_	

#Text=Prevalence of depression in patients with hypertension: a systematic review and meta-analysis
74-1	32883-32893	Prevalence	_	
74-2	32894-32896	of	_	
74-3	32897-32907	depression	_	
74-4	32908-32910	in	_	
74-5	32911-32919	patients	_	
74-6	32920-32924	with	_	
74-7	32925-32937	hypertension	_	
74-8	32937-32938	:	_	
74-9	32939-32940	a	_	
74-10	32941-32951	systematic	_	
74-11	32952-32958	review	_	
74-12	32959-32962	and	_	
74-13	32963-32976	meta-analysis	_	

#Text=Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives
75-1	32977-32991	Neurocognitive	_	
75-2	32992-33000	deficits	_	
75-3	33001-33003	in	_	
75-4	33004-33017	first-episode	_	
75-5	33018-33031	schizophrenic	_	
75-6	33032-33040	patients	_	
75-7	33041-33044	and	_	
75-8	33045-33050	their	_	
75-9	33051-33063	first-degree	_	
75-10	33064-33073	relatives	_	

#Text=Factor structures of the neurocognitive assessments and familial analysis in first-episode schizophrenia patients, their relatives and controls
76-1	33074-33080	Factor	_	
76-2	33081-33091	structures	_	
76-3	33092-33094	of	_	
76-4	33095-33098	the	_	
76-5	33099-33113	neurocognitive	_	
76-6	33114-33125	assessments	_	
76-7	33126-33129	and	_	
76-8	33130-33138	familial	_	
76-9	33139-33147	analysis	_	
76-10	33148-33150	in	_	
76-11	33151-33164	first-episode	_	
76-12	33165-33178	schizophrenia	_	
76-13	33179-33187	patients	_	
76-14	33187-33188	,	_	
76-15	33189-33194	their	_	
76-16	33195-33204	relatives	_	
76-17	33205-33208	and	_	
76-18	33209-33217	controls	_	

#Text=DNA repair and mutant frequency in schizophrenia
77-1	33218-33221	DNA	_	
77-2	33222-33228	repair	_	
77-3	33229-33232	and	_	
77-4	33233-33239	mutant	_	
77-5	33240-33249	frequency	_	
77-6	33250-33252	in	_	
77-7	33253-33266	schizophrenia	_	

#Text=Genetic polymorphism in the DNA repair gene XRCC1 and susceptibility to schizophrenia
78-1	33267-33274	Genetic	_	
78-2	33275-33287	polymorphism	_	
78-3	33288-33290	in	_	
78-4	33291-33294	the	_	
78-5	33295-33298	DNA	_	
78-6	33299-33305	repair	_	
78-7	33306-33310	gene	_	
78-8	33311-33316	XRCC1	_	
78-9	33317-33320	and	_	
78-10	33321-33335	susceptibility	_	
78-11	33336-33338	to	_	
78-12	33339-33352	schizophrenia	_	

#Text=Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes
79-1	33353-33361	Abnormal	_	
79-2	33362-33369	indices	_	
79-3	33370-33372	of	_	
79-4	33373-33377	cell	_	
79-5	33378-33383	cycle	_	
79-6	33384-33392	activity	_	
79-7	33393-33395	in	_	
79-8	33396-33409	schizophrenia	_	
79-9	33410-33413	and	_	
79-10	33414-33419	their	_	
79-11	33420-33429	potential	_	
79-12	33430-33441	association	_	
79-13	33442-33446	with	_	
79-14	33447-33463	oligodendrocytes	_	

#Text=Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition
80-1	33464-33477	Schizophrenia	_	
80-2	33478-33480	is	_	
80-3	33481-33491	associated	_	
80-4	33492-33496	with	_	
80-5	33497-33510	dysregulation	_	
80-6	33511-33513	of	_	
80-7	33514-33515	a	_	
80-8	33516-33520	Cdk5	_	
80-9	33521-33530	activator	_	
80-10	33531-33535	that	_	
80-11	33536-33545	regulates	_	
80-12	33546-33554	synaptic	_	
80-13	33555-33562	protein	_	
80-14	33563-33573	expression	_	
80-15	33574-33577	and	_	
80-16	33578-33587	cognition	_	

#Text=Cell cycle regulatory failure in neurones: causes and consequences
81-1	33588-33592	Cell	_	
81-2	33593-33598	cycle	_	
81-3	33599-33609	regulatory	_	
81-4	33610-33617	failure	_	
81-5	33618-33620	in	_	
81-6	33621-33629	neurones	_	
81-7	33629-33630	:	_	
81-8	33631-33637	causes	_	
81-9	33638-33641	and	_	
81-10	33642-33654	consequences	_	

#Text=The human hippocampus and spatial and episodic memory
82-1	33655-33658	The	_	
82-2	33659-33664	human	_	
82-3	33665-33676	hippocampus	_	
82-4	33677-33680	and	_	
82-5	33681-33688	spatial	_	
82-6	33689-33692	and	_	
82-7	33693-33701	episodic	_	
82-8	33702-33708	memory	_	

#Text=Major depressive disorder
83-1	33709-33714	Major	_	
83-2	33715-33725	depressive	_	
83-3	33726-33734	disorder	_	

#Text=Prevalence of depression and depressive symptoms among resident physicians: a systematic review and meta-analysis
84-1	33735-33745	Prevalence	_	
84-2	33746-33748	of	_	
84-3	33749-33759	depression	_	
84-4	33760-33763	and	_	
84-5	33764-33774	depressive	_	
84-6	33775-33783	symptoms	_	
84-7	33784-33789	among	_	
84-8	33790-33798	resident	_	
84-9	33799-33809	physicians	_	
84-10	33809-33810	:	_	
84-11	33811-33812	a	_	
84-12	33813-33823	systematic	_	
84-13	33824-33830	review	_	
84-14	33831-33834	and	_	
84-15	33835-33848	meta-analysis	_	

#Text=The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
85-1	33850-33853	The	_	
85-2	33854-33862	Positive	_	
85-3	33863-33866	and	_	
85-4	33867-33875	Negative	_	
85-5	33876-33884	Syndrome	_	
85-6	33885-33890	Scale	_	
85-7	33891-33892	(	_	
85-8	33892-33897	PANSS	_	
85-9	33897-33898	)	_	
85-10	33899-33902	for	_	
85-11	33903-33916	schizophrenia	_	

#Text=Fast and accurate short read alignment with Burrowsâ€“Wheeler transform
86-1	33918-33922	Fast	_	
86-2	33923-33926	and	_	
86-3	33927-33935	accurate	_	
86-4	33936-33941	short	_	
86-5	33942-33946	read	_	
86-6	33947-33956	alignment	_	
86-7	33957-33961	with	_	
86-8	33962-33977	Burrowsâ€“Wheeler	_	
86-9	33978-33987	transform	_	

#Text=The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data
87-1	33988-33991	The	_	
87-2	33992-33998	Genome	_	
87-3	33999-34007	Analysis	_	
87-4	34008-34015	Toolkit	_	
87-5	34015-34016	:	_	
87-6	34017-34018	a	_	
87-7	34019-34028	MapReduce	_	
87-8	34029-34038	framework	_	
87-9	34039-34042	for	_	
87-10	34043-34052	analyzing	_	
87-11	34053-34068	next-generation	_	
87-12	34069-34072	DNA	_	
87-13	34073-34083	sequencing	_	
87-14	34084-34088	data	_	

#Text=PLINK: a tool set for whole-genome association and population-based linkage analyses
88-1	34089-34094	PLINK	_	
88-2	34094-34095	:	_	
88-3	34096-34097	a	_	
88-4	34098-34102	tool	_	
88-5	34103-34106	set	_	
88-6	34107-34110	for	_	
88-7	34111-34123	whole-genome	_	
88-8	34124-34135	association	_	
88-9	34136-34139	and	_	
88-10	34140-34156	population-based	_	
88-11	34157-34164	linkage	_	
88-12	34165-34173	analyses	_	

#Text=A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases
89-1	34174-34175	A	_	
89-2	34176-34189	comprehensive	_	
89-3	34190-34199	framework	_	
89-4	34200-34203	for	_	
89-5	34204-34216	prioritizing	_	
89-6	34217-34225	variants	_	
89-7	34226-34228	in	_	
89-8	34229-34234	exome	_	
89-9	34235-34245	sequencing	_	
89-10	34246-34253	studies	_	
89-11	34254-34256	of	_	
89-12	34257-34266	Mendelian	_	
89-13	34267-34275	diseases	_	

#Text=A general framework for weighted gene co-expression network analysis
90-1	34276-34277	A	_	
90-2	34278-34285	general	_	
90-3	34286-34295	framework	_	
90-4	34296-34299	for	_	
90-5	34300-34308	weighted	_	
90-6	34309-34313	gene	_	
90-7	34314-34327	co-expression	_	
90-8	34328-34335	network	_	
90-9	34336-34344	analysis	_	

#Text=WGCNA: an R package for weighted correlation network analysis
91-1	34345-34350	WGCNA	_	
91-2	34350-34351	:	_	
91-3	34352-34354	an	_	
91-4	34355-34356	R	_	
91-5	34357-34364	package	_	
91-6	34365-34368	for	_	
91-7	34369-34377	weighted	_	
91-8	34378-34389	correlation	_	
91-9	34390-34397	network	_	
91-10	34398-34406	analysis	_	

#Text=Spatio-temporal transcriptome of the human brain
92-1	34407-34422	Spatio-temporal	_	
92-2	34423-34436	transcriptome	_	
92-3	34437-34439	of	_	
92-4	34440-34443	the	_	
92-5	34444-34449	human	_	
92-6	34450-34455	brain	_	

#Text=Accurate whole human genome sequencing using reversible terminator chemistry
93-1	34456-34464	Accurate	_	
93-2	34465-34470	whole	_	
93-3	34471-34476	human	_	
93-4	34477-34483	genome	_	
93-5	34484-34494	sequencing	_	
93-6	34495-34500	using	_	
93-7	34501-34511	reversible	_	
93-8	34512-34522	terminator	_	
93-9	34523-34532	chemistry	_	

#Text=Testing for an unusual distribution of rare variants
94-1	34533-34540	Testing	_	
94-2	34541-34544	for	_	
94-3	34545-34547	an	_	
94-4	34548-34555	unusual	_	
94-5	34556-34568	distribution	_	
94-6	34569-34571	of	_	
94-7	34572-34576	rare	_	
94-8	34577-34585	variants	_	

#Text=A versatile gene-based test for genome-wide association studies
95-1	34586-34587	A	_	
95-2	34588-34597	versatile	_	
95-3	34598-34608	gene-based	_	
95-4	34609-34613	test	_	
95-5	34614-34617	for	_	
95-6	34618-34629	genome-wide	_	
95-7	34630-34641	association	_	
95-8	34642-34649	studies	_	

#Text=Autism spectrum disorder susceptibility gene TAOK2 affects basal dendrite formation in the neocortex
96-1	34650-34656	Autism	_	
96-2	34657-34665	spectrum	_	
96-3	34666-34674	disorder	_	
96-4	34675-34689	susceptibility	_	
96-5	34690-34694	gene	_	
96-6	34695-34700	TAOK2	_	
96-7	34701-34708	affects	_	
96-8	34709-34714	basal	_	
96-9	34715-34723	dendrite	_	
96-10	34724-34733	formation	_	
96-11	34734-34736	in	_	
96-12	34737-34740	the	_	
96-13	34741-34750	neocortex	_	

#Text=Large recurrent microdeletions associated with schizophrenia
97-1	34751-34756	Large	_	
97-2	34757-34766	recurrent	_	
97-3	34767-34781	microdeletions	_	
97-4	34782-34792	associated	_	
97-5	34793-34797	with	_	
97-6	34798-34811	schizophrenia	_	

#Text=Relationship of GAD(67) regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus: bipolar disorder versus schizophrenia
98-1	34812-34824	Relationship	_	
98-2	34825-34827	of	_	
98-3	34828-34831	GAD	_	
98-4	34831-34832	(	_	
98-5	34832-34834	67	_	
98-6	34834-34835	)	_	
98-7	34836-34846	regulation	_	
98-8	34847-34849	to	_	
98-9	34850-34854	cell	_	
98-10	34855-34860	cycle	_	
98-11	34861-34864	and	_	
98-12	34865-34868	DNA	_	
98-13	34869-34875	repair	_	
98-14	34876-34878	in	_	
98-15	34879-34883	GABA	_	
98-16	34884-34891	neurons	_	
98-17	34892-34894	in	_	
98-18	34895-34898	the	_	
98-19	34899-34904	adult	_	
98-20	34905-34916	hippocampus	_	
98-21	34916-34917	:	_	
98-22	34918-34925	bipolar	_	
98-23	34926-34934	disorder	_	
98-24	34935-34941	versus	_	
98-25	34942-34955	schizophrenia	_	

#Text=Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders
99-1	34956-34966	Regulation	_	
99-2	34967-34969	of	_	
99-3	34970-34974	cell	_	
99-4	34975-34980	cycle	_	
99-5	34981-34984	and	_	
99-6	34985-34988	DNA	_	
99-7	34989-34995	repair	_	
99-8	34996-34998	in	_	
99-9	34999-35011	post-mitotic	_	
99-10	35012-35016	GABA	_	
99-11	35017-35024	neurons	_	
99-12	35025-35027	in	_	
99-13	35028-35037	psychotic	_	
99-14	35038-35047	disorders	_	

#Text=Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenic versus bipolars
100-1	35048-35061	Site-specific	_	
100-2	35062-35072	regulation	_	
100-3	35073-35075	of	_	
100-4	35076-35080	cell	_	
100-5	35081-35086	cycle	_	
100-6	35087-35090	and	_	
100-7	35091-35094	DNA	_	
100-8	35095-35101	repair	_	
100-9	35102-35104	in	_	
100-10	35105-35117	post-mitotic	_	
100-11	35118-35122	GABA	_	
100-12	35123-35128	cells	_	
100-13	35129-35131	in	_	
100-14	35132-35145	schizophrenic	_	
100-15	35146-35152	versus	_	
100-16	35153-35161	bipolars	_	

#Text=The neurodevelopmental model of schizophrenia: update 2005
101-1	35162-35165	The	_	
101-2	35166-35184	neurodevelopmental	_	
101-3	35185-35190	model	_	
101-4	35191-35193	of	_	
101-5	35194-35207	schizophrenia	_	
101-6	35207-35208	:	_	
101-7	35209-35215	update	_	
101-8	35216-35220	2005	_	

#Text=Neurodevelopmental hypothesis of schizophrenia
102-1	35221-35239	Neurodevelopmental	_	
102-2	35240-35250	hypothesis	_	
102-3	35251-35253	of	_	
102-4	35254-35267	schizophrenia	_	

#Text=Inferior parietal lobule function in spatial perception and visuomotor integration
103-1	35268-35276	Inferior	_	
103-2	35277-35285	parietal	_	
103-3	35286-35292	lobule	_	
103-4	35293-35301	function	_	
103-5	35302-35304	in	_	
103-6	35305-35312	spatial	_	
103-7	35313-35323	perception	_	
103-8	35324-35327	and	_	
103-9	35328-35338	visuomotor	_	
103-10	35339-35350	integration	_	

#Text=Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes
104-1	35351-35359	Abnormal	_	
104-2	35360-35367	indices	_	
104-3	35368-35370	of	_	
104-4	35371-35375	cell	_	
104-5	35376-35381	cycle	_	
104-6	35382-35390	activity	_	
104-7	35391-35393	in	_	
104-8	35394-35407	schizophrenia	_	
104-9	35408-35411	and	_	
104-10	35412-35417	their	_	
104-11	35418-35427	potential	_	
104-12	35428-35439	association	_	
104-13	35440-35444	with	_	
104-14	35445-35461	oligodendrocytes	_	

#Text=Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus
105-1	35462-35467	Adult	_	
105-2	35468-35480	neurogenesis	_	
105-3	35481-35489	produces	_	
105-4	35490-35491	a	_	
105-5	35492-35497	large	_	
105-6	35498-35502	pool	_	
105-7	35503-35505	of	_	
105-8	35506-35509	new	_	
105-9	35510-35517	granule	_	
105-10	35518-35523	cells	_	
105-11	35524-35526	in	_	
105-12	35527-35530	the	_	
105-13	35531-35538	dentate	_	
105-14	35539-35544	gyrus	_	

#Text=Resolving new memories: a critical look at the dentate gyrus, adult neurogenesis, and pattern separation
106-1	35545-35554	Resolving	_	
106-2	35555-35558	new	_	
106-3	35559-35567	memories	_	
106-4	35567-35568	:	_	
106-5	35569-35570	a	_	
106-6	35571-35579	critical	_	
106-7	35580-35584	look	_	
106-8	35585-35587	at	_	
106-9	35588-35591	the	_	
106-10	35592-35599	dentate	_	
106-11	35600-35605	gyrus	_	
106-12	35605-35606	,	_	
106-13	35607-35612	adult	_	
106-14	35613-35625	neurogenesis	_	
106-15	35625-35626	,	_	
106-16	35627-35630	and	_	
106-17	35631-35638	pattern	_	
106-18	35639-35649	separation	_	

#Text=Could adult hippocampal neurogenesis be relevant for human behavior
107-1	35650-35655	Could	_	
107-2	35656-35661	adult	_	
107-3	35662-35673	hippocampal	_	
107-4	35674-35686	neurogenesis	_	
107-5	35687-35689	be	_	
107-6	35690-35698	relevant	_	
107-7	35699-35702	for	_	
107-8	35703-35708	human	_	
107-9	35709-35717	behavior	_	

#Text=The inferior parietal lobule is the target of output from the superior colliculus, hippocampus, and cerebellum
108-1	35718-35721	The	_	
108-2	35722-35730	inferior	_	
108-3	35731-35739	parietal	_	
108-4	35740-35746	lobule	_	
108-5	35747-35749	is	_	
108-6	35750-35753	the	_	
108-7	35754-35760	target	_	
108-8	35761-35763	of	_	
108-9	35764-35770	output	_	
108-10	35771-35775	from	_	
108-11	35776-35779	the	_	
108-12	35780-35788	superior	_	
108-13	35789-35799	colliculus	_	
108-14	35799-35800	,	_	
108-15	35801-35812	hippocampus	_	
108-16	35812-35813	,	_	
108-17	35814-35817	and	_	
108-18	35818-35828	cerebellum	_	

#Text=Supplementary Material
109-1	35829-35842	Supplementary	_	
109-2	35843-35851	Material	_	

#Text=The developmental expression profile of 22 genes in the cell cycle pathway and 20 genes in the DNA repair pathway in hippocampus. Following colors for different Gene Ontology (GO) categories were used: red for DNA repair and blue for cell cycle, and a smooth curve with confidence interval (gray range). The expression profiles show high expression during the stage of brain development before birth, with a sharp decrease in expression after birth.
110-1	35852-35855	The	_	
110-2	35856-35869	developmental	_	
110-3	35870-35880	expression	_	
110-4	35881-35888	profile	_	
110-5	35889-35891	of	_	
110-6	35892-35894	22	_	
110-7	35895-35900	genes	_	
110-8	35901-35903	in	_	
110-9	35904-35907	the	_	
110-10	35908-35912	cell	_	
110-11	35913-35918	cycle	_	
110-12	35919-35926	pathway	_	
110-13	35927-35930	and	_	
110-14	35931-35933	20	_	
110-15	35934-35939	genes	_	
110-16	35940-35942	in	_	
110-17	35943-35946	the	_	
110-18	35947-35950	DNA	_	
110-19	35951-35957	repair	_	
110-20	35958-35965	pathway	_	
110-21	35966-35968	in	_	
110-22	35969-35980	hippocampus	_	
110-23	35980-35981	.	_	
110-24	35982-35991	Following	_	
110-25	35992-35998	colors	_	
110-26	35999-36002	for	_	
110-27	36003-36012	different	_	
110-28	36013-36017	Gene	_	
110-29	36018-36026	Ontology	_	
110-30	36027-36028	(	_	
110-31	36028-36030	GO	_	
110-32	36030-36031	)	_	
110-33	36032-36042	categories	_	
110-34	36043-36047	were	_	
110-35	36048-36052	used	_	
110-36	36052-36053	:	_	
110-37	36054-36057	red	_	
110-38	36058-36061	for	_	
110-39	36062-36065	DNA	_	
110-40	36066-36072	repair	_	
110-41	36073-36076	and	_	
110-42	36077-36081	blue	_	
110-43	36082-36085	for	_	
110-44	36086-36090	cell	_	
110-45	36091-36096	cycle	_	
110-46	36096-36097	,	_	
110-47	36098-36101	and	_	
110-48	36102-36103	a	_	
110-49	36104-36110	smooth	_	
110-50	36111-36116	curve	_	
110-51	36117-36121	with	_	
110-52	36122-36132	confidence	_	
110-53	36133-36141	interval	_	
110-54	36142-36143	(	_	
110-55	36143-36147	gray	_	
110-56	36148-36153	range	_	
110-57	36153-36154	)	_	
110-58	36154-36155	.	_	
110-59	36156-36159	The	_	
110-60	36160-36170	expression	_	
110-61	36171-36179	profiles	_	
110-62	36180-36184	show	_	
110-63	36185-36189	high	_	
110-64	36190-36200	expression	_	
110-65	36201-36207	during	_	
110-66	36208-36211	the	_	
110-67	36212-36217	stage	_	
110-68	36218-36220	of	_	
110-69	36221-36226	brain	_	
110-70	36227-36238	development	_	
110-71	36239-36245	before	_	
110-72	36246-36251	birth	_	
110-73	36251-36252	,	_	
110-74	36253-36257	with	_	
110-75	36258-36259	a	_	
110-76	36260-36265	sharp	_	
110-77	36266-36274	decrease	_	
110-78	36275-36277	in	_	
110-79	36278-36288	expression	_	
110-80	36289-36294	after	_	
110-81	36295-36300	birth	_	
110-82	36300-36301	.	_	

#Text=Aberrant resting-state functional connectivity (rsFC) of the left hippocampus among three groups. (a) Left inferior parietal cortex and right cerebellum posterior lobe showed significantly different rsFC with left hippocampus among three groups. The statistical significance threshold was set at P<0.05 and corrected for multiple comparisons based on Monte Carlo simulations, for main effect for diagnosis of functional connectivity (FC) of left hippocampus. (b) ANCOVA with sex, age, education and the hippocampal volume as covariances. rsFC between left hippocampus and left inferior parietal cortex is increased, whereas rsFC between left hippocampus and cerebellum is decreased only in schizophrenic patients with rare damage variants (RDVs). The statistical significance threshold was set at P<0.05, post hoc test by least significant difference. ANCOVA, analysis of covariance; HIP, hippocampus; IPL, inferior parietal cortex; L, left; PCL, cerebellum posterior lobe; R, right. Notes: s.e. for all figures.
111-1	36302-36310	Aberrant	_	
111-2	36311-36324	resting-state	_	
111-3	36325-36335	functional	_	
111-4	36336-36348	connectivity	_	
111-5	36349-36350	(	_	
111-6	36350-36354	rsFC	_	
111-7	36354-36355	)	_	
111-8	36356-36358	of	_	
111-9	36359-36362	the	_	
111-10	36363-36367	left	_	
111-11	36368-36379	hippocampus	_	
111-12	36380-36385	among	_	
111-13	36386-36391	three	_	
111-14	36392-36398	groups	_	
111-15	36398-36399	.	_	
111-16	36400-36401	(	_	
111-17	36401-36402	a	_	
111-18	36402-36403	)	_	
111-19	36404-36408	Left	_	
111-20	36409-36417	inferior	_	
111-21	36418-36426	parietal	_	
111-22	36427-36433	cortex	_	
111-23	36434-36437	and	_	
111-24	36438-36443	right	_	
111-25	36444-36454	cerebellum	_	
111-26	36455-36464	posterior	_	
111-27	36465-36469	lobe	_	
111-28	36470-36476	showed	_	
111-29	36477-36490	significantly	_	
111-30	36491-36500	different	_	
111-31	36501-36505	rsFC	_	
111-32	36506-36510	with	_	
111-33	36511-36515	left	_	
111-34	36516-36527	hippocampus	_	
111-35	36528-36533	among	_	
111-36	36534-36539	three	_	
111-37	36540-36546	groups	_	
111-38	36546-36547	.	_	
111-39	36548-36551	The	_	
111-40	36552-36563	statistical	_	
111-41	36564-36576	significance	_	
111-42	36577-36586	threshold	_	
111-43	36587-36590	was	_	
111-44	36591-36594	set	_	
111-45	36595-36597	at	_	
111-46	36598-36599	P	_	
111-47	36599-36600	<	_	
111-48	36600-36604	0.05	_	
111-49	36605-36608	and	_	
111-50	36609-36618	corrected	_	
111-51	36619-36622	for	_	
111-52	36623-36631	multiple	_	
111-53	36632-36643	comparisons	_	
111-54	36644-36649	based	_	
111-55	36650-36652	on	_	
111-56	36653-36658	Monte	_	
111-57	36659-36664	Carlo	_	
111-58	36665-36676	simulations	_	
111-59	36676-36677	,	_	
111-60	36678-36681	for	_	
111-61	36682-36686	main	_	
111-62	36687-36693	effect	_	
111-63	36694-36697	for	_	
111-64	36698-36707	diagnosis	_	
111-65	36708-36710	of	_	
111-66	36711-36721	functional	_	
111-67	36722-36734	connectivity	_	
111-68	36735-36736	(	_	
111-69	36736-36738	FC	_	
111-70	36738-36739	)	_	
111-71	36740-36742	of	_	
111-72	36743-36747	left	_	
111-73	36748-36759	hippocampus	_	
111-74	36759-36760	.	_	
111-75	36761-36762	(	_	
111-76	36762-36763	b	_	
111-77	36763-36764	)	_	
111-78	36765-36771	ANCOVA	_	
111-79	36772-36776	with	_	
111-80	36777-36780	sex	_	
111-81	36780-36781	,	_	
111-82	36782-36785	age	_	
111-83	36785-36786	,	_	
111-84	36787-36796	education	_	
111-85	36797-36800	and	_	
111-86	36801-36804	the	_	
111-87	36805-36816	hippocampal	_	
111-88	36817-36823	volume	_	
111-89	36824-36826	as	_	
111-90	36827-36838	covariances	_	
111-91	36838-36839	.	_	
111-92	36840-36844	rsFC	_	
111-93	36845-36852	between	_	
111-94	36853-36857	left	_	
111-95	36858-36869	hippocampus	_	
111-96	36870-36873	and	_	
111-97	36874-36878	left	_	
111-98	36879-36887	inferior	_	
111-99	36888-36896	parietal	_	
111-100	36897-36903	cortex	_	
111-101	36904-36906	is	_	
111-102	36907-36916	increased	_	
111-103	36916-36917	,	_	
111-104	36918-36925	whereas	_	
111-105	36926-36930	rsFC	_	
111-106	36931-36938	between	_	
111-107	36939-36943	left	_	
111-108	36944-36955	hippocampus	_	
111-109	36956-36959	and	_	
111-110	36960-36970	cerebellum	_	
111-111	36971-36973	is	_	
111-112	36974-36983	decreased	_	
111-113	36984-36988	only	_	
111-114	36989-36991	in	_	
111-115	36992-37005	schizophrenic	_	
111-116	37006-37014	patients	_	
111-117	37015-37019	with	_	
111-118	37020-37024	rare	_	
111-119	37025-37031	damage	_	
111-120	37032-37040	variants	_	
111-121	37041-37042	(	_	
111-122	37042-37046	RDVs	_	
111-123	37046-37047	)	_	
111-124	37047-37048	.	_	
111-125	37049-37052	The	_	
111-126	37053-37064	statistical	_	
111-127	37065-37077	significance	_	
111-128	37078-37087	threshold	_	
111-129	37088-37091	was	_	
111-130	37092-37095	set	_	
111-131	37096-37098	at	_	
111-132	37099-37100	P	_	
111-133	37100-37101	<	_	
111-134	37101-37105	0.05	_	
111-135	37105-37106	,	_	
111-136	37107-37111	post	_	
111-137	37112-37115	hoc	_	
111-138	37116-37120	test	_	
111-139	37121-37123	by	_	
111-140	37124-37129	least	_	
111-141	37130-37141	significant	_	
111-142	37142-37152	difference	_	
111-143	37152-37153	.	_	
111-144	37154-37160	ANCOVA	_	
111-145	37160-37161	,	_	
111-146	37162-37170	analysis	_	
111-147	37171-37173	of	_	
111-148	37174-37184	covariance	_	
111-149	37184-37185	;	_	
111-150	37186-37189	HIP	_	
111-151	37189-37190	,	_	
111-152	37191-37202	hippocampus	_	
111-153	37202-37203	;	_	
111-154	37204-37207	IPL	_	
111-155	37207-37208	,	_	
111-156	37209-37217	inferior	_	
111-157	37218-37226	parietal	_	
111-158	37227-37233	cortex	_	
111-159	37233-37234	;	_	
111-160	37235-37236	L	_	
111-161	37236-37237	,	_	
111-162	37238-37242	left	_	
111-163	37242-37243	;	_	
111-164	37244-37247	PCL	_	
111-165	37247-37248	,	_	
111-166	37249-37259	cerebellum	_	
111-167	37260-37269	posterior	_	
111-168	37270-37274	lobe	_	
111-169	37274-37275	;	_	
111-170	37276-37277	R	_	
111-171	37277-37278	,	_	
111-172	37279-37284	right	_	
111-173	37284-37285	.	_	
111-174	37286-37291	Notes	_	
111-175	37291-37292	:	_	
111-176	37293-37296	s.e	_	
111-177	37296-37297	.	_	
111-178	37298-37301	for	_	
111-179	37302-37305	all	_	
111-180	37306-37313	figures	_	
111-181	37313-37314	.	_	

#Text=Aberrant resting-state functional connectivity (rsFC) of hippocampal subregions. (a) The brain map of aberrant rsFC with hippocampal subregions among three groups. The statistical significance threshold was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations, for main effect for diagnosis of functional connectivity (FC) of the different hippocampal subregions. (b) rsFC between left DG and left IPL increased only in schizophrenic patients with rare damage variants, whereas decreased rsFC of left SC with MFG was only found in schizophrenic patients without rare damage variants. The statistical significance threshold was set at P<0.05, post hoc test by least significant difference. CA, cornuammonis; Cal, calcarine; DG, dentate gyrus; Fus, fusiform; IPL, inferior parietal cortex; L, left; MFG, medial frontal cortex; PCC, posterior cingulate cortex; R, right; RDV, rare damaging variant; SC, subicular complex. Notes: s.e. for all figures.
112-1	37315-37323	Aberrant	_	
112-2	37324-37337	resting-state	_	
112-3	37338-37348	functional	_	
112-4	37349-37361	connectivity	_	
112-5	37362-37363	(	_	
112-6	37363-37367	rsFC	_	
112-7	37367-37368	)	_	
112-8	37369-37371	of	_	
112-9	37372-37383	hippocampal	_	
112-10	37384-37394	subregions	_	
112-11	37394-37395	.	_	
112-12	37396-37397	(	_	
112-13	37397-37398	a	_	
112-14	37398-37399	)	_	
112-15	37400-37403	The	_	
112-16	37404-37409	brain	_	
112-17	37410-37413	map	_	
112-18	37414-37416	of	_	
112-19	37417-37425	aberrant	_	
112-20	37426-37430	rsFC	_	
112-21	37431-37435	with	_	
112-22	37436-37447	hippocampal	_	
112-23	37448-37458	subregions	_	
112-24	37459-37464	among	_	
112-25	37465-37470	three	_	
112-26	37471-37477	groups	_	
112-27	37477-37478	.	_	
112-28	37479-37482	The	_	
112-29	37483-37494	statistical	_	
112-30	37495-37507	significance	_	
112-31	37508-37517	threshold	_	
112-32	37518-37521	was	_	
112-33	37522-37525	set	_	
112-34	37526-37528	at	_	
112-35	37529-37530	P	_	
112-36	37530-37531	<	_	
112-37	37531-37535	0.05	_	
112-38	37535-37536	,	_	
112-39	37537-37546	corrected	_	
112-40	37547-37550	for	_	
112-41	37551-37559	multiple	_	
112-42	37560-37571	comparisons	_	
112-43	37572-37577	based	_	
112-44	37578-37580	on	_	
112-45	37581-37586	Monte	_	
112-46	37587-37592	Carlo	_	
112-47	37593-37604	simulations	_	
112-48	37604-37605	,	_	
112-49	37606-37609	for	_	
112-50	37610-37614	main	_	
112-51	37615-37621	effect	_	
112-52	37622-37625	for	_	
112-53	37626-37635	diagnosis	_	
112-54	37636-37638	of	_	
112-55	37639-37649	functional	_	
112-56	37650-37662	connectivity	_	
112-57	37663-37664	(	_	
112-58	37664-37666	FC	_	
112-59	37666-37667	)	_	
112-60	37668-37670	of	_	
112-61	37671-37674	the	_	
112-62	37675-37684	different	_	
112-63	37685-37696	hippocampal	_	
112-64	37697-37707	subregions	_	
112-65	37707-37708	.	_	
112-66	37709-37710	(	_	
112-67	37710-37711	b	_	
112-68	37711-37712	)	_	
112-69	37713-37717	rsFC	_	
112-70	37718-37725	between	_	
112-71	37726-37730	left	_	
112-72	37731-37733	DG	_	
112-73	37734-37737	and	_	
112-74	37738-37742	left	_	
112-75	37743-37746	IPL	_	
112-76	37747-37756	increased	_	
112-77	37757-37761	only	_	
112-78	37762-37764	in	_	
112-79	37765-37778	schizophrenic	_	
112-80	37779-37787	patients	_	
112-81	37788-37792	with	_	
112-82	37793-37797	rare	_	
112-83	37798-37804	damage	_	
112-84	37805-37813	variants	_	
112-85	37813-37814	,	_	
112-86	37815-37822	whereas	_	
112-87	37823-37832	decreased	_	
112-88	37833-37837	rsFC	_	
112-89	37838-37840	of	_	
112-90	37841-37845	left	_	
112-91	37846-37848	SC	_	
112-92	37849-37853	with	_	
112-93	37854-37857	MFG	_	
112-94	37858-37861	was	_	
112-95	37862-37866	only	_	
112-96	37867-37872	found	_	
112-97	37873-37875	in	_	
112-98	37876-37889	schizophrenic	_	
112-99	37890-37898	patients	_	
112-100	37899-37906	without	_	
112-101	37907-37911	rare	_	
112-102	37912-37918	damage	_	
112-103	37919-37927	variants	_	
112-104	37927-37928	.	_	
112-105	37929-37932	The	_	
112-106	37933-37944	statistical	_	
112-107	37945-37957	significance	_	
112-108	37958-37967	threshold	_	
112-109	37968-37971	was	_	
112-110	37972-37975	set	_	
112-111	37976-37978	at	_	
112-112	37979-37980	P	_	
112-113	37980-37981	<	_	
112-114	37981-37985	0.05	_	
112-115	37985-37986	,	_	
112-116	37987-37991	post	_	
112-117	37992-37995	hoc	_	
112-118	37996-38000	test	_	
112-119	38001-38003	by	_	
112-120	38004-38009	least	_	
112-121	38010-38021	significant	_	
112-122	38022-38032	difference	_	
112-123	38032-38033	.	_	
112-124	38034-38036	CA	_	
112-125	38036-38037	,	_	
112-126	38038-38050	cornuammonis	_	
112-127	38050-38051	;	_	
112-128	38052-38055	Cal	_	
112-129	38055-38056	,	_	
112-130	38057-38066	calcarine	_	
112-131	38066-38067	;	_	
112-132	38068-38070	DG	_	
112-133	38070-38071	,	_	
112-134	38072-38079	dentate	_	
112-135	38080-38085	gyrus	_	
112-136	38085-38086	;	_	
112-137	38087-38090	Fus	_	
112-138	38090-38091	,	_	
112-139	38092-38100	fusiform	_	
112-140	38100-38101	;	_	
112-141	38102-38105	IPL	_	
112-142	38105-38106	,	_	
112-143	38107-38115	inferior	_	
112-144	38116-38124	parietal	_	
112-145	38125-38131	cortex	_	
112-146	38131-38132	;	_	
112-147	38133-38134	L	_	
112-148	38134-38135	,	_	
112-149	38136-38140	left	_	
112-150	38140-38141	;	_	
112-151	38142-38145	MFG	_	
112-152	38145-38146	,	_	
112-153	38147-38153	medial	_	
112-154	38154-38161	frontal	_	
112-155	38162-38168	cortex	_	
112-156	38168-38169	;	_	
112-157	38170-38173	PCC	_	
112-158	38173-38174	,	_	
112-159	38175-38184	posterior	_	
112-160	38185-38194	cingulate	_	
112-161	38195-38201	cortex	_	
112-162	38201-38202	;	_	
112-163	38203-38204	R	_	
112-164	38204-38205	,	_	
112-165	38206-38211	right	_	
112-166	38211-38212	;	_	
112-167	38213-38216	RDV	_	
112-168	38216-38217	,	_	
112-169	38218-38222	rare	_	
112-170	38223-38231	damaging	_	
112-171	38232-38239	variant	_	
112-172	38239-38240	;	_	
112-173	38241-38243	SC	_	
112-174	38243-38244	,	_	
112-175	38245-38254	subicular	_	
112-176	38255-38262	complex	_	
112-177	38262-38263	.	_	
112-178	38264-38269	Notes	_	
112-179	38269-38270	:	_	
112-180	38271-38274	s.e	_	
112-181	38274-38275	.	_	
112-182	38276-38279	for	_	
112-183	38280-38283	all	_	
112-184	38284-38291	figures	_	
112-185	38291-38292	.	_	

#Text=Relationships between resting-state functional connectivity (rsFC) of hippocampus and spatial working memory. Increased rsFC between left dentate gyrus and left inferior parietal cortex was positively related to number of errors of spatial working memory in schizophrenic patients with rare damaging variants and negatively related to number of errors of spatial working memory in healthy controls, uncorrected P<0.05. The difference in the degree of correlation was statistically significant between schizophrenic patients with RDVs and healthy controls (Z=3.331, P=8.65 Ã— 10âˆ’4) after the Bonferroni correction, and a trend toward significance between patients with RDVs and patients without RDVs (Z=2.171, P=0.030 before Bonferroni correction), but not significant between patients without RDVs and healthy controls (Z=0.884, P=0.377). DG, dentate gyrus; IPL, inferior parietal cortex; NoE, number of error; L, left; RDV, rare damaging variant. Note: partial correlation analysis was used to analyze the relationship between rsFC of hippocampus and spatial working memory with age, sex and educations and structural hippocampal volume as covariates.
113-1	38293-38306	Relationships	_	
113-2	38307-38314	between	_	
113-3	38315-38328	resting-state	_	
113-4	38329-38339	functional	_	
113-5	38340-38352	connectivity	_	
113-6	38353-38354	(	_	
113-7	38354-38358	rsFC	_	
113-8	38358-38359	)	_	
113-9	38360-38362	of	_	
113-10	38363-38374	hippocampus	_	
113-11	38375-38378	and	_	
113-12	38379-38386	spatial	_	
113-13	38387-38394	working	_	
113-14	38395-38401	memory	_	
113-15	38401-38402	.	_	
113-16	38403-38412	Increased	_	
113-17	38413-38417	rsFC	_	
113-18	38418-38425	between	_	
113-19	38426-38430	left	_	
113-20	38431-38438	dentate	_	
113-21	38439-38444	gyrus	_	
113-22	38445-38448	and	_	
113-23	38449-38453	left	_	
113-24	38454-38462	inferior	_	
113-25	38463-38471	parietal	_	
113-26	38472-38478	cortex	_	
113-27	38479-38482	was	_	
113-28	38483-38493	positively	_	
113-29	38494-38501	related	_	
113-30	38502-38504	to	_	
113-31	38505-38511	number	_	
113-32	38512-38514	of	_	
113-33	38515-38521	errors	_	
113-34	38522-38524	of	_	
113-35	38525-38532	spatial	_	
113-36	38533-38540	working	_	
113-37	38541-38547	memory	_	
113-38	38548-38550	in	_	
113-39	38551-38564	schizophrenic	_	
113-40	38565-38573	patients	_	
113-41	38574-38578	with	_	
113-42	38579-38583	rare	_	
113-43	38584-38592	damaging	_	
113-44	38593-38601	variants	_	
113-45	38602-38605	and	_	
113-46	38606-38616	negatively	_	
113-47	38617-38624	related	_	
113-48	38625-38627	to	_	
113-49	38628-38634	number	_	
113-50	38635-38637	of	_	
113-51	38638-38644	errors	_	
113-52	38645-38647	of	_	
113-53	38648-38655	spatial	_	
113-54	38656-38663	working	_	
113-55	38664-38670	memory	_	
113-56	38671-38673	in	_	
113-57	38674-38681	healthy	_	
113-58	38682-38690	controls	_	
113-59	38690-38691	,	_	
113-60	38692-38703	uncorrected	_	
113-61	38704-38705	P	_	
113-62	38705-38706	<	_	
113-63	38706-38710	0.05	_	
113-64	38710-38711	.	_	
113-65	38712-38715	The	_	
113-66	38716-38726	difference	_	
113-67	38727-38729	in	_	
113-68	38730-38733	the	_	
113-69	38734-38740	degree	_	
113-70	38741-38743	of	_	
113-71	38744-38755	correlation	_	
113-72	38756-38759	was	_	
113-73	38760-38773	statistically	_	
113-74	38774-38785	significant	_	
113-75	38786-38793	between	_	
113-76	38794-38807	schizophrenic	_	
113-77	38808-38816	patients	_	
113-78	38817-38821	with	_	
113-79	38822-38826	RDVs	_	
113-80	38827-38830	and	_	
113-81	38831-38838	healthy	_	
113-82	38839-38847	controls	_	
113-83	38848-38849	(	_	
113-84	38849-38850	Z	_	
113-85	38850-38851	=	_	
113-86	38851-38856	3.331	_	
113-87	38856-38857	,	_	
113-88	38858-38859	P	_	
113-89	38859-38860	=	_	
113-90	38860-38864	8.65	_	
113-91	38865-38866	Ã—	_	
113-92	38867-38869	10	_	
113-93	38869-38870	âˆ’	_	
113-94	38870-38871	4	_	
113-95	38871-38872	)	_	
113-96	38873-38878	after	_	
113-97	38879-38882	the	_	
113-98	38883-38893	Bonferroni	_	
113-99	38894-38904	correction	_	
113-100	38904-38905	,	_	
113-101	38906-38909	and	_	
113-102	38910-38911	a	_	
113-103	38912-38917	trend	_	
113-104	38918-38924	toward	_	
113-105	38925-38937	significance	_	
113-106	38938-38945	between	_	
113-107	38946-38954	patients	_	
113-108	38955-38959	with	_	
113-109	38960-38964	RDVs	_	
113-110	38965-38968	and	_	
113-111	38969-38977	patients	_	
113-112	38978-38985	without	_	
113-113	38986-38990	RDVs	_	
113-114	38991-38992	(	_	
113-115	38992-38993	Z	_	
113-116	38993-38994	=	_	
113-117	38994-38999	2.171	_	
113-118	38999-39000	,	_	
113-119	39001-39002	P	_	
113-120	39002-39003	=	_	
113-121	39003-39008	0.030	_	
113-122	39009-39015	before	_	
113-123	39016-39026	Bonferroni	_	
113-124	39027-39037	correction	_	
113-125	39037-39038	)	_	
113-126	39038-39039	,	_	
113-127	39040-39043	but	_	
113-128	39044-39047	not	_	
113-129	39048-39059	significant	_	
113-130	39060-39067	between	_	
113-131	39068-39076	patients	_	
113-132	39077-39084	without	_	
113-133	39085-39089	RDVs	_	
113-134	39090-39093	and	_	
113-135	39094-39101	healthy	_	
113-136	39102-39110	controls	_	
113-137	39111-39112	(	_	
113-138	39112-39113	Z	_	
113-139	39113-39114	=	_	
113-140	39114-39119	0.884	_	
113-141	39119-39120	,	_	
113-142	39121-39122	P	_	
113-143	39122-39123	=	_	
113-144	39123-39128	0.377	_	
113-145	39128-39129	)	_	
113-146	39129-39130	.	_	
113-147	39131-39133	DG	_	
113-148	39133-39134	,	_	
113-149	39135-39142	dentate	_	
113-150	39143-39148	gyrus	_	
113-151	39148-39149	;	_	
113-152	39150-39153	IPL	_	
113-153	39153-39154	,	_	
113-154	39155-39163	inferior	_	
113-155	39164-39172	parietal	_	
113-156	39173-39179	cortex	_	
113-157	39179-39180	;	_	
113-158	39181-39184	NoE	_	
113-159	39184-39185	,	_	
113-160	39186-39192	number	_	
113-161	39193-39195	of	_	
113-162	39196-39201	error	_	
113-163	39201-39202	;	_	
113-164	39203-39204	L	_	
113-165	39204-39205	,	_	
113-166	39206-39210	left	_	
113-167	39210-39211	;	_	
113-168	39212-39215	RDV	_	
113-169	39215-39216	,	_	
113-170	39217-39221	rare	_	
113-171	39222-39230	damaging	_	
113-172	39231-39238	variant	_	
113-173	39238-39239	.	_	
113-174	39240-39244	Note	_	
113-175	39244-39245	:	_	
113-176	39246-39253	partial	_	
113-177	39254-39265	correlation	_	
113-178	39266-39274	analysis	_	
113-179	39275-39278	was	_	
113-180	39279-39283	used	_	
113-181	39284-39286	to	_	
113-182	39287-39294	analyze	_	
113-183	39295-39298	the	_	
113-184	39299-39311	relationship	_	
113-185	39312-39319	between	_	
113-186	39320-39324	rsFC	_	
113-187	39325-39327	of	_	
113-188	39328-39339	hippocampus	_	
113-189	39340-39343	and	_	
113-190	39344-39351	spatial	_	
113-191	39352-39359	working	_	
113-192	39360-39366	memory	_	
113-193	39367-39371	with	_	
113-194	39372-39375	age	_	
113-195	39375-39376	,	_	
113-196	39377-39380	sex	_	
113-197	39381-39384	and	_	
113-198	39385-39395	educations	_	
113-199	39396-39399	and	_	
113-200	39400-39410	structural	_	
113-201	39411-39422	hippocampal	_	
113-202	39423-39429	volume	_	
113-203	39430-39432	as	_	
113-204	39433-39443	covariates	_	
113-205	39443-39444	.	_	

#Text=Statistic of demographic data for all samples
114-1	39445-39454	Statistic	_	
114-2	39455-39457	of	_	
114-3	39458-39469	demographic	_	
114-4	39470-39474	data	_	
114-5	39475-39478	for	_	
114-6	39479-39482	all	_	
114-7	39483-39490	samples	_	

#Text=Â \tCase (N=94)\tControl (N=134)\tP-value\t \tGender (male/female)\t46/48\t71/63\t0.64\t \tAge (meanÂ±s.d)\t23.94Â±6.92\t24.39Â±10.95\t0.37\t \tEducation (meanÂ±s.d)\t12.79Â±3.15\t13.50Â±2.89\t0.07
115-1	39491-39492	Â 	_	
115-2	39493-39497	Case	_	
115-3	39498-39499	(	_	
115-4	39499-39500	N	_	
115-5	39500-39501	=	_	
115-6	39501-39503	94	_	
115-7	39503-39504	)	_	
115-8	39505-39512	Control	_	
115-9	39513-39514	(	_	
115-10	39514-39515	N	_	
115-11	39515-39516	=	_	
115-12	39516-39519	134	_	
115-13	39519-39520	)	_	
115-14	39521-39528	P-value	_	
115-15	39531-39537	Gender	_	
115-16	39538-39539	(	_	
115-17	39539-39543	male	_	
115-18	39543-39544	/	_	
115-19	39544-39550	female	_	
115-20	39550-39551	)	_	
115-21	39552-39554	46	_	
115-22	39554-39555	/	_	
115-23	39555-39557	48	_	
115-24	39558-39560	71	_	
115-25	39560-39561	/	_	
115-26	39561-39563	63	_	
115-27	39564-39568	0.64	_	
115-28	39571-39574	Age	_	
115-29	39575-39576	(	_	
115-30	39576-39580	mean	_	
115-31	39580-39581	Â±	_	
115-32	39581-39584	s.d	_	
115-33	39584-39585	)	_	
115-34	39586-39591	23.94	_	
115-35	39591-39592	Â±	_	
115-36	39592-39596	6.92	_	
115-37	39597-39602	24.39	_	
115-38	39602-39603	Â±	_	
115-39	39603-39608	10.95	_	
115-40	39609-39613	0.37	_	
115-41	39616-39625	Education	_	
115-42	39626-39627	(	_	
115-43	39627-39631	mean	_	
115-44	39631-39632	Â±	_	
115-45	39632-39635	s.d	_	
115-46	39635-39636	)	_	
115-47	39637-39642	12.79	_	
115-48	39642-39643	Â±	_	
115-49	39643-39647	3.15	_	
115-50	39648-39653	13.50	_	
115-51	39653-39654	Â±	_	
115-52	39654-39658	2.89	_	
115-53	39659-39663	0.07	_	

#Text=Summary for sequencing quality
116-1	39667-39674	Summary	_	
116-2	39675-39678	for	_	
116-3	39679-39689	sequencing	_	
116-4	39690-39697	quality	_	

#Text=Â \tTotal (N=228)\tCase (N=94)\tControl (N=134)\tP-value\t \tTotal reads\t75â€‰918â€‰287\t76â€‰078â€‰777\t75â€‰805â€‰704\t0.45\t \tTotal yield (bp)\t7â€‰667â€‰746â€‰978\t7â€‰683â€‰956â€‰451\t7â€‰656â€‰376â€‰154\t0.45\t \tInitial mappable reads (%)\t75â€‰731â€‰958 (99.75%)\t75â€‰897â€‰153 (99.76%)\t75â€‰616â€‰076 (99.75%)\t0.44\t \t1 Ã—, Target genotypes (%)\t58â€‰570â€‰040 (94.34%)\t58â€‰500â€‰027 (94.23%)\t58â€‰619â€‰153 (94.42%)\t0.08\t \t10 Ã—, Target genotypes (%)\t55â€‰003â€‰180 (88.60%)\t54â€‰965â€‰986 (88.53%)\t55â€‰029â€‰271 (88.64%)\t0.33\t \tMean target depth\t44.95\t46.54\t43.84\t0.009\t \tSNPs\t74â€‰413\t74501\t74351\t0.25\t \tCoding SNPs\t20â€‰229\t20157\t20280\t<0.001\t \tSynonymous SNPs\t10â€‰491\t10457\t10516\t0.001\t \tNonsynonymous SNPs\t9220\t9185\t9245\t<0.001\t \tIndels\t7645\t7664\t7632\t0.19\t \tCoding indels\t383\t378\t386\t<0.001
117-1	39698-39699	Â 	_	
117-2	39700-39705	Total	_	
117-3	39706-39707	(	_	
117-4	39707-39708	N	_	
117-5	39708-39709	=	_	
117-6	39709-39712	228	_	
117-7	39712-39713	)	_	
117-8	39714-39718	Case	_	
117-9	39719-39720	(	_	
117-10	39720-39721	N	_	
117-11	39721-39722	=	_	
117-12	39722-39724	94	_	
117-13	39724-39725	)	_	
117-14	39726-39733	Control	_	
117-15	39734-39735	(	_	
117-16	39735-39736	N	_	
117-17	39736-39737	=	_	
117-18	39737-39740	134	_	
117-19	39740-39741	)	_	
117-20	39742-39749	P-value	_	
117-21	39752-39757	Total	_	
117-22	39758-39763	reads	_	
117-23	39764-39766	75	_	
117-24	39767-39770	918	_	
117-25	39771-39774	287	_	
117-26	39775-39777	76	_	
117-27	39778-39781	078	_	
117-28	39782-39785	777	_	
117-29	39786-39788	75	_	
117-30	39789-39792	805	_	
117-31	39793-39796	704	_	
117-32	39797-39801	0.45	_	
117-33	39804-39809	Total	_	
117-34	39810-39815	yield	_	
117-35	39816-39817	(	_	
117-36	39817-39819	bp	_	
117-37	39819-39820	)	_	
117-38	39821-39822	7	_	
117-39	39823-39826	667	_	
117-40	39827-39830	746	_	
117-41	39831-39834	978	_	
117-42	39835-39836	7	_	
117-43	39837-39840	683	_	
117-44	39841-39844	956	_	
117-45	39845-39848	451	_	
117-46	39849-39850	7	_	
117-47	39851-39854	656	_	
117-48	39855-39858	376	_	
117-49	39859-39862	154	_	
117-50	39863-39867	0.45	_	
117-51	39870-39877	Initial	_	
117-52	39878-39886	mappable	_	
117-53	39887-39892	reads	_	
117-54	39893-39894	(	_	
117-55	39894-39895	%	_	
117-56	39895-39896	)	_	
117-57	39897-39899	75	_	
117-58	39900-39903	731	_	
117-59	39904-39907	958	_	
117-60	39908-39909	(	_	
117-61	39909-39915	99.75%	_	
117-62	39915-39916	)	_	
117-63	39917-39919	75	_	
117-64	39920-39923	897	_	
117-65	39924-39927	153	_	
117-66	39928-39929	(	_	
117-67	39929-39935	99.76%	_	
117-68	39935-39936	)	_	
117-69	39937-39939	75	_	
117-70	39940-39943	616	_	
117-71	39944-39947	076	_	
117-72	39948-39949	(	_	
117-73	39949-39955	99.75%	_	
117-74	39955-39956	)	_	
117-75	39957-39961	0.44	_	
117-76	39964-39965	1	_	
117-77	39966-39967	Ã—	_	
117-78	39967-39968	,	_	
117-79	39969-39975	Target	_	
117-80	39976-39985	genotypes	_	
117-81	39986-39987	(	_	
117-82	39987-39988	%	_	
117-83	39988-39989	)	_	
117-84	39990-39992	58	_	
117-85	39993-39996	570	_	
117-86	39997-40000	040	_	
117-87	40001-40002	(	_	
117-88	40002-40008	94.34%	_	
117-89	40008-40009	)	_	
117-90	40010-40012	58	_	
117-91	40013-40016	500	_	
117-92	40017-40020	027	_	
117-93	40021-40022	(	_	
117-94	40022-40028	94.23%	_	
117-95	40028-40029	)	_	
117-96	40030-40032	58	_	
117-97	40033-40036	619	_	
117-98	40037-40040	153	_	
117-99	40041-40042	(	_	
117-100	40042-40048	94.42%	_	
117-101	40048-40049	)	_	
117-102	40050-40054	0.08	_	
117-103	40057-40059	10	_	
117-104	40060-40061	Ã—	_	
117-105	40061-40062	,	_	
117-106	40063-40069	Target	_	
117-107	40070-40079	genotypes	_	
117-108	40080-40081	(	_	
117-109	40081-40082	%	_	
117-110	40082-40083	)	_	
117-111	40084-40086	55	_	
117-112	40087-40090	003	_	
117-113	40091-40094	180	_	
117-114	40095-40096	(	_	
117-115	40096-40102	88.60%	_	
117-116	40102-40103	)	_	
117-117	40104-40106	54	_	
117-118	40107-40110	965	_	
117-119	40111-40114	986	_	
117-120	40115-40116	(	_	
117-121	40116-40122	88.53%	_	
117-122	40122-40123	)	_	
117-123	40124-40126	55	_	
117-124	40127-40130	029	_	
117-125	40131-40134	271	_	
117-126	40135-40136	(	_	
117-127	40136-40142	88.64%	_	
117-128	40142-40143	)	_	
117-129	40144-40148	0.33	_	
117-130	40151-40155	Mean	_	
117-131	40156-40162	target	_	
117-132	40163-40168	depth	_	
117-133	40169-40174	44.95	_	
117-134	40175-40180	46.54	_	
117-135	40181-40186	43.84	_	
117-136	40187-40192	0.009	_	
117-137	40195-40199	SNPs	_	
117-138	40200-40202	74	_	
117-139	40203-40206	413	_	
117-140	40207-40212	74501	_	
117-141	40213-40218	74351	_	
117-142	40219-40223	0.25	_	
117-143	40226-40232	Coding	_	
117-144	40233-40237	SNPs	_	
117-145	40238-40240	20	_	
117-146	40241-40244	229	_	
117-147	40245-40250	20157	_	
117-148	40251-40256	20280	_	
117-149	40257-40258	<	_	
117-150	40258-40263	0.001	_	
117-151	40266-40276	Synonymous	_	
117-152	40277-40281	SNPs	_	
117-153	40282-40284	10	_	
117-154	40285-40288	491	_	
117-155	40289-40294	10457	_	
117-156	40295-40300	10516	_	
117-157	40301-40306	0.001	_	
117-158	40309-40322	Nonsynonymous	_	
117-159	40323-40327	SNPs	_	
117-160	40328-40332	9220	_	
117-161	40333-40337	9185	_	
117-162	40338-40342	9245	_	
117-163	40343-40344	<	_	
117-164	40344-40349	0.001	_	
117-165	40352-40358	Indels	_	
117-166	40359-40363	7645	_	
117-167	40364-40368	7664	_	
117-168	40369-40373	7632	_	
117-169	40374-40378	0.19	_	
117-170	40381-40387	Coding	_	
117-171	40388-40394	indels	_	
117-172	40395-40398	383	_	
117-173	40399-40402	378	_	
117-174	40403-40406	386	_	
117-175	40407-40408	<	_	
117-176	40408-40413	0.001	_	

#Text=Abbreviation: SNP, single-nucleotide polymorphism.
118-1	40417-40429	Abbreviation	_	
118-2	40429-40430	:	_	
118-3	40431-40434	SNP	_	
118-4	40434-40435	,	_	
118-5	40436-40453	single-nucleotide	_	
118-6	40454-40466	polymorphism	_	
118-7	40466-40467	.	_	

#Text=Bold values show significant statistic difference.
119-1	40468-40472	Bold	_	
119-2	40473-40479	values	_	
119-3	40480-40484	show	_	
119-4	40485-40496	significant	_	
119-5	40497-40506	statistic	_	
119-6	40507-40517	difference	_	
119-7	40517-40518	.	_	

#Text=Aberrant functional connectivity of hippocampus and hippocampal subregions in patients group
120-1	40519-40527	Aberrant	_	
120-2	40528-40538	functional	_	
120-3	40539-40551	connectivity	_	
120-4	40552-40554	of	_	
120-5	40555-40566	hippocampus	_	
120-6	40567-40570	and	_	
120-7	40571-40582	hippocampal	_	
120-8	40583-40593	subregions	_	
120-9	40594-40596	in	_	
120-10	40597-40605	patients	_	
120-11	40606-40611	group	_	

#Text=Â \tBrain region\tPeak MNI (x y z)\tPeak Z-score\tCluster size\t \tHippocampus_L\tInferior parietal lobule_L\tâˆ’36 âˆ’56 43\t6.8463\t42\t \tÂ \tCerebellar posterior lobe\t9 âˆ’75 âˆ’45\t7.3691\t40\t \tÂ \tÂ \tÂ \tÂ \tÂ \t \tHippocampal subregions\t \tâ€ƒDG_L\tInferior parietal lobule_L\tâˆ’36 âˆ’54 42\t10.7382\t77\t \tâ€ƒDG_R\tInferior parietal lobule_L\tâˆ’48 âˆ’54 48\t8.2654\t46\t \tÂ \tPosterior cingulate cortex\tâˆ’6 âˆ’33 30\t7.0922\t33\t \tâ€ƒCA_L\tCalcarine_R\t24 âˆ’93 0\t11.1746\t68\t \tâ€ƒCA_R\tCalcarine_R\t21 âˆ’93 3\t13.0346\t97\t \tÂ \tFusiform extent to lingual_L\tâˆ’27 âˆ’54 âˆ’3\t9.205\t32\t \tâ€ƒSUB_L\tMedial frontal cortex\t3 30 âˆ’12\t7.1874\t37
121-1	40612-40613	Â 	_	
121-2	40614-40619	Brain	_	
121-3	40620-40626	region	_	
121-4	40627-40631	Peak	_	
121-5	40632-40635	MNI	_	
121-6	40636-40637	(	_	
121-7	40637-40638	x	_	
121-8	40639-40640	y	_	
121-9	40641-40642	z	_	
121-10	40642-40643	)	_	
121-11	40644-40648	Peak	_	
121-12	40649-40656	Z-score	_	
121-13	40657-40664	Cluster	_	
121-14	40665-40669	size	_	
121-15	40672-40685	Hippocampus_L	_	
121-16	40686-40694	Inferior	_	
121-17	40695-40703	parietal	_	
121-18	40704-40712	lobule_L	_	
121-19	40713-40714	âˆ’	_	
121-20	40714-40716	36	_	
121-21	40717-40718	âˆ’	_	
121-22	40718-40720	56	_	
121-23	40721-40723	43	_	
121-24	40724-40730	6.8463	_	
121-25	40731-40733	42	_	
121-26	40736-40737	Â 	_	
121-27	40738-40748	Cerebellar	_	
121-28	40749-40758	posterior	_	
121-29	40759-40763	lobe	_	
121-30	40764-40765	9	_	
121-31	40766-40767	âˆ’	_	
121-32	40767-40769	75	_	
121-33	40770-40771	âˆ’	_	
121-34	40771-40773	45	_	
121-35	40774-40780	7.3691	_	
121-36	40781-40783	40	_	
121-37	40786-40795	Â 	Â 	Â 	Â 	Â 	_	
121-38	40798-40809	Hippocampal	_	
121-39	40810-40820	subregions	_	
121-40	40824-40828	DG_L	_	
121-41	40829-40837	Inferior	_	
121-42	40838-40846	parietal	_	
121-43	40847-40855	lobule_L	_	
121-44	40856-40857	âˆ’	_	
121-45	40857-40859	36	_	
121-46	40860-40861	âˆ’	_	
121-47	40861-40863	54	_	
121-48	40864-40866	42	_	
121-49	40867-40874	10.7382	_	
121-50	40875-40877	77	_	
121-51	40881-40885	DG_R	_	
121-52	40886-40894	Inferior	_	
121-53	40895-40903	parietal	_	
121-54	40904-40912	lobule_L	_	
121-55	40913-40914	âˆ’	_	
121-56	40914-40916	48	_	
121-57	40917-40918	âˆ’	_	
121-58	40918-40920	54	_	
121-59	40921-40923	48	_	
121-60	40924-40930	8.2654	_	
121-61	40931-40933	46	_	
121-62	40936-40937	Â 	_	
121-63	40938-40947	Posterior	_	
121-64	40948-40957	cingulate	_	
121-65	40958-40964	cortex	_	
121-66	40965-40966	âˆ’	_	
121-67	40966-40967	6	_	
121-68	40968-40969	âˆ’	_	
121-69	40969-40971	33	_	
121-70	40972-40974	30	_	
121-71	40975-40981	7.0922	_	
121-72	40982-40984	33	_	
121-73	40988-40992	CA_L	_	
121-74	40993-41004	Calcarine_R	_	
121-75	41005-41007	24	_	
121-76	41008-41009	âˆ’	_	
121-77	41009-41011	93	_	
121-78	41012-41013	0	_	
121-79	41014-41021	11.1746	_	
121-80	41022-41024	68	_	
121-81	41028-41032	CA_R	_	
121-82	41033-41044	Calcarine_R	_	
121-83	41045-41047	21	_	
121-84	41048-41049	âˆ’	_	
121-85	41049-41051	93	_	
121-86	41052-41053	3	_	
121-87	41054-41061	13.0346	_	
121-88	41062-41064	97	_	
121-89	41067-41068	Â 	_	
121-90	41069-41077	Fusiform	_	
121-91	41078-41084	extent	_	
121-92	41085-41087	to	_	
121-93	41088-41097	lingual_L	_	
121-94	41098-41099	âˆ’	_	
121-95	41099-41101	27	_	
121-96	41102-41103	âˆ’	_	
121-97	41103-41105	54	_	
121-98	41106-41107	âˆ’	_	
121-99	41107-41108	3	_	
121-100	41109-41114	9.205	_	
121-101	41115-41117	32	_	
121-102	41121-41126	SUB_L	_	
121-103	41127-41133	Medial	_	
121-104	41134-41141	frontal	_	
121-105	41142-41148	cortex	_	
121-106	41149-41150	3	_	
121-107	41151-41153	30	_	
121-108	41154-41155	âˆ’	_	
121-109	41155-41157	12	_	
121-110	41158-41164	7.1874	_	
121-111	41165-41167	37	_	

#Text=Abbreviations: CA, cornuammonis; DG, dentate gyrus; L, left; MNI, Montreal Neurological Institute; SC, subicular complex; R, right.
122-1	41171-41184	Abbreviations	_	
122-2	41184-41185	:	_	
122-3	41186-41188	CA	_	
122-4	41188-41189	,	_	
122-5	41190-41202	cornuammonis	_	
122-6	41202-41203	;	_	
122-7	41204-41206	DG	_	
122-8	41206-41207	,	_	
122-9	41208-41215	dentate	_	
122-10	41216-41221	gyrus	_	
122-11	41221-41222	;	_	
122-12	41223-41224	L	_	
122-13	41224-41225	,	_	
122-14	41226-41230	left	_	
122-15	41230-41231	;	_	
122-16	41232-41235	MNI	_	
122-17	41235-41236	,	_	
122-18	41237-41245	Montreal	_	
122-19	41246-41258	Neurological	_	
122-20	41259-41268	Institute	_	
122-21	41268-41269	;	_	
122-22	41270-41272	SC	_	
122-23	41272-41273	,	_	
122-24	41274-41283	subicular	_	
122-25	41284-41291	complex	_	
122-26	41291-41292	;	_	
122-27	41293-41294	R	_	
122-28	41294-41295	,	_	
122-29	41296-41301	right	_	
122-30	41301-41302	.	_	

#Text=Note: The statistical significance threshold for main effect for diagnosis of functional connectivity of each hippocampal subregions was set at P<0.05, corrected for multiple comparisons based on Monte Carlo simulations.
123-1	41303-41307	Note	_	
123-2	41307-41308	:	_	
123-3	41309-41312	The	_	
123-4	41313-41324	statistical	_	
123-5	41325-41337	significance	_	
123-6	41338-41347	threshold	_	
123-7	41348-41351	for	_	
123-8	41352-41356	main	_	
123-9	41357-41363	effect	_	
123-10	41364-41367	for	_	
123-11	41368-41377	diagnosis	_	
123-12	41378-41380	of	_	
123-13	41381-41391	functional	_	
123-14	41392-41404	connectivity	_	
123-15	41405-41407	of	_	
123-16	41408-41412	each	_	
123-17	41413-41424	hippocampal	_	
123-18	41425-41435	subregions	_	
123-19	41436-41439	was	_	
123-20	41440-41443	set	_	
123-21	41444-41446	at	_	
123-22	41447-41448	P	_	
123-23	41448-41449	<	_	
123-24	41449-41453	0.05	_	
123-25	41453-41454	,	_	
123-26	41455-41464	corrected	_	
123-27	41465-41468	for	_	
123-28	41469-41477	multiple	_	
123-29	41478-41489	comparisons	_	
123-30	41490-41495	based	_	
123-31	41496-41498	on	_	
123-32	41499-41504	Monte	_	
123-33	41505-41510	Carlo	_	
123-34	41511-41522	simulations	_	
123-35	41522-41523	.	_	

#Text=Sample summary and test scores for imaging
124-1	41524-41530	Sample	_	
124-2	41531-41538	summary	_	
124-3	41539-41542	and	_	
124-4	41543-41547	test	_	
124-5	41548-41554	scores	_	
124-6	41555-41558	for	_	
124-7	41559-41566	imaging	_	

#Text=Category (meanÂ±s.d.)\tCases with RDVs (n=26)\tCases without RDVs (n=48)\tControl (n=74)\tdf\tF/t/Î»/value\tP-value\t \tAge (years)\t25.69Â±7.2\t23.00Â±6.92\t23.23Â±6.52\t2\t1.54\t0.22\t \tGender (male/female)\t13/13\t24/24\t41/33\t2\t0.43\t0.81\t \tYears of education\t13.42Â±3.19\t11.90Â±3.08\t13.44Â±3.24\t2\t3.72\t0.03\t \tDuration of disease\t3.5\t2\tÂ \t72\t0.57\t0.57\t \tPANSS total\t87.08Â±17.16\t88.06Â±12.55\tÂ \t71\tâˆ’0.28\t0.78\t \tPANSS positive\t23.65Â±8.27\t24.34Â±5.55\tÂ \t37.72\tâˆ’0.38\t0.71\t \tPANSS negative\t18.69Â±8.50\t18.87Â±6.75\tÂ \t42.68\tâˆ’0.09\t0.93\t \tPANSS general psychopathology\t44.73Â±8.84\t44.85Â±7.47\tÂ \t71\tâˆ’0.06\t0.95\t \tLogical memory immediate\t6.16Â±3.31\t7.84Â±4.62\t12.94Â±3.89\t2\t45.47\t<0.001\t \tLogical memory delay\t4.09Â±3.19\t5.65Â±4.39\t11.02Â±4.12\t2\t44.51\t<0.001\t \tHippocampus L milliliter\t2534.70Â±291.31\t2512.42Â±239.22\t2722.55Â±301.57\t2\t7.42\t0.001\t \tHippocampus R milliliter\t2573.12Â±305.71\t2559.78Â±262.83\t2741.44Â±289.61\t2\t5.63\t0.004
125-1	41567-41575	Category	_	
125-2	41576-41577	(	_	
125-3	41577-41581	mean	_	
125-4	41581-41582	Â±	_	
125-5	41582-41585	s.d	_	
125-6	41585-41586	.	_	
125-7	41586-41587	)	_	
125-8	41588-41593	Cases	_	
125-9	41594-41598	with	_	
125-10	41599-41603	RDVs	_	
125-11	41604-41605	(	_	
125-12	41605-41606	n	_	
125-13	41606-41607	=	_	
125-14	41607-41609	26	_	
125-15	41609-41610	)	_	
125-16	41611-41616	Cases	_	
125-17	41617-41624	without	_	
125-18	41625-41629	RDVs	_	
125-19	41630-41631	(	_	
125-20	41631-41632	n	_	
125-21	41632-41633	=	_	
125-22	41633-41635	48	_	
125-23	41635-41636	)	_	
125-24	41637-41644	Control	_	
125-25	41645-41646	(	_	
125-26	41646-41647	n	_	
125-27	41647-41648	=	_	
125-28	41648-41650	74	_	
125-29	41650-41651	)	_	
125-30	41652-41654	df	_	
125-31	41655-41656	F	_	
125-32	41656-41657	/	_	
125-33	41657-41658	t	_	
125-34	41658-41659	/	_	
125-35	41659-41660	Î»	_	
125-36	41660-41661	/	_	
125-37	41661-41666	value	_	
125-38	41667-41674	P-value	_	
125-39	41677-41680	Age	_	
125-40	41681-41682	(	_	
125-41	41682-41687	years	_	
125-42	41687-41688	)	_	
125-43	41689-41694	25.69	_	
125-44	41694-41695	Â±	_	
125-45	41695-41698	7.2	_	
125-46	41699-41704	23.00	_	
125-47	41704-41705	Â±	_	
125-48	41705-41709	6.92	_	
125-49	41710-41715	23.23	_	
125-50	41715-41716	Â±	_	
125-51	41716-41720	6.52	_	
125-52	41721-41722	2	_	
125-53	41723-41727	1.54	_	
125-54	41728-41732	0.22	_	
125-55	41735-41741	Gender	_	
125-56	41742-41743	(	_	
125-57	41743-41747	male	_	
125-58	41747-41748	/	_	
125-59	41748-41754	female	_	
125-60	41754-41755	)	_	
125-61	41756-41758	13	_	
125-62	41758-41759	/	_	
125-63	41759-41761	13	_	
125-64	41762-41764	24	_	
125-65	41764-41765	/	_	
125-66	41765-41767	24	_	
125-67	41768-41770	41	_	
125-68	41770-41771	/	_	
125-69	41771-41773	33	_	
125-70	41774-41775	2	_	
125-71	41776-41780	0.43	_	
125-72	41781-41785	0.81	_	
125-73	41788-41793	Years	_	
125-74	41794-41796	of	_	
125-75	41797-41806	education	_	
125-76	41807-41812	13.42	_	
125-77	41812-41813	Â±	_	
125-78	41813-41817	3.19	_	
125-79	41818-41823	11.90	_	
125-80	41823-41824	Â±	_	
125-81	41824-41828	3.08	_	
125-82	41829-41834	13.44	_	
125-83	41834-41835	Â±	_	
125-84	41835-41839	3.24	_	
125-85	41840-41841	2	_	
125-86	41842-41846	3.72	_	
125-87	41847-41851	0.03	_	
125-88	41854-41862	Duration	_	
125-89	41863-41865	of	_	
125-90	41866-41873	disease	_	
125-91	41874-41877	3.5	_	
125-92	41878-41879	2	_	
125-93	41880-41881	Â 	_	
125-94	41882-41884	72	_	
125-95	41885-41889	0.57	_	
125-96	41890-41894	0.57	_	
125-97	41897-41902	PANSS	_	
125-98	41903-41908	total	_	
125-99	41909-41914	87.08	_	
125-100	41914-41915	Â±	_	
125-101	41915-41920	17.16	_	
125-102	41921-41926	88.06	_	
125-103	41926-41927	Â±	_	
125-104	41927-41932	12.55	_	
125-105	41933-41934	Â 	_	
125-106	41935-41937	71	_	
125-107	41938-41939	âˆ’	_	
125-108	41939-41943	0.28	_	
125-109	41944-41948	0.78	_	
125-110	41951-41956	PANSS	_	
125-111	41957-41965	positive	_	
125-112	41966-41971	23.65	_	
125-113	41971-41972	Â±	_	
125-114	41972-41976	8.27	_	
125-115	41977-41982	24.34	_	
125-116	41982-41983	Â±	_	
125-117	41983-41987	5.55	_	
125-118	41988-41989	Â 	_	
125-119	41990-41995	37.72	_	
125-120	41996-41997	âˆ’	_	
125-121	41997-42001	0.38	_	
125-122	42002-42006	0.71	_	
125-123	42009-42014	PANSS	_	
125-124	42015-42023	negative	_	
125-125	42024-42029	18.69	_	
125-126	42029-42030	Â±	_	
125-127	42030-42034	8.50	_	
125-128	42035-42040	18.87	_	
125-129	42040-42041	Â±	_	
125-130	42041-42045	6.75	_	
125-131	42046-42047	Â 	_	
125-132	42048-42053	42.68	_	
125-133	42054-42055	âˆ’	_	
125-134	42055-42059	0.09	_	
125-135	42060-42064	0.93	_	
125-136	42067-42072	PANSS	_	
125-137	42073-42080	general	_	
125-138	42081-42096	psychopathology	_	
125-139	42097-42102	44.73	_	
125-140	42102-42103	Â±	_	
125-141	42103-42107	8.84	_	
125-142	42108-42113	44.85	_	
125-143	42113-42114	Â±	_	
125-144	42114-42118	7.47	_	
125-145	42119-42120	Â 	_	
125-146	42121-42123	71	_	
125-147	42124-42125	âˆ’	_	
125-148	42125-42129	0.06	_	
125-149	42130-42134	0.95	_	
125-150	42137-42144	Logical	_	
125-151	42145-42151	memory	_	
125-152	42152-42161	immediate	_	
125-153	42162-42166	6.16	_	
125-154	42166-42167	Â±	_	
125-155	42167-42171	3.31	_	
125-156	42172-42176	7.84	_	
125-157	42176-42177	Â±	_	
125-158	42177-42181	4.62	_	
125-159	42182-42187	12.94	_	
125-160	42187-42188	Â±	_	
125-161	42188-42192	3.89	_	
125-162	42193-42194	2	_	
125-163	42195-42200	45.47	_	
125-164	42201-42202	<	_	
125-165	42202-42207	0.001	_	
125-166	42210-42217	Logical	_	
125-167	42218-42224	memory	_	
125-168	42225-42230	delay	_	
125-169	42231-42235	4.09	_	
125-170	42235-42236	Â±	_	
125-171	42236-42240	3.19	_	
125-172	42241-42245	5.65	_	
125-173	42245-42246	Â±	_	
125-174	42246-42250	4.39	_	
125-175	42251-42256	11.02	_	
125-176	42256-42257	Â±	_	
125-177	42257-42261	4.12	_	
125-178	42262-42263	2	_	
125-179	42264-42269	44.51	_	
125-180	42270-42271	<	_	
125-181	42271-42276	0.001	_	
125-182	42279-42290	Hippocampus	_	
125-183	42291-42292	L	_	
125-184	42293-42303	milliliter	_	
125-185	42304-42311	2534.70	_	
125-186	42311-42312	Â±	_	
125-187	42312-42318	291.31	_	
125-188	42319-42326	2512.42	_	
125-189	42326-42327	Â±	_	
125-190	42327-42333	239.22	_	
125-191	42334-42341	2722.55	_	
125-192	42341-42342	Â±	_	
125-193	42342-42348	301.57	_	
125-194	42349-42350	2	_	
125-195	42351-42355	7.42	_	
125-196	42356-42361	0.001	_	
125-197	42364-42375	Hippocampus	_	
125-198	42376-42377	R	_	
125-199	42378-42388	milliliter	_	
125-200	42389-42396	2573.12	_	
125-201	42396-42397	Â±	_	
125-202	42397-42403	305.71	_	
125-203	42404-42411	2559.78	_	
125-204	42411-42412	Â±	_	
125-205	42412-42418	262.83	_	
125-206	42419-42426	2741.44	_	
125-207	42426-42427	Â±	_	
125-208	42427-42433	289.61	_	
125-209	42434-42435	2	_	
125-210	42436-42440	5.63	_	
125-211	42441-42446	0.004	_	

#Text=Abbreviations: L, left; PANSS, Positive and Negative Syndrome Scale; R, right; RDV, rare damage variant.
126-1	42450-42463	Abbreviations	_	
126-2	42463-42464	:	_	
126-3	42465-42466	L	_	
126-4	42466-42467	,	_	
126-5	42468-42472	left	_	
126-6	42472-42473	;	_	
126-7	42474-42479	PANSS	_	
126-8	42479-42480	,	_	
126-9	42481-42489	Positive	_	
126-10	42490-42493	and	_	
126-11	42494-42502	Negative	_	
126-12	42503-42511	Syndrome	_	
126-13	42512-42517	Scale	_	
126-14	42517-42518	;	_	
126-15	42519-42520	R	_	
126-16	42520-42521	,	_	
126-17	42522-42527	right	_	
126-18	42527-42528	;	_	
126-19	42529-42532	RDV	_	
126-20	42532-42533	,	_	
126-21	42534-42538	rare	_	
126-22	42539-42545	damage	_	
126-23	42546-42553	variant	_	
126-24	42553-42554	.	_	

#Text=Note: values are mean (s.d.).
127-1	42555-42559	Note	_	
127-2	42559-42560	:	_	
127-3	42561-42567	values	_	
127-4	42568-42571	are	_	
127-5	42572-42576	mean	_	
127-6	42577-42578	(	_	
127-7	42578-42581	s.d	_	
127-8	42581-42582	.	_	
127-9	42582-42583	)	_	
127-10	42583-42584	.	_	
